Medical Dictionary: Hepatocellular carcinoma (fibrolamell
ABCDEFGHIJKLMNOPQRSTUVWXYZ#
Hepatocellular carcinoma (fibrolamellar variant): Rare Disease
Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) Hepatocellular carcinoma (fibrolamellar variant) is listed as a "rare disease" by the Office of Rare Dise Institutes of Health (NIH). This means that Hepatocellular carcinoma (fibrolamellar variant), or a subtype of (fibrolamellar variant), affects less than 200,000 people in the US population. Source - National Institutes of Health (NIH)
Terms associated with Hepatocellular carcinoma (fibrolamellar variant):
Terms that may be interchangeable with Hepatocellular carcinoma (fibrolamellar Fibrolamellar hepatocellular carcinoma Fibrolamellar variant of hepatocellular carcinoma Source - NIH
Interesting Medical Articles:
 Symptoms of the Silent Killer Diseases Online Diagnosis Self Diagnosis Pitfalls Pitfalls of Online Diagnosis Research Your Symptoms Diseases & Medical Conditions Medical Diagnosis [Full list of premium articles on symptoms, diseases, and diagnosis]
Medical dictionaries:
 Medical dictionary, Medical Acronymns/Abbreviations
Need more information? enter keyword Search
Other Medical Articles:
Other Predical Articles:

Research your symptoms

Research multiple symptoms

- Diseases and treatments
- Online Diagnosis
- Misdiagnosis Overview
- Full list of premium articles on symptoms, diagnosis and misdiagnosis

Alzheimer's Sy Learn About Siç

Ads by Google

Treatment Info. www.aricept.com

ADVERTISEMENT

Search Sourced by Google

O Search the Web

Search wrongdiagnosis.com

Things to do:

- Bookmark this page
- Print this page
- Email this page to a friend (or yourself)
- Join in at the Boards
 - I cannot get a diagnosis. Please help.
 - Tell us your medical story.
 - Share your misdiagnosis story.
 - What is the best treatment for my condition?
 - See all the Boards.
- Give us some feedback Tell us what you think or make some suggestions

BY USING THIS SITE YOU AGREE TO OUR <u>TERMS OF USE</u>. INFORMATION PROVIDED ON THIS SITE IS FOR INFORMATIONAL PURPOSES ONLY; IT IS FROM YOUR OWN MEDICAL TEAM. THE INFORMATION ON THIS SITE IS NOT TO BE USED FOR DIAGNOSING OR TREATING ANY HEALTH CONCERN: PHYSICIAN OR HEALTH CARE PROFESSIONAL FOR ALL YOUR MEDICAL NEEDS. PLEASE SEE OUR <u>TERMS OF USE</u>.

 $Wrong Diagnosis.com^{TM}\\$

Copyright © 2000-2006 Adviware Pty Ltd. All rights reserved.

Home | Symptoms | Diseases | Site Map | Feedback

Terms of Use | Privacy Policy | About Us

Last updated: 15 November, 2006



- L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
- RN 114977-28-5 REGISTRY
- ED Entered STN: 25 Jun 1988
- CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR, 4s, 4aS, 6R, 9s, 11s, 12s, 12aR, 12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11-trihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


- CN 7,11-Methaño-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
- CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-ylester, [2aR-[2a α ,4 β ,4a β ,6 β ,9 α (α R*, β S*),11 α ,12 α ,12a α ,12b α]]-

OTHER NAMES:

- CN Docetaxel
- CN Docetaxol
- CN N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
- CN RP 56976
- CN Taxotere
- FS STEREOSEARCH
- DR 216252-50-5
- MF C43 H53 N O14
- CI COM
- SR CA
- LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 3431 REFERENCES IN FILE CA (1907 TO DATE)
- 132 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
- 3480 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/083565

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:35:31 ON 06 DEC 2006

=> file caplus medline biosis embase
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:35:51 ON 06 DEC 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:35:51 ON 06 DEC 2006

FILE 'BIOSIS' ENTERED AT 12:35:51 ON 06 DEC 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:35:51 ON 06 DEC 2006 Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s docetaxol or docetaxel or txotere or rp 56976 or 114977-28-5 L1 20746 DOCETAXOL OR DOCETAXEL OR TXOTERE OR RP 56976 OR 114977-28-5

=> s docetaxol or docetaxel or txotere or rp 56976 or 114977-28-5/rn

'RN' IS NOT A VALID FIELD CODE

'RN' IS NOT A VALID FIELD CODE

'RN' IS NOT A VALID FIELD CODE

L2 18876 DOCETAXOL OR DOCETAXEL OR TXOTERE OR RP 56976 OR 114977-28-5/RN

=> s (hepatocellular or hepatic or liver or hepato) (w) (cancer or neoplasm or neoplastic or tumor or tumour or cancerous)

L3 183161 (HEPATOCELLULAR OR HEPATIC OR LIVER OR HEPATO) (W) (CANCER OR NEOPLASM OR NEOPLASTIC OR TUMOR OR TUMOUR OR CANCEROUS)

=> s 12 and 13

L4 434 L2 AND L3

=> dup rem 14

PROCESSING COMPLETED FOR L4

L5 403 DUP REM L4 (31 DUPLICATES REMOVED)

=> focus

PROCESSING COMPLETED FOR L5

L6 403 FOCUS L5 1-

=> s (hepatocellular or hepatic or liver or hepato) (w) (cancer or neoplasm or neoplastic or tumor or tumour or cancerous or carcinoma or carci?)

L7 231795 (HEPATOCELLULAR OR HEPATIC OR LIVER OR HEPATO) (W) (CANCER OR NEOPLASM OR NEOPLASTIC OR TUMOR OR TUMOUR OR CANCEROUS OR CARCIN OMA OR CARCI?)

=> s 12 and 137 L37 NOT FOUND

The L-number entered could not be found. To see the definition of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

```
Welcome to STN International!
                               Enter x:
Welcome to STN International!
                               Enter x:
LOGINID:SSSPTA1616BSK
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
                      Welcome to STN International
NEWS
      1
                  Web Page URLs for STN Seminar Schedule - N. America
                  "Ask CAS" for self-help around the clock
NEWS
      2
NEWS
      3
         AUG 09
                  INSPEC enhanced with 1898-1968 archive
NEWS
         AUG 28
                  ADISCTI Reloaded and Enhanced
NEWS
         AUG 30
      5
                  CA(SM)/CAplus(SM) Austrian patent law changes
NEWS
      6
         SEP 11
                  CA/CAplus enhanced with more pre-1907 records
NEWS
          SEP 21
                  CA/CAplus fields enhanced with simultaneous left and right
                  truncation
NEWS 8
          SEP 25
                  CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS
      9
         SEP 25
                  CAS REGISTRY (SM) no longer includes Concord 3D coordinates
NEWS 10
         SEP 25
                  CAS REGISTRY (SM) updated with amino acid codes for pyrrolysine
NEWS 11
         SEP 28
                  CEABA-VTB classification code fields reloaded with new
                  classification scheme
NEWS 12
         OCT 19
                  LOGOFF HOLD duration extended to 120 minutes
         OCT 19
NEWS 13
                  E-mail format enhanced
NEWS 14
         OCT 23
                  Option to turn off MARPAT highlighting enhancements available
NEWS 15
         OCT 23
                  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases
         OCT 23
NEWS 16
                  The Derwent World Patents Index suite of databases on STN
                  has been enhanced and reloaded
NEWS 17
         OCT 30
                  CHEMLIST enhanced with new search and display field
NEWS 18
         NOV 03
                  JAPIO enhanced with IPC 8 features and functionality
NEWS 19
         NOV 10
                  CA/CAplus F-Term thesaurus enhanced
NEWS 20
         NOV 10
                  STN Express with Discover! free maintenance release Version
                  8.01c now available
NEWS 21
         NOV 13
                  CA/CAplus pre-1967 chemical substance index entries enhanced
                  with preparation role
NEWS 22
         NOV 20
                  CAS Registry Number crossover limit increased to 300,000 in
                  additional databases
NEWS 23
         NOV 20
                  CA/CAplus to MARPAT accession number crossover limit increased
                  to 50,000
NEWS 24
         NOV 20
                  CA/CAplus patent kind codes will be updated
NEWS 25
         DEC 01
                  CAS REGISTRY updated with new ambiguity codes
NEWS EXPRESS
              NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS
               STN Operating Hours Plus Help Desk Availability
NEWS LOGIN
               Welcome Banner and News Items
```

Enter NEWS followed by the item number or name to see news on that specific topic.

X.25 communication option no longer available

For general information regarding STN implementation of IPC 8

NEWS IPC8

NEWS X25

=> s 12 and 17

L8 469 L2 AND L7

=> dup rem 18

PROCESSING COMPLETED FOR L8

L9 420 DUP REM L8 (49 DUPLICATES REMOVED)

=> focus

PROCESSING COMPLETED FOR L9 L10 420 FOCUS L9 1-

=> s l10 and pd<=2000 · 2 FILES SEARCHED...

L11 55 L10 AND PD<=2000

=> focus

PROCESSING COMPLETED FOR L11 L12 55 FOCUS L11 1-

=> d ibib abs hitstr 1-55

L12 ANSWER 1 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:650912 CAPLUS

DOCUMENT NUMBER:

134:141449

TITLE:

Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced

apoptosis in hepatoma cells and its correlation with

reactive oxygen species

AUTHOR(S):

Lin, Heng-Liang; Liu, Tsung-Yun; Chau, Gar-Yang; Lui,

Wing-Yiu; Chi, Chin-Wen

CORPORATE SOURCE:

Institute of Pharmacology, National Yang-Ming

University, Taipei, Taiwan

SOURCE:

Cancer (New York) (2000), 89(5), 983-994

CODEN: CANCAR; ISSN: 0008-543X

PUBLISHER:

John Wiley & Sons, Inc.

DOCUMENT TYPE: LANGUAGE:

Journal English

Previously, the authors observed that paclitaxel treatment of hepatoma cells resulted in differential cytotoxicity. Whether other antimicrotubule agents (docetaxel and 2-methoxyestradiol) are more effective than paclitaxel is not clear. Moreover, whether the modulation of reactive oxygen species (ROS) is involved in the drug-induced growth inhibition of hepatoma cells is not known. The authors examined the effects of 2-methoxyestradiol, paclitaxel, and docetaxel on HepG2, Hep3B, HA22T/VGH, and Hepal-6 hepatoma cell lines. The parameters examined included cell viability, cell membrane permeability, cell cycle distribution, DNA fragmentation, and ROS generation. Docetaxel and paclitaxel inhibited the growth of hepatoma cells at submicromolar concns., whereas that of 2-methoxyestradiol was within a micromolar range. This drug-induced growth inhibition was cell cycle dependent. 2-Methoxyestradiol-treated (10-50 μM) cells resulted in G2/M block prior to apoptosis. High dose (0.1 μM) docetaxel- and paclitaxel-treated cells resulted in a G2/M arrest followed by generation of polyploidy or apoptosis; however, low dose (0.01 μM) treatment induced apoptosis without G2/M arrest. The low dose effect was more significant in docetaxel-treated cells than in paclitaxel-treated cells. Although these antimicrotubule agents increased the formation of ROS, antioxidant treatment did not block drug-induced cell cycle and growth inhibition effects. The current results suggest that the growth inhibition of hepatoma cells induced by 2-methoxyestradiol, paclitaxel, and docetaxel was mediated through G2/M-phase arrest, caspase activation, and DNA fragmentation. drug-induced apoptosis was independent of ROS formation. Docetaxel was more effective than paclitaxel in killing hepatoma

The potential of using 2-methoxyestradiol and docetaxel cells. for the treatment of patients with hepatoma is worthy of further study.

114977-28-5, Docetaxel TΤ

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(2-methoxyestradiol-, docetaxel-, and paclitaxel-induced apoptosis in hepatoma cells)

RN114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 58 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

COPYRIGHT 2006 ACS on STN L12 ANSWER 2 OF 55 CAPLUS

ACCESSION NUMBER:

2000:126569 CAPLUS

DOCUMENT NUMBER:

132:175461

TITLE:

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients

AUTHOR (S):

Alexandre, J.; Bleuzen, P.; Bonneterre, J.; Sutherland, W.; Misset, J. L.; Guastalla, J.-P.; Viens, P.; Faivre, S.; Chahine, A.; Spielman, M.; Bensmaine, A.; Marty, M.; Mahjoubi, M.; Cvitkovic, E. Paul Brousse Hospital and Institut Gustave Roussy,

CORPORATE SOURCE:

Villejuif, 94804, Fr.

SOURCE:

Journal of Clinical Oncology (2000), 18(3),

562-573

CODEN: JCONDN; ISSN: 0732-183X Lippincott Williams & Wilkins

DOCUMENT TYPE:

PUBLISHER:

Journal English

LANGUAGE:

Purpose: To identify predictive factors for efficacy and safety in advanced breast cancer (ABC) patients treated in the French compassionate-use docetaxel program. Patients and Methods: A total of 825 ABC patients treated with docetaxel (100 mg/m2 every 3 wk) were source-reviewed and analyzed for prognostic factors associated with overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), febrile neutropenia, mucositis, and severe fluid retention syndrome by univariate and multivariate anal. Results: The ORR was 22.9% (95% confidence interval, 20.2% to 26.2%). The median TTF and

OS were 4.0 and 9.8 mo, resp. By multivariate anal., secondary anthracycline-resistant disease was significantly associated (P <.05) with lower ORR and shorter TTF and OS, whereas anthracycline-refractory disease was associated with shorter OS. Poor performance status was associated with lower ORR, shorter TTF, and shorter OS. Liver dysfunction (transaminase levels > 1.5 times the upper limit of normal [ULN] and alkaline phosphatase [AP] level > three times ULN) and time since first relapse less than 24 mo were associated with shorter TTF and OS. Other significant correlations included the following: elevated CA 15-3 serum level with lower ORR; more than two involved sites, and minor transaminase and AP level abnormalities with shorter OS; and no previous chemotherapy for ABC with shorter TTF. According to multivariate anal., ORR, TTF, and OS were not decreased in patients with liver metastases but without liver dysfunction. Docetaxel activity was maintained in heavily pretreated ABC patients and in those with liver metastasis; docetaxel must be used cautiously, however, in patients with liver dysfunction in whom high morbidity risk necessitates strict adherence to dose-adaptation quidelines.

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (factors predicting for efficacy and safety of docetaxel in pretreated humans with advanced breast cancer)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:60933 CAPLUS

DOCUMENT NUMBER:

132:102535

TITLE:

A Phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors

AUTHOR (S):

Ryan, David P.; Lynch, Thomas J.; Grossbard, Michael L.; Seiden, Michael V.; Fuchs, Charles S.; Grenon, Nina; Baccala, Paul; Berg, Deborah; Finkelstein,

Dianne; Mayer, Robert J.; Clark, Jeffrey W.

CORPORATE SOURCE:

Gastrointestinal Cancer Clinic, Dana-Farber/Partners

CancerCare, Boston, MA, 02114, USA

SOURCE:

Cancer (New York) (2000), 88(1), 180-185

CODEN: CANCAR; ISSN: 0008-543X

PUBLISHER:

John Wiley & Sons, Inc.

DOCUMENT TYPE:

Journal English

LANGUAGE:

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. Patients with metastatic solid tumors were treated with docetaxel , 60 mg/m2, on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and 15 and underwent dose adjustment in cohorts of 3-6 patients. At the maximum tolerated dose, 11 addnl. patients were enrolled. Twenty-six patients received 85 cycles of therapy. At the first dose level, the planned gemcitabine dose on Days 1, 8, and 15 was 800 mg/m2. Two of the 6 patients treated at this dose level experienced dose-limiting toxicities (DLTs) requiring the reduction of gemcitabine to 600 mg/m2 per dose and the administration of ciprofloxacin, 500 mg orally twice daily, on Days 8-18. At the second dose level the first 3 patients experienced no DLTs and the dose of gemcitabine was increased to 700 mg/m2. Two of the 6 patients treated at the 700 mg/m2 dose level experienced DLTs. Eleven addnl. patients were enrolled at the recommended Phase II dose of gemcitabine (600 mg/m2). At this dose level, Grade 3/4 (according the National Cancer Institute's common toxicity criteria) neutropenia and thrombocytopenia occurred in 12.5% and 2.1% of cycles, resp. Grade 3 and 4 nonhematol. toxicities were uncommon. Three of seven evaluable patients with pancreatic carcinoma had evidence of significant antineoplastic activity (three partial responses). In addition, two complete responses (one patient

partial response (patient with hepatocellular carcinoma) were noted in patients with other solid tumors. The regimen comprised of docetaxel, 60 mg/m2, on Day 1 and gemcitabine, 600 mg/m2, on Days 1, 8, and 15 with ciprofloxacin on Days 8-18 every 28 days is safe, well tolerated, and active.

with gastric carcinoma and one patient with ovarian carcinoma) and one

IT 114977-28-5, Docetaxel

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gemcitabine and docetaxel in human patients with metastatic solid tumors)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

. 26

REFERENCE COUNT:

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN 1999:641123 CAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 132:117128 Efficacy and safety of docetaxel (Taxotere) TITLE: in heavily pretreated advanced breast cancer patients; the French compassionate use program experience AUTHOR (S): Bonneterre, J.; Spielman, M.; Guastalla, J. -P.; Marty, M.; Viens, P.; Chollet, P.; Roche, H.; Fumoleau, P.; Mauriac, L.; Bourgeois, H.; Namer, M.; Bergerat, J. P.; Misset, J. -L.; Trandafir, L.; Mahjoubi, M. CORPORATE SOURCE: Centre Oscar Lambret, Lille, 59020, Fr. SOURCE: European Journal of Cancer (1999), 35(10), 1431-1439 CODEN: EJCAEL; ISSN: 0959-8049 PUBLISHER: Elsevier Science Ltd. DOCUMENT TYPE: Journal LANGUAGE: English The aim was to assess retrospectively doceaxel safety and efficacy in advanced breast cancer patients in a French compassionate use program. Patients had received >1 prior chemotherapy regimen for advanced disease, were either anthracycline-resistant (that is progressed within 6 mo after anthracycline-based chemotherapy) or had received the maximum cumulative The recommended docetaxel dose was 100 mg/m2/cycle (75 mg/m2) prior palliative chemotherapy lines. The most frequent severe toxicity, febrile neutropenia (reported in 223/870 (25.6%) patients evaluable for safety), caused 10 deaths, 6 of these being patients with severe liver impairment before inclusion. Fluid retention syndrome and other common non-Hematol. toxicities were well tolerated. 3.1% (28/889) of all patients and 11.4% of those with liver dysfunction, died from treatment-related causes. The overall response rate in 825 assessable patients was 22.9% (95% confidence interval (CI): 20.2-26.2%). Median time to treatment failure was 4 mo (95% CI: 3.6-4.3) and median survival was 9.8 mo (95% CI: 8.8-10.7). This report on the largest series of unselected advanced breast cancer patients treated with docetaxel , supports previous phase II studies, confirming docetaxel's utility in patients relapsing after failing anthracycline-containing palliative chemotherapy.

IT 114977-28-5, Docetaxel

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (efficacy and safety of docetaxel in heavily pretreated

advanced breast cancer patients)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:790283 CAPLUS

DOCUMENT NUMBER:

133:344606

TITLE:

Combined pharmaceuticals comprising anthracycline

derivatives

INVENTOR(S):

Geroni, Maria Cristina; Ripamonti, Marina; Caruso,

Michele; Suarato, Antonino

PATENT ASSIGNEE(S):

Pharmacia & Upjohn S.p.A., Italy

SOURCE:

PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT NO.					KIN	ND DATE			i	APP						D	ATE		
						-			_							_			
	2000						2000			MO	2000) – E	EP292	23		20	0000	404	<
MO	2000		-																
	₩:	•	•	•	•	•	ΑZ,	•	•		•	•	,	•	•		•		
		CZ,	DE,	DK,	DM,	EE,	ES,	FI,	GB,	GD	, GE	Ξ,	GH,	GM,	HR,	ΗU,	ID,	IL,	
		IN,	IS,	JP,	KΕ,	KG,	KΡ,	KR,	ΚZ,	LC	, LF	ζ,	LR,	LS,	LT,	LU.,	LV,	MA,	
		MD,	MG,	ΜK,	MN,	MW,	MX,	NO,	ΝZ,	PL	, P7	Γ,	RO,	RU,	SD,	SE,	SG,	SI,	
		SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	UG	, US	3,	UZ,	VN,	ΥU,	ZA,	ZW		
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	ŚZ,	TZ	, UG	3,	ZW,	AT,	BE,	CH,	CY,	DE,	
		DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU	, MC	Ξ,	NL,	PT,	SE,	BF,	ВJ,	CF,	
		CG,	CI,	CM,	GA,	GN,	GW,	ML,	MR,	NE	, SN	1,	TD,	TG			•		
ЕP	1173				A2		2002	0123	.]	EΡ	2000	· 9	251	58		20	00004	404	
EР	1173	187			В1		2003	0806											
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR	, IT	Γ,	LI,	LU,	NL,	SE,	MC,	PT,	
					LV,			•	•				•	- •	•	•		,	
JP	2002	5431	12	•	T2	•	2002	1217		JΡ	2000) - 6	149	78	•	20	00004	404	
	1323																		
							ES,												
		•	•	•			RO,	•	•		•	- ,	,	,	,	,	,	,	
ΑТ	2465		•	•	•		2003	•	•) - 9	2519	58		20	10004	104	
РТ	1173	187			T														
	2204	572	•		T3		2004												
	1507				A		2004												
	1535				A		2004												
	1853				A		2006:												
	1853				A		2006: 2006:												
	2228				B1		2004:												
	6537				B1														
	10454						2003												
пN	1045	402			ΑI		2006	1428	, 1	ır.	2002	: - T	0/02	49		20	0209	726	

AD The manage introducti						
			US	2001-926392	A1	20011025
			WO	2000-EP2923	W	20000404
			EP	2000-925158	A3	20000404
			CN	2003-10114911	A3	20000404
			CN	2003-10114909	A3	20000404
			CN	2000-806897	Α	20000404
PRIORITY APPLN. INFO.:			GB	1999-9925	Α	19990429
US 6586428	B:	2 20030	701			
US 2003087839	· A:	1 20030	508 US	2002-284144		20021031

The present invention relates to combined pharmaceuticals comprising a morpholinylanthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inhibitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful in anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer. At doses 5.9 and 7,7 mg/kg cis-platin administered alone and 0.05 mg/kg PNU-152243 (morpholinylanthracycline) administered alone, the increase in lifespan values was 33, 33 and 50%. Sequential administration of these drugs showed a therapeutic advantage of the combination in comparison with each drug administered alone.

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combined pharmaceuticals comprising anthracycline derivs.)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456927 CAPLUS

DOCUMENT NUMBER:

133:84243

TITLE:

Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy

in the treatment of neoplasia

INVENTOR(S):

McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

L.

PATENT ASSIGNEE(S):

SOURCE:

G.D. Searle and Co., USA PCT Int. Appl., 236 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	WO 2000038730 WO 2000038730	A2 A3	20000706	WO 1999-US30693	19991222 <
	W: AE, AL, AM,	AT, AU	, AZ, BA,	BB, BG, BR, BY, CA, CI	
				GB, GD, GE, GH, GM, HI	
				KZ, LC, LK, LR, LS, LT	
				NZ, PL, PT, RO, RU, SI	
				UA, UG, US, UZ, VN, YU	
				SZ, TZ, UG, ZW, AT, BI	
				IT, LU, MC, NL, PT, SI	E, BF, BJ, CF,
		GA, GN AA	, GW, ML,	MR, NE, SN, TD, TG CA 1999-2356606	10001222
				AU 2000-23805	
	AU 783992	R2	20060112	A0 2000 23003	
	EP 1140192	A2	20011111	EP 1999-967543	19991222
	EP 1140192	B1	20060405		
				GB, GR, IT, LI, LU, NI	L, SE, MC, PT,
	IE, SI, LT,			, , , , , ,	
	TR 200102499	T2	20011221	TR 2001-200102499	19991222
	BR 9916518	Α		BR 1999-16518	19991222
				HU 2001-4814	19991222
	JP 2002533416	T2	20021008	JP 2000-590681	19991222
	EP 1522313	A1		, EP 2004-26577	19991222
			, ES, FR,	GB, GR, IT, LI, LU, NI	L, SE, MC, PT,
	IE, FI, RO,		00000415	NE 1000 065543	
	AT 322290 ZA 2001005055	E A	20060415	AT 1999-967543 ZA 2001-5055	19991222
	ZA 2001005055 ZA 2001005120	A	20020920 20020107	ZA 2001-5055 ZA 2001-5120	20010620 20010621
	NO 2001003155		20020107		20010621
	US 2003119895		20030626		20010022
•	US 2003203956	A1	20031030	US 2002-212523	20020805
		A1	20041007	AU 2004-210578	20040910
		A1	20050217	US 2004-945422	20040920
PRIO:	RITY APPLN. INFO.:			US 1998-113786P	P 19981223
					A 19990827
			•	AU 2000-25936	A3 19991222
	•			EP 1999-968939	
				WO 1999-US30693	
3.00	Wathada and and da			US 2001-857873	A2 20011005
AB	using a combination			event neoplasia disorde nase-2 inhibitor and ar	
IT	agent. 114977-28-5, Doceta:	vol.			•
11			ty or effe	ector, except adverse);	PCII (Riological
				cic use); BIOL (Biologi	
	(Uses)	, ,	(210 450,, 2102 (210105)	, ,
		2 inhib	itor-antir	neoplastic agent combir	nation for
	neoplasia treatme			<u>.</u>	
RN	114977-28-5 CAPLUS				
CN				ethylethoxy)carbonyl]am	
				2S,12aR,12bS)-12b-(acet	
				12,12a,12b-dodecahydro-	4,6,11-
				-oxo-7,11-methano-1H-	100
		1,2-bjo	xet-9-yl e	ester, $(\alpha R, \beta S)$ - $(9CI)$	(CA
	INDEX NAME)				

L12 ANSWER 7 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456915 CAPLUS

DOCUMENT NUMBER:

133:84242

TITLE:

Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination

therapy in the treatment of neoplasia

INVENTOR(S):

McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

L.

PATENT ASSIGNEE(S):

SOURCE:

G.D. Searle and Co., USA

PCT Int. Appl., 277 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 21

								,									
PA	PATENT NO.				KIND DATE			1	APPL	ICAT	ION	NO.		D.	ATE		
WO	2000038	 718		A2	-	2000	0706	1	WO 1	.999-1	 US30	 699		1	 9991.	222	<
WO	2000038	718		. A3		2000	1109									-	
	W: AE								BG.	BR.	BY.	CA.	CH.	CN.	CR.	CU.	
		, DE,															
		, JS,		•			•	•	•	•		•	•	•	•		
		, 18, , MG,															
		, MG, , SL,														υ,	
	RW: GH								-							ישת	
		, GM, , ES,			•	•						•	•	•			
														DF,	ъυ,	CF,	
G A	2256020	, CI,	CM,	GA,	GN,	GW,	ML,	MR,	NE,	2N,	ים. מבר	16.		-	0001	222	
CA	2356929			AA		2000	0/06		CAI	999-	2356	929		1	9991	222	<
	2000027																<
EP	1140182																
	R: AT						FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
	IE																
TR	2001024	99		T2		2001	1221	•	rr 2	001-	2001	0249	9	1	9991:	222	
	2002533																
EP	1522313																
	R: AT	, BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
	IE	, FI,	RO,	CY													
AT	322290			E		2006	0415		AT 1	999-	9675	43		1:	9991:	222	
	2001005									001-							
ZA	2001005	120		Α.		2002	0107	:	ZA 2	001-	5120			2	0010	621	•
US	6858598			B1		2005	0222	1	JS 2	001-	8579	95		2	0011	005	
AU	2004210	578		A1		2004	1007	i	AU 2	004-	2105	78		2	0040	910	
US	2005058	725		A1		2005	0317	1	JS 2	004-	9450	02		2	0040	920	
	6916800					2005					•						
PRIORIT	Y APPLN.	INFO	.:					τ	JS 1	998-	1137	86P	1	P 1:	9981	223	-

US 1999-385214 A 19990827
AU 2000-25936 A3 19991222
EP 1999-968939 A3 19991222
WO 1999-US30699 W 19991222
US 2001-857995 A1 20011005

AB Methods are provided for the prevention and treatment of neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(matrix metalloproteinase inhibitor and antineoplastic agent as combination therapy in neoplasia treatment)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456866 CAPLUS

DOCUMENT NUMBER:

133:84239

TITLE:

Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the

treatment of neoplasia

INVENTOR(S):

McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

L.

PATENT ASSIGNEE(S):

G.D. Searle and Co., USA PCT Int. Appl., 220 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

SOURCE:

Г: 21

FAMILY ACC. NUM. COUNT:

PATENT NO. KI						D	DATE		APPL	ICAT:	ION I	NO.		D	ATE		
	WO 2000038665					-											
WO 2000038665 WO 2000038665					A2 A3		2000		WO 1:	999-	05300	570		Τ.	9991.	222 <	,
			-	AM,			AZ,		BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,	
							ES,										

```
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                 20000706
                                             CA 1999-2356462
                                                                      19991222 <--
     CA 2356462
                          AΑ
     AU 2000025926
                          A5
                                 20000731
                                             AU 2000-25926
                                                                      19991222 <--
                                 20011010
                                             EP 1999-968529
     EP 1140193
                          A2
                                                                      19991222
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
    TR 200102499
                          T2
                                 20011221
                                             TR 2001-200102499
                                                                      19991222
     JP 2002533387
                          T2
                                 20021008
                                             JP 2000-590619
                                                                      19991222
     EP 1522313
                          A1
                                 20050413
                                             EP 2004-26577
                                                                      19991222
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, RO, CY
     AT 322290
                          Ε
                                 20060415
                                             AT 1999-967543
                                                                      19991222
     ZA 2001005055
                          Α
                                 20020920
                                             ZA 2001-5055
                                                                      20010620
     ZA 2001005120
                          Α
                                 20020107
                                             ZA 2001-5120
                                                                      20010621
     US 6833373
                          B1
                                 20041221
                                             US 2001-857994
                                                                      20011005
    US 2004234624
                          A1
                                 20041125
                                             US 2004-865414
                                                                      20040610
    AU 2004210578
                          Α1
                                 20041007
                                             AU 2004-210578
                                                                      20040910
PRIORITY APPLN. INFO.:
                                             US 1998-113786P
                                                                  Р
                                                                     19981223
                                             US 1999-385214
                                                                     19990827
                                                                  Α
                                             AU 2000-25936
                                                                  A3 19991222
                                             EP 1999-968939
                                                                  A3 19991222
                                             WO 1999-US30670
                                                                  W
                                                                     19991222
                                             US 2001-857994
                                                                  A1 20011005
```

AB The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(integrin antagonist-antineoplastic agent combination for neoplasia treatment)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

L12 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:368032 CAPLUS

DOCUMENT NUMBER: 133:26843

TITLE: Methods and compositions for diagnosis and treatment

of cancer based on the transcription factor ets2

INVENTOR(S): Papas, Takis S.; Watson, Dennis K.

PATENT ASSIGNEE(S): Musc Foundation for Research Development, USA; Papas,

Tula Christy

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

WO 2000030590 A2 20000602 WO 1999-US27805 19991123 < WO 2000030590 A3 20000817 W: AU, CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE CA 2351627 AA 20000602 CA 1999-2351627 19991123 < AU 2000024740 A5 20000613 AU 2000-24740 19991123 < EP 1133575 A2 20010919 EP 1999-968046 19991123 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	PA'	PATENT NO.					KIND DATE			API	PLIC	CATION	NO.		D	ATE		
WO 2000030590 A3 20000817 W: AU, CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE CA 2351627 AA 20000602 CA 1999-2351627 19991123 < AU 2000024740 A5 20000613 AU 2000-24740 19991123 < EP 1133575 A2 20010919 EP 1999-968046 19991123							-								-			
W: AU, CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE CA 2351627	WO	200003	3059	0		A2		2000	0602	WO	199	99-US2	7805		1	9991	123	<
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE CA 2351627 AA 20000602 CA 1999-2351627 19991123 < AU 2000024740 A5 20000613 AU 2000-24740 19991123 < EP 1133575 A2 20010919 EP 1999-968046 19991123	WO	200003	3059	0		A 3		2000	0817									
PT, SE CA 2351627 AA 20000602 CA 1999-2351627 19991123 < AU 2000024740 A5 20000613 AU 2000-24740 19991123 < EP 1133575 A2 20010919 EP 1999-968046 19991123	•	W: 2	AU,	CA,	JP,	US												
CA 2351627 AA 20000602 CA 1999-2351627 19991123 < AU 2000024740 A5 20000613 AU 2000-24740 19991123 < EP 1133575 A2 20010919 EP 1999-968046 19991123		RW: A	ΑT,	BE,	CH,	CY,	DE,	, DK,	ES,	FI, F	₹, 0	B, GF	R, IE,	IT,	LU,	MC,	NL,	
AU 2000024740 A5 20000613 AU 2000-24740 19991123 < EP 1133575 A2 20010919 EP 1999-968046 19991123			PT,	SE		•												
EP 1133575 A2 20010919 EP 1999-968046 19991123	CA	235162	27			AA		2000	0602	CA	199	99-235	1627		1	9991	123	<
	AU	200002	2474	. 0		A5		2000	0613	AU	200	0-247	40		1	9991	123	<
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	EP	11335	75			A2		2001	0919	, EP	199	99-968	3046		1:	9991	123	
		R: 2	AT,	ΒE,	CH,	DE,	DK,	, ES,	FR,	GB, GI	R, I	T, LI	LU,	NL,	SE,	MC,	PT,	
IE, FI		-	ΙE,	FΙ														
JP 2002530102 T2 20020917 JP 2000-583475 19991123	JP	200253	3010	2		T2		2002	0917	JP	200	0-583	475		1	9991:	123	
US 2002081601 A1 20020627 US 2001-841963 20010425	US	200208	8160	1		A1		2002	0627	US	200	1-841	963		2	0104	425	
US 2004047845 A1 20040311 US 2001-841960 20010425	·US	200404	4784	5		A1		2004	0311	US	200	1-841	.960		2	00104	425	
PRIORITY APPLN. INFO.: US 1998-109850P P 19981125	PRIORIT	Y APPLI	v. I	NFO.	. :					US	199	8-109	850P	I	2 1:	9981	125	
WO 1999-US27805 W 19991123										WO	199	99-US2	7805	V	1 1	9991:	123	

AB The present invention relates to methods for treating and preventing cancer by modifying the expression of ets2 gene expression or the activity of the gene product. The invention also relates to sensitizing cancer cells to chemotherapeutic or radiotherapeutic agents. Ets2 gene expression and/or activity of the gene product can be modulated using antisense ets2 nucleic acids and/or modified ets2 proteins. The present invention also provides pharmaceutical compns. which comprise antisense ets2 nucleic acid, and nucleic acid that encode modified ets2 proteins and/or modified ets2 proteins.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(diagnosis and treatment of cancer based on the transcription factor ets2)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456950 CAPLUS

DOCUMENT NUMBER:

133:84244

TITLE:

Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the

treatment of neoplasia

INVENTOR(S):

McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

L.

PATENT ASSIGNEE(S):

SOURCE:

G.D. Searle and Co., USA

PCT Int. Appl., 348 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

English LANGUAGE:

FAMILY ACC. NUM. COUNT: 21

					APPLICATION NO.	
WO	20000387	86	A2	20000706	WO 1999-US30692	19991222 <
WO	20000387	86	A3	20010308		
	W: AE,	AL, AM	, AT,	AU, AZ, BA,	BB, BG, BR, BY, CA, CH	, CN, CR, CU,
	CZ,	DE, DK	, DM,	EE, ES, FI,	GB, GD, GE, GH, GM, HR	, HU, ID, IL,
	IN,	IS, JP	, KE,	KG, KP, KR,	KZ, LC, LK, LR, LS, LT	, LU, LV, MA,
	MD,	MG, MK	, MN,	MW, MX, NO,	NZ, PL, PT, RO, RU, SD	, SE, SG, SI,
	SK,	SL, TJ	, TM,	TR, TT, TZ,	UA, UG, US, UZ, VN, YU	, ZA, ZW
					SZ, TZ, UG, ZW, AT, BE	
			-		IT, LU, MC, NL, PT, SE	
	•	•			MR, NE, SN, TD, TG	
CA					CA 1999-2356302	19991222 <
AU	20000221	04	A5	20000731	AU 2000-22104	19991222 <
					EP 1999-966594	
					GB, GR, IT, LI, LU, NL	
				FI, RO	02, 011, 22, 20, 012	, ==, ==,
TR					TR 2001-200102499	19991222
.тр	20025334	22	Т2	20021008	JP 2000-590734	19991222
					EP 2004-26577	
21					GB, GR, IT, LI, LU, NL	
		FI, RO		DR, 10, 1R,	GD, GR, 11, D1, D0, ND	, 6B, NC, 11,
ΔͲ	•	•		20060415	AT 1999-967543	19991222
7.A	20010050	55	2	20020920	ZA 2001-5055	
7.0	20010050	20	Δ	20020320	ZA 2001-5033 ZA 2001-5120	
י דות	20010031	7.0	7.1	20020107	AU 2004-210578	20010021
PRIORITY			AT	20041007	US 1998-113786P	D 10001222
PRIORITI	APPLIN.	INFO.:				
					US 1999-385214	
					AU 2000-25936	
					, EP 1999-968939	A3 19991222

AB Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor, an integrin antagonist and an antineoplastic agent.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclooxygenase-2 inhibitor and integrin antagonist in combination for neoplasia treatment)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456916 CAPLUS

DOCUMENT NUMBER:

INVENTOR(S):

133:68929

TITLE:

Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

L.

PATENT ASSIGNEE(S):

SOURCE:

G.D. Searle and Co., USA PCT Int. Appl., 358 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 21

P	ATENT	NO.			KIN	D :	DATE		į	APPL	ICAT	ION I	NO.		D	ATE		
· -						_									-			
W	O 2000	0387	19		A1		2000	0706	1	WO 1	999-1	US30'	700		1:	9991:	222 <-	· -
	W:	ΑE,	AL,	AM,	AT,	AU,	ΑZ,	ВA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,	-
		CZ,	DE,	DK,	DM,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	
		IN,	IS,	JP,	KΕ,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	
		MD,	MG,	MK,	MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	
		SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZW	-	
	RW:	GH,															DE,	
			ES,															
			CI,											-		•	•	

CA	2356402	A	A 20000706	CA 1999-2356402	19991222 <
AU	2000027136	Α	5 20000731	AU 2000-27136	19991222 <
EP	1140183	A	1 20011010	EP 1999-968942	19991222
	R: AT, BE	, CH, DE	, DK, ES, FR,	GB, GR, IT, LI, LU, NL,	SE, MC, PT,
	IE, SI	, LT, LV	, FI, RO		
TR	200102499	T	2 20011221	TR 2001-200102499	19991222
JP	2002533407	T	2 20021008	' JP 2000-590670	19991222
		A		EP 2004-26577	19991222
	R: AT, BE	, CH, DE	, DK, ES, FR,	GB, GR, IT, LI, LU, NL,	SE, MC, PT,
	IE, FI	, RO, CY			
AT	322290	E	20060415	AT 1999-967543	19991222
ZA	2001005055	A	20020920	ZA 2001-5055	20010620
ZA	2001005120	A	20020107	ZA 2001-5120	20010621
AU	2004210578	A	1 20041007	AU 2004-210578	20040910
PRIORITY	APPLN. INF	0.:		US 1998-113786P	P 19981223
				US 1999-385214	A 19990827
				AU 2000-25936	A3 19991222
			•	EP 1999-968939	A3 19991222
				WO 1999-US30700	W 19991222
AD Mot	hada awa mw		- ++		

AB Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor, an integrin antagonist, and an antineoplastic agent.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(matrix metalloproteinase inhibitor and integrin antagonist in neoplasia treatment)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

5

ACCESSION NUMBER:

2000:441655 CAPLUS

DOCUMENT NUMBER:

133:68922

TITLE:

Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination

therapy in the treatment of neoplasia

INVENTOR(S):

McKearn, John P.; Gordon, Gary; Cunningham, James J.;

Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.
G.D. Searle and Co., USA
PCT Int. Appl., 437 pp.
CODEN: PIXXD2
Patent
English
21

FAMILY ACC. NUM. COUNT:

PATENT ASSIGNEE(S):

DOCUMENT TYPE:

SOURCE:

LANGUAGE:

PATENT INFORMATION:

```
DATE
     PATENT NO.
                         KIND
                                           APPLICATION NO.
                                                                   DATE
                                -----
     -----
                         ----
                                           -----
                                                                   -----
     WO 2000037107
                         A2
                                20000629
                                           WO 1999-US30776
                                                                   19991222 <--
    WO 2000037107
                         A3
                                20010201
            AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
            MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2356426
                         AΑ
                                20000629
                                           CA 1999-2356426
                                                                   19991222 <--
     AU 2000025936
                         A5
                                20000712
                                           AU 2000-25936
                                                                   19991222 <--
                         A2
                                20011010
                                           EP 1999-968540
     EP 1140194
                                                                   19991222
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     TR 200102499
                         T2
                                20011221
                                            TR 2001-200102499
                                                                   19991222
     BR 9916536
                         Α
                                20020102
                                           BR 1999-16536
                                                                   19991222
     HU 200104747
                         A2
                                20020429
                                           HU 2001-4747
                                                                   19991222
                         T2
     JP 2002532563
                                20021002
                                           JP 2000-589217
                                                                   19991222
                                20050413
     EP 1522313
                         A1
                                           EP 2004-26577
                                                                   19991222
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, RO, CY
     AT 322290
                         F
                                20060415
                                           AT 1999-967543
                                                                   19991222
     ZA 2001005055
                         Α
                                20020920
                                           ZA 2001-5055
                                                                   20010620
     ZA 2001005120
                         Α
                                20020107
                                           ZA 2001-5120
                                                                   20010621
     NO 2001003156
                         Α
                                20010823
                                           NO 2001-3156
                                                                   20010622
     AU 2004210578
                         A1
                                20041007
                                           AU 2004-210578
                                                                   20040910
PRIORITY APPLN. INFO.:
                                           US 1998-113786P
                                                                P 19981223
                                           US 1999-385214
                                                                A 19990827
                                           AU 2000-25936
                                                                A3 19991222
                                           EP 1999-968939
                                                                A3 19991222
                                           WO 1999-US30776
                                                                W 19991222
```

AB Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor, a matrix metalloproteinase inhibitor and an antineoplastic agent.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclooxygenase-2 inhibitor and matrix metalloproteinase inhibitor in combination therapy for neoplasia treatment)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

L12 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1997:400101 CAPLUS

DOCUMENT NUMBER:

127:23742

TITLE:

Method, compositions and kits for increasing the oral

bioavailability of pharmaceutical agents

INVENTOR(S): PATENT ASSIGNEE(S): Broder, Samuel; Duchin, Kenneth L.; Selim, Sami

Baker Norton Pharmaceuticals, Inc., USA PCT Int. Appl., 136 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PA'	PATENT NO.			KIN	D	DATE APPLICATION NO.					D.	ATE						
WO	9715: 9715:	269			A2		1997	0501										<
0							BR,			CH	CM	CZ	שת	DK	다다	FC	DТ	
	** .						KE,											
•							NZ,											
		-	•	UZ,	•	140,	МД,	PВ,	г,	RO,	RO,	, ענ	JE,	36,	31,	SIC,	10,	
	RW:	•	•	•		97	ΙΙC	אידי	DE	. כם	חבי	DK	FC	₽Т	ED.	CB	CP	
	ICW .						PT,											
					TD,			J11,	ы,	ъ,	CF,	CG,	CI,	CI-1,	GA,	GN,	ти,	
us	5968			•	•			1019		115 1	996-	6087	76		1	9960	229	
	6245																	•
AU	9712	056			A1		1997	0515		AIJ 1	997-	1205	6		1	9961	024	<
ΔII	6981	42			R2		1998	1022										
EP	7947	94			A1		1997	0917		EP 1	996-	9432	68		1	9961	024	<
EP	7947	94			В1		2005	1207										
							ES,			GB,	GR,	ΙE,	IT,	LI,	LU,	MC,	NL,	
				_			·	•	•	•	•	·	•	•	·	•	•	
JP	1050	9741			T2		1998	0922		JP 1	997-	5164	49		1	9961	024	<
JP	3361	102			B2		2003	0107										
BR	9607	066			A		2002	1210		BR 1	996-	7066			1	9961	024	
RU	2217	135					2003	1127		RU 1	997-	1128	88		1	9961	024	
	1882				В1		2005											
	3119				E		2005	1215		AT 1	996-	9432	68		1	9961	024	
	96090				Α		1997				996-							
	9702	968			Α		1997			NO 1	997-	2968			1:	9970	525 ·	<
	3210				B1		2006											
	10019				A1		2006											
	20020						2002			AU 2	002-	3558	4		2	00204	122	
	7841				B2		2006	0216					_					
PRIORITY	Y APPI	LN.	LNFO	. :					,	US 1	995-'	7071	Ρ					
									' 1	us 1	996-0	50871	76	1	A 1	99602	229	

US 1996-733142 A 19961016 WO 1996-IB1485 W 19961024 AU 1998-71300 A3 19980422

AB A method of increasing the bioavailability upon oral administration of a pharmacol. active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F, or ketoconazole). The oral bioavailability-enhancing agents are known to be MDR (P-glycoprotein) inhibitors. The enhancing agent may be administered orally from 0.5-24 h prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent, or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailabilityenhancing agents and target agents kits containing enhancing and target agent ' dosage forms and dosing information for the co-administration of the same are also disclosed.

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (target; increasing oral bioavailability of pharmaceutical agents)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1998:799989 CAPLUS

DOCUMENT NUMBER:

130:43304

TITLE:

Method and compositions for administering taxanes orally to human patients using a cyclosporin to

enhance bioavailability

INVENTOR(S):

Broder, Samuel; Duchin, Kenneth L.; Selim, Sami

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., USA

SOURCE:

PCT Int. Appl., 44 pp.

DOCUMENT TYPE:

CODEN: PIXXD2 Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

7117

```
APPLICATION NO.
                                                                  DATE
     PATENT NO.
                        KIND
                               DATE
                                           -----
     -----
                        ____
                               _____
                                                                 -----
                                         WO 1998-US7776
                                                                19980422 <--
     WO 9853811
                               19981203
                         A1
        W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
            KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
            NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
            UA, UG, UZ, VN, YU, ZW
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, ML, MR, NE, SN, TD, TG
     CA 2290446
                         AΑ
                               19981203
                                           CA 1998-2290446
                                                                  19980422 <--
     AU 9871300
                         A1
                               19981230
                                           AU 1998-71300
                                                                  19980422 <--
                               20000426 , EP 1998-918361
     EP 994706
                         Α1
                                                                  19980422 <--
     EP 994706
                         В1
                               20051102
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, RO
     BR 9809694
                         Α
                               20001003
                                           BR 1998-9694
                                                                  19980422 <--
     JP 2002500667
                         T2
                               20020108
                                           JP 1999-500663
                                                                  19980422
     HU 200003546
                         A2
                               20021128
                                           HU 2000-3546
                                                                  19980422
                         C2
     RU 2205005
                               20030527
                                           RU 1999-128033
                                                                  19980422
     NZ 516026
                        Α
                               20030630
                                           NZ 1998-516026
                                                                 19980422
     CN 1550231
                        Α
                               20041201
                                           CN 2004-10030478
                                                                 19980422
     AT 308365
                        E
                               20051115
                                           AT 1998-918361
                                                                 19980422
                               20060301
                        Т3
     ES 2247690
                                           ES 1998-918361
                                                                 19980422
     ZA 9804268
                        Α
                               19990623
                                           ZA 1998-4268
                                                                 19980520 <--
     HK 1026637
                        A1
                               20060106
                                           HK 2000-105943
                                                                  20000920
     AU 2002035584
                        A5
                               20020606
                                           AU 2002-35584
                                                                  20020422
     AU 784159
                         B2
                               20060216
PRIORITY APPLN. INFO.:
                                           US 1997-863513
                                                              A 19970527
                                           AU 1998-71300
                                                              A3 19980422
                                           NZ 1998-501127
                                                               A1 19980422
                                           WO 1998-US7776
                                                               W 19980422
AΒ
     Taxane antineoplastic agents which have heretofore exhibited poor or
     non-existent oral bioavailability are administered orally to human
     patients suffering from taxane-responsive disease conditions and made
     sufficiently bioavailable to achieve therapeutic blood levels.
     preferred embodiment, the taxane, preferably paclitaxel, is
     co-administered to the patient with an oral cyclosporin enhancing agent,
     preferably cyclosporin A. By one preferred method, a dose of oral
     enhancer is administered about 0.5-72 h before the taxane and a second
     dose of the enhancer and administered immediately before, together with or
```

immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for

pre-medication. IT114977-28-5, Docetaxel

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and compns. for administering taxanes orally to human patients using a cyclosporin to enhance bioavailability).

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1999:215571 CAPLUS

DOCUMENT NUMBER:

130:247032

TITLE:

Fused imidazole derivatives for improving oral

bioavailability of pharmaceutical agents

INVENTOR(S):

Snoeck, Henricus Johannes Matheus Janssen Pharmaceutica N.V., Belg.

PATENT ASSIGNEE(S):

PCT Int. Appl., 45 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND, DATE	APPLICATION NO.	DATE
WO 9913871	A2 19990325	WO 1998-EP5751	19980910 <
WO 9913871			
		BG, BR, BY, CA, CH,	CN, CU, CZ, DE,
		GM, HR, HU, ID, IL,	
		LT, LU, LV, MD, MG,	• • • • • •
		SE, SG, SI, SK, SL,	
	UZ, VN, YU, ZW	5E, 50, 51, 5K, 5E,	10, 111, 111,
		HC CW AM DE CH	CV DE DV EC
		UG, ZW, AT, BE, CH,	
		MC, NL, PT, SE, BF,	BJ, CF, CG, CI,
CM, GA, GN,			
		AU 1999-11460	
		EP 1998-954268	19980910 <
EP 1011726	B1 20030226		
R: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, PT, IE,
SI, LT, LV,	FI, RO	•	•
JP 2001516716	T2 20011002	JP 2000-511494	19980910
JP 3775780	B2 20060517		
AT 233104	E 20030315	AT 1998-954268	19980910
ZA 9808527	A 20000322	ZA 1998-8527	19980917 <
		US 2000-508748	
PRIORITY APPLN. INFO.:	D1 20030400	EP 1997-202862	
PRIORITI APPEN. INFO			
OTHER COIDCE (C).	MADDAM 120 0450	WO 1998-EP5751	M 13300310
OTHER SOURCE(S):	MARPAT 130:2470	3 <i>2</i>	
GI			

QA² O
$$\mathbb{R}^{4}$$
 \mathbb{R}^{1} \mathbb{R}^{2} \mathbb{R}^{1}

AB Compds. I [dotted line = optional bond; n = 1, 2; R1 = H, halo, formyl, (substituted) C1-4 alkyl, etc.; R2 = H, halo, C1-4 alkyl, hydroxy-C1-4 alkyl, etc.; R3 = H, C1-4 alkyl, C1-4 alkyloxy; R4 = H, halo, C1-4 alkyl, C1-4 alkyloxy, halo-C1-4 alkyl; Z = CH2, CH2CH2, CH=CH, CH(OH)CH2, OCH2, C(O)CH2, C(=NOH)CH2; AB = bivalent radical; A1 = direct bond, (substituted) C1-6 alkanediyl, C1-6 alkanediyl-oxy-C1-6 alkanediyl, carbonyl, C1-6 alkanediylcarbonyl, (substituted) C1-6 alkanediyloxy; A2 = direct bond, C1-6 alkanediyl; Q = aryl], and N-oxide forms, pharmaceutically acceptable addition salts, and stereochem. isomeric forms thereof, are used for the manufacture of a medicine for improving the bioavailability of a second pharmaceutical agent which is co-administered orally to a warm-blooded animal. The second pharmaceutical agent is e.g. an antitumor agent. Preparation of compds. of the invention, and intermediates thereto, is described.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fused imidazole derivs., and preparation thereof, for improving oral bioavailability of pharmaceutical agents)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 1998:65802 CAPLUS

DOCUMENT NUMBER:

128:123804

```
TITLE:

Down-regulation of DNA repair to enhance sensitivity to p53-mediated suppression in cancer therapy
INVENTOR(S):

Gjerset, Ruth A.

PATENT ASSIGNEE(S):
Sidney Kimmel Cancer Center, USA; Gjerset, Ruth A.

PCT Int. Appl., 88 pp.
```

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PAT	CENT I	NO.			KIN	D	DATE		I						D	ATE		
	WO	9801	123			A1	-	1998	0115	V			 US12			1:	9970	702	<
		₩:	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
			DK,	EE,	ES,	FI,	GB,	GE,	GH,	HU,	IL,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	
			LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MX,	NO,	NZ,	PL,	
				•				SG,	•						•				
				-		•		AZ,	•								•		
		RW:	-			•	•	SZ,	•	•				•		ES.	FI.	FR.	
				•		-		MC,	-	-	-		-	-	-		•		
			•			-	-	TD,		,	,	,	,	,	,	- -,	 ,	,	
	US	6054	•	•	•	A	•	2000		τ	IS 1	996-	6758	87		1.	9960'	705	<
		2259				AA		1998											
	-	9736				A1		1998									9970'		
		7242						2000		_	10 1	,,,	50,0	-			,,,,	, 02	`
		9103						1999			יו סי	997_	0335	13		7.0	9970	702	
		9103						2003			SF I.	J J 7	,,,,,	ŦJ .		4.	,,,,	702	`
	D.F							ES,			CP	TT	T.T	T.TT	NT.	CE	MC	חת	
			IE,		-	DE,	DR,	EG,	ţĸ,	GB,	GR,	ΤΤ,	шт,	цо,	мп,	æ,	MC,	F1,	
	.TD					тэ		2000	1205	_	יו מז	000	E O E 4 i	00		7.	יחדמנ	702	_
		2000! 2419	72	<i>J</i> /		E		2000											<
										-									
		2005				AI		2005	0505								0040		
PRIOR	T.T.7	APPI	LN.	INFO	. :									B7					
														542					
						_	_			Ţ	JS 2	000-	5564	40	I	31 20	00004	124	

AB The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis in cancer cells following treatment with inhibitors of DNA repair in combination with p53 gene therapy. Treatment of glioblastoma and breast tumor cells with inhibitors of DNA repair induced growth suppression that was a result of p53-mediated apoptosis. Thus it appears that inhibitors of DNA repair in combination with p53 gene therapy is involved in restoration of p53-mediated apoptosis.

IT 114977-28-5, Taxotere

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(down-regulation of DNA repair to enhance sensitivity to p53-mediated suppression in cancer therapy)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1999:405000 CAPLUS

DOCUMENT NUMBER:

131:43591

TITLE:

Combination therapy of cancer with anti-ErbB2

antibodies

INVENTOR(S):

Shak, Steven; Paton, Virginia E.

PATENT ASSIGNEE(S):

Genentech, Inc., USA PCT Int. Appl., 42 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

. PA	TENT 1	NO.			KIN)	DATE			APPL	ICAT	ION 1	NO.		D	ATE		
	9931	140			A1		1999	0624		WO 1	998-	US26:	266		1			
	W:																	
			_				-	-		-	HR,	-	-	-		-		
											LU,					-	-	
		•	•	•	UZ,	•	•	•	SD,	SE,	SG,	21,	SK,	ъL,	IJ,	IM,	TR,	
	DW.		•	•	•	•			ΙΙC	7147	AT,	DE	CH	CV	שת	DK	E.C	
	KW.										PT,							
		-				-		NE,				56,	Dr,	ъо,	Cr,	co,	CI,	
ZA	9811											1116	2		1	9981:	207	<
CA	2311	409			AA		1999	0624	1	CA 1	998-	2311	409		1	9981	210	<
AU	9919	081			A1		1999	0705		AU 1	999-	1908	1		1	9981	210	<
EP	1037	926			A1		2000	0927		EP 1	998-	9638	40		1	9981	210	<
	R:								GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FI,	RO											
	2000																	
CN	1281 9815	468			Α		2001	0124		CN 1	998-	8120	97		1	9981	210	
BR	9815	363			A		2001	1016		BR 1	998-	1536	3		1	9981	210	
JP	2002	5083	97		T2	,	2002	0319		JP 2	000-	5390	62		1	9981	210	
CN	1820° 5045°	734			A						006-							
											000-							
	20000							0811			000-							<
	2003									US 2	003-3	35682	24		2	0030	203	
	20040							0226			003-4	4000			_	0000		
							2003	0106		US 2	003-4	1069	25		2			
PRIORIT	2005				VI	•	2005	0100			997-6					0040		
FRIORII	. AFF	m14 · ·	LIVE	• •							998-8							•
											998-2							
										UD 1	J J Q - 2		± 9	4	ד כי	220I	LIO	

US 1998-209023 A3 19981210 WO 1998-US26266 W 19981210

The authors disclose the treatment of disorders characterized by the AB overexpression of ErbB2. More specifically, human patients are treated with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline (e.g., doxorubicin or epirubicin). Preferably, the chemotherapeutic agent is Taxol.

IT 114977-28-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (in combination cancer therapy with anti-erbB-2 receptor antibodies)

RN 114977-28-5 CAPLUS

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:911036 CAPLUS

DOCUMENT NUMBER:

134:76383

TITLE:

Oral pharmaceutical compositions containing taxanes Gutierrez-Rocca, Jose C.; Cacace, Janice L.; Selim,

PATENT ASSIGNEE(S):

Sami; Testman, Robert; Rutledge, J. Michael Baker Norton Pharmaceuticals, Inc., USA

SOURCE:

PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

INVENTOR(S):

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT NO	ο.			KINI)	DATE		ž	APPL	ICAT:	ION I	NO.		D	ATE	•
					-							- -		-		
WO 200007	7824	7		A1	:	2000	1228	1	WO 1	999-1	US13	821		1:	9900	518 <
W: 7	ΑE,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,
I	DΕ,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,
ن	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,
N	MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,
7	ГΜ,	TR,	TT,	UA,	UG,	UΖ,	VN,	YU,	ZA,	ZW						
RW: C	3H,	GM,	KΕ,	LS,	MW,	SD,	SL,	SZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	DE,	DK,
I	ΞS,	FI,	FR,	GB,	GR,	ΙE,	IT,	ĽU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,
C	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG					

CA	2371	924			AA	2	2000	1228	CF	. :	1999-	2371	924		19	9906	518	<
ΑU	9946	955			A1	2	2001	0109	AU	,	1999-	4695	5		19	9906	518	
AU	7740	60			B2	2	2004	0617										
BR	9917	403			A,	2	2002	0709	BF	2 2	1999-	1740	3		19	9906	518	
EΡ	1221	908			A1	2	2002	0717	EF)]	L999-	9304	80		19	9906	518	
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB, G	R,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	FI,	RO,	CY													
JP	2003	5023	49		T2	2	2003	0121	JF	2	2001-	5043	16		19	9906	518	
HU	2003	0083	6		A2		2003	0828	HU	7 2	2003 -	836			19	9906	518	
NZ	5162	79			Α	2	2004	0625	NZ	: 1	1999-	5162	79		19	9906	518	
RU	2236	226			C2	2	2004	0920	RU	7 2	2002-	1007	03		19	9906	18	
EP	1479	382			A1	2	2004	1124	EF	2	2004-	7706:	2		19	9906	18	
•	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB, G	R,	IT,	LI,	LU,	ΝL,	SE,	MC,	PT,	
		ΙE,	FI,	RO,	CY													
TIRC	Y APP	LN.	INFO	.:					EF)]	L999-	9304	08	1	43 19	9906	18	

PRIO

WO 1999-US13821 19990618

AB Pharmaceutical compns. for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, the carrier having an HLB value of at least about 10. The compns. may also comprise 0-70% of a viscosity-reducing co-solubilizer. The compns. may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a 2-part drug wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compns. are also disclosed, whereby the compns. can be administered alone or in association with an oral bioavailability enhancing agent. A formulation containing Tween 80 at 18 mg/kg and paclitaxel gave an absolute bioavailability of 54% which was >15% for i.v. drug. IT 114977-28-5, Docetaxel

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (oral pharmaceuticals containing taxanes)

RN114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

1

ACCESSION NUMBER: 2005:1210172 CAPLUS

DOCUMENT NUMBER: 143:466194

TITLE: Oral pharmaceutical compositions containing taxanes

and methods of cancer therapy employing the same Gutierrez-Rocca, Jose C.; Cacace, Janice L.; Selim,

Sami; Testman, Robert; Rutledge, J. Michael

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., USA

SOURCE: U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 863,513,

abandoned.
CODEN: USXXAM

DOCUMENT TYPE:

INVENTOR (S):

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	1	APPLICATION NO.	_	DATE
US 6964946 US 5968972 US 6245805 ZA 9609001 NZ 516026 AU 2002035584 AU 784159 US 2005267201	B1 A B1 A A A A5 B2	20051115 19991019 20010612 19970617 20030630 20020606 20060216 20051201	•	US 1998-55818 US 1996-608776 US 1996-733142 ZA 1996-9001 NZ 1998-516026 AU 2002-35584 US 2005-165896	_	19980406 19960229 < 19961016 19961025 < 19980422 20020422
PRIORITY APPLN. INFO.:				US 1995-7071P US 1996-608776 US 1996-733142 US 1997-863513 US 1998-55818 AU 1998-71300 NZ 1998-501127	A2 B2 A3 A3	19951026 19960229 19961016 19970527 19980406 19980422 19980422

AB The present invention relates to pharmaceutical compns. for oral administration to mammalian subjects comprising a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compns. may also comprise 0-70% of a viscosity-reducing co-solubilizer. The compns. may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compns. are also disclosed, whereby the compns. can be administered alone or in association with an oral bioavailability enhancing agent.

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral pharmaceutical compns. containing taxanes and methods of cancer therapy employing same)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:191189 CAPLUS

DOCUMENT NUMBER:

132:227475

TITLE:

Treatment of oncologic tumors with an injectable formulation of a Golgi apparatus disturbing agent

INVENTOR(S):

Singh, Saira Sayed

PATENT ASSIGNEE(S):

Oncopharmaceutical, Inc., USA

SOURCE:

PCT Int. Appl., 32 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.					KIN)	DATE	}	,	API	PLICA	ATIC	I NO	. 01		Ι	DATE		
	WO	2000	0157	66		A1	-	2000	0323		WO	1999	9 - US	521:	312		1	. 9990	915	<
		W:	ΑU,	CA,	JP,	KR														
		RW:	ΑT,	BE,	CH,	CY,	DE,	, DK,	ES,	FI,	F	R, GE	3, 0	∃R,	ΙE,	IT,	LU,	MC,	ΝĻ,	
			PT,	SE																
	CA	2344	316			AA		2000	0323		CA	1999	-23	3443	316		1	9990	915	<
	ΑU	9959	253			A1		2000	0403		ΑU	1999	-59	9253	3		1	9990	915	<
	ΕP	1114	144			A1		2001	0711		ΕP	1999	9-94	1699	55		1	9990	915	
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GI	R, IT	?, I	ĿΙ,	LU,	NL,	SE,	MC,	PT,	
			ΙE,	FI																
	US	6287	602			B1		2001	0911	H	US	1999	-39	739	90		1	9990	915	
	JΡ	2002	5252	68		T2		2002	0813		JP	2000	-57	7029	93		1	.9990	915	
	US	2002	0127	03		A1		2002	0131		US	2001	91	121	15		2	20010	723	
	US	6497	904			B2		2002	1224											
PRIO	RITY	APP	LN.	INFO	. :						US	1998	-10	047	79P]	P 1	.9980	916	
											US	1999	-39	739	90	1	A1 1	.9990	915	
											WO	1999	-US	3213	312	1	₩ 1	.9990	915	

AB Novel pharmaceutical formulations for treating a cellular proliferative disease are provided comprising: a therapeutically effective amount of a Golgi apparatus disturbing agent; a biocompatible carrier; and a solvent. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A (BFA) and the biocompatible carrier is a polymer such as chitin or chitosan. Methods of treating cellular proliferative diseases using the pharmaceutical formulations are also described. Nude mice bearing human epithelial (KB-1) tumors were treated with a BFA/chitin/dimethylacetamide composition

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as addnl. pharmacol. agent; treatment of oncol. tumors with injectable formulation of golgi apparatus disturbing agent)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456819 CAPLUS

DOCUMENT NUMBER:

133:84238

TITLE:

3-heteroarylidenyl-2-indolinone compounds for

modulating protein kinase activity and for use in

cancer chemotherapy

INVENTOR(S):

Langecker, Peter J.; Shawver, Laura Kay; Tang, Peng

Cho; Sun, Li

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PA.	TENT :	NO.			KIN	D :	DATE			APPL	ICAT:	ION 1	10.		D2	ATE	•
						-				-				-			
WO	2000	0385	19		A1		2000	0706		WO 1	999-1	JS312	232		19	99912	230 <
	W:	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
		DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	ΗU,	ID,	ΙL,	IN,	IS,	JP,
		ΚE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,
		MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,
		TR,	TT,	UΑ,	ŪĠ,	UΖ,	VN,	YU,	ZW								
	RW:	GH,	GM,	ΚE,	LS,	MW,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,
•		DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,
		CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG				
CA	2357	042			AA	;	2000	706		CA 1	999-2	23570	142		19	99912	230 <
BR	9916	735			Α	:	2001	925		BR 1	999-:	1673	5		19	99912	230
EP	1139	754			A1	:	2001	1010		EP 1	999-9	96672	25		19	99912	230
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FI,	RO										
JP	2002	5333	50		T2	:	2002	1008		JP 2	000-5	59048	34		19	99912	230
ΑU	7609	64			B2	:	2003	0522	1	AU 2	000-2	22215	5		19	99912	230
WO	2001	0492	37		A1	:	20010	712	1	WO 2	7-000	JS18(58		20	0000	530

```
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                            EP 2000-943334
                                                                     20000630
    EP 1259234
                          A1
                                20021127
    EP 1259234
                          B1
                                20060816
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
    JP 2003535038
                          T2
                                20031125
                                             JP 2001-549655
                                                                    20000630
    AT 336245
                          Ε
                                20060915
                                             AT 2000-943334
                                                                    20000630
    US 2003191162
                          A1
                                20031009
                                             US 2002-307483
                                                                    20021202
PRIORITY APPLN. INFO.:
                                             US 1998-114313P
                                                                 Р
                                                                    19981231
                                             US 1999-476232
                                                                 Α
                                                                    19991230
                                             WO 1999-US31232
                                                                 W
                                                                    19991230
                                             US 2000-569545
                                                                 Α
                                                                    20000512
                                             WO 2000-US18058
                                                                 W
                                                                    20000630
```

OTHER SOURCE(S): MARPAT 133:84238

AB 3-Heteroarylidenyl-2-indolinone compds. are provided that modulate the enzymic activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase-related cellular disorders, e.g. cancer. Furthermore, these compds. are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(heteroarylidenylindolinone derivs. for modulating protein kinase activity and in cancer chemotherapy)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2000:880923 CAPLUS

DOCUMENT NUMBER:

134:37055

TITLE:

Methods and compositions using FGF inhibitors and agonists for modulating cell proliferation and cell

death

INVENTOR(S):

Au, Jessie L. S.; Wientjes, M. Guillaume

PATENT ASSIGNEE(S): U

USA

SOURCE:

PCT Int. Appl., 143 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA:	CENT 1						DATE			APPL	ICAT:	ION I	NO.		D	ATE	
		0746	34		A2				ł.	WO 2	000-1	US40:	103		2	0000	605 <
		AE, CZ, IL, MA,	AL, DE, IN, MD,	AM, DK, IS, MG,	AT, DM, JP,	AU, DZ, KE,	EE, KG,	ES, KP,	FI, KR,	GB, KZ,	GD, LC,	GE, LK,	GH, LR,	GM, LS,	HR, LT,	HU, LU,	ID, LV,
	RW:	GH, DE,	GM, DK,	KE, ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,			
EP																	
	R:	-	-	-	-		-		-		IT,	LI,	LU,	ŅL,	SE,	MC,	PT,
TD	2002	-	-	-	-	-	-	-	-		001	- 0111	7 7		2	0000	COF
												-					
					AI		2004	0115									
KIT:	APP.	LN.	INFO	. :								-					
															-		
		_			_	_	_			-							
	WO WO WO TO WO	WO 2000 WO 2000 W: RW: CA 2377 EP 1206 R: JP 2003 US 6599 AU 7804 US 2004 RITY APP	WO 20000746: WO 20000746: W: AE, CZ, IL, MA, SG, RW: GH, DE, CF, CA 2377385 EP 1206234 R: AT, IE, JP 20035033: US 6599912 AU 780454 US 200401000 RITY APPLN.	WO 2000074634 WO 2000074634 W: AE, AL, CZ, DE, IL, IN, MA, MD, SG, SI, RW: GH, GM, DE, DK, CF, CG, CA 2377385 EP 1206234 R: AT, BE, IE, SI, JP 2003503313 US 6599912 AU 780454 US 2004010001 RITY APPLN. INFO	WO 2000074634 WO 2000074634 W: AE, AL, AM, CZ, DE, DK, IL, IN, IS, MA, MD, MG, SG, SI, SK RW: GH, GM, KE, DE, DK, ES, CF, CG, CI, CA 2377385 EP 1206234 R: AT, BE, CH, IE, SI, LT, JP 2003503313 US 6599912 AU 780454 US 2004010001 RITY APPLN. INFO.:	WO 2000074634 A2 WO 2000074634 C2 W: AE, AL, AM, AT, CZ, DE, DK, DM, IL, IN, IS, JP, MA, MD, MG, MK, SG, SI, SK RW: GH, GM, KE, LS, DE, DK, ES, FI, CF, CG, CI, CM, CA 2377385 AA EP 1206234 A2 R: AT, BE, CH, DE, IE, SI, LT, LV, JP 2003503313 T2 US 6599912 B1 AU 780454 B2 US 2004010001 A1 RITY APPLN. INFO.:	WO 2000074634 A2 WO 2000074634 C2 W: AE, AL, AM, AT, AU, CZ, DE, DK, DM, DZ, IL, IN, IS, JP, KE, MA, MD, MG, MK, MN, SG, SI, SK RW: GH, GM, KE, LS, MW, DE, DK, ES, FI, FR, CF, CG, CI, CM, GA, EP 1206234 A2 R: AT, BE, CH, DE, DK, IE, SI, LT, LV, FI, JP 2003503313 T2 US 6599912 B1 AU 780454 B2 US 2004010001 A1 RITY APPLN. INFO::	WO 2000074634 A2 2000 W: AE, AL, AM, AT, AU, AZ, CZ, DE, DK, DM, DZ, EE, IL, IN, IS, JP, KE, KG, MA, MD, MG, MK, MN, MW, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, DE, DK, ES, FI, FR, GB, CF, CG, CI, CM, GA, GN, CA 2377385 AA 2000 EP 1206234 A2 2002 R: AT, BE, CH, DE, DK, ES, IE, SI, LT, LV, FI, RO, JP 2003503313 T2 2003 US 6599912 B1 2003 AU 780454 B2 2005 RITY APPLN. INFO.:	WO 2000074634 A2 20001214 WO 2000074634 C2 20020926 W: AE, AL, AM, AT, AU, AZ, BA, CZ, DE, DK, DM, DZ, EE, ES, IL, IN, IS, JP, KE, KG, KP, MA, MD, MG, MK, MN, MW, MX, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, DE, DK, ES, FI, FR, GB, GR, CF, CG, CI, CM, GA, GN, GW, CA 2377385 AA 20001214 EP 1206234 A2 20020522 R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO, MK, JP 2003503313 T2 20030128 US 6599912 B1 20030729 AU 780454 B2 20050324 US 2004010001 A1 20040115 RITY APPLN. INFO::	WO 2000074634 A2 20001214 WO 2000074634 C2 20020926 W: AE, AL, AM, AT, AU, AZ, BA, BB, CZ, DE, DK, DM, DZ, EE, ES, FI, IL, IN, IS, JP, KE, KG, KP, KR, MA, MD, MG, MK, MN, MW, MX, MZ, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, SL, DE, DK, ES, FI, FR, GB, GR, IE, CF, CG, CI, CM, GA, GN, GW, ML, CA 2377385 AA 20001214 EP 1206234 A2 20020522 R: AT, BE, CH, DE, DK, ES, FR, GB, IE, SI, LT, LV, FI, RO, MK, CY, JP 2003503313 T2 20030128 US 6599912 B1 20030729 AU 780454 B2 20050324 US 2004010001 A1 20040115 RITY APPLN. INFO::	WO 2000074634 A2 20001214 WO 2 WO 2000074634 C2 20020926 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, IL, IN, IS, JP, KE, KG, KP, KR, KZ, MA, MD, MG, MK, MN, MW, MX, MZ, NO, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, CF, CG, CI, CM, GA, GN, GW, ML, MR, CA 2377385 AA 20001214 CA 2 20020522 EP 2 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003503313 T2 20030128 JP 2 US 6599912 B1 20030729 US 2 AU 780454 B2 20050324 AU 2 RITY APPLN. INFO: US 1 US 2	WO 2000074634 A2 20001214 WO 2000-1 WO 2000074634 C2 20020926 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, CA 2377385 AA 20001214 CA 2000-2 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003503313 T2 20030128 JP 2001-2 AU 780454 B2 20050324 AU 2000-2 AU 78045 B2 AU 2000-	WO 2000074634 WO 2000074634 WO 2000074634 C2 20020926 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, EP 1206234 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003503313 T2 20030128 US 6599912 B1 20030729 US 2000-58759 AU 780454 B2 20050324 AU 2000-58759 US 1999-13734 US 2000-18744 US 2000-58755 US 1999-17203 US 2000-58755 US 2000-58755 US 2000-US403	WO 2000074634 WO 2000074634 WO 2000074634 WO 2000074634 C2 20020926 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, CA 2377385 AA 20001214 CA 2000-2377385 EP 1206234 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003503313 T2 20030128 JP 2001-501171 US 6599912 B1 20030729 US 2004010001 A1 20040115 US 2003-464018 RITY APPLN. INFO: US 1999-137345P US 1999-172031P US 2000-587559 WO 2000-US40103	WO 2000074634 A2 20001214 WO 2000-US40103 WO 2000074634 C2 20020926 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2377385 AA 20001214 CA 2000-2377385 EP 1206234 A2 20020522 EP 2000-943429 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003503313 T2 20030128 JP 2001-501171 US 6599912 B1 20030729 US 2000-587559 AU 780454 B2 20050324 AU 2000-57903 US 2004010001 A1 20040115 US 2003-464018 RITY APPLN. INFO: US 1999-137345P US 1999-172031P US 2000-587559 WO 2000-US40103	WO 2000074634 WO 2000074634 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2377385 AA 20001214 CA 2000-2377385 AB 20001214 CA 2000-2377385 EP 1206234 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003503313 T2 20030128 JP 2001-501171 20 3004010001 A1 20040115 US 2000-587559 US 1999-172031P US 1999-172031P US 1999-172031P US 2000-587559 A3 20 US 2000-587559 US 2000-587559 A3 20 US 2000-587559	WO 2000074634 WO 2000074634 WE AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2377385 AA 20001214 CA 2000-2377385 AA 20001214 CA 2000-2377385 AB 200020522 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003503313 T2 20030128 JP 2001-501171 200000 AU 780454 B2 20050324 AU 2000-587559 200000 AU 780454 B2 20050324 AU 2000-587559 AU 2000-187445P P 19991: US 1999-172031P P 19991: US 2000-587559 A3 200000

AB Methods and compns. for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compns. for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compns. include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promote apoptosis and/or necrosis, an interferon, an interleukin, a tumor necrosis factor, and radiation. In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes administering to the subject an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent. FGF gene expression-based methods for diagnosis of proliferative disorders are also disclosed.

IT 114977-28-5, Taxotere

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(FGF inhibitors and agonists for modulating cell proliferation and cell death)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:824125 CAPLUS

DOCUMENT NUMBER:

134:4050

TITLE:

Treatment with anti-erbB2 antibodies

INVENTOR(S):

Cohen, Robert L.

PATENT ASSIGNEE(S):

Genentech, Inc., USA

SOURCE:

PCT Int. Appl., 39 pp.

JURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

	PA'	TENT	NO.			KIN		DATE				ICAT				D	ATE	
	WO	2000	0694	60												2	0000	 509 <
		W:						AU,										
								DZ,										
	•							KE,										
					-	•		MN,			•	•	•	•	•		•	•
						-		TM,	-		-		•	-				•
								MD,				,	,	,	,	,	,	,
		RW:	-		-	•	•	SD,	•	•		UG.	ZW.	AT.	BE.	CH.	CY.	DE.
								GR,										
								GW,							,	,	,	
	CA	2374		,		•			•		•		•			. 20	0000	509 <
•	ΕP	1187	632					2002										
								ES,										
						LV,			,	-	,	,	,	,	,	J_,	,	,
	JP	2002				-		2002	1224		JP 2	000-	51793	2.0		20	ימממנ	509
		7823						2005									0000!	
		2003	_					2003				003-4		-			0030!	
PRIO												999-:					9909	
					- •							000-!		-			0000	
												000-t			-		0000	

AB A method treating a human patient to or diagnosed with a tumor in which erbB2 protein is expressed comprising the following steps, performed sequentially: (a) treating the patient with a therapeutically effective amount of an anti-erbB2 antibody; (b) surgically removing the tumor, and then (c) treating the patient with a therapeutically effective amount of an anti-erbB2 antibody or of a chemotherapeutic agent.

IT 114977-28-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cancer treatment with anti-erbB2 antibodies)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 24 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2002:158387 CAPLUS

DOCUMENT NUMBER:

136:210551

TITLE:

Method of treating hyperproliferative diseases using

active vitamin D analogues

INVENTOR(S):

Bishop, Charles W.; Mazess, Richard B.

PATENT ASSIGNEE(S):

Bone Care International, Inc., USA

SOURCE:

U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S.

Ser. No. 596,149.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

20

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002025950	A1	20020228	US 2001-891814	20010626
US 6503893	B2	20030107		
US 5763429	A	19980609	US 1996-781910	19961230 <
US 6537982	B1	20030325	US 1998-596149	19980223
US 2002128240	A1	20020912	US 2001-995911	20011128
CA 2450942	AA	20030103	CA 2002-2450942	20020626
WO 2003000023	A2	20030103	WO 2002-US20475	20020626
WO 2003000023	A3	20030731		
W: AE, AG, AL	, AM, AT	, AU, AZ, BA	, BB, BG, BR, BY, BZ,	CA, CH, CN,

```
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                             EP 2002-756332
     EP 1408983
                                 20040421
                                                                     20020626
                          A2
             AT, BE, CH,
                         DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY,
                         TR
     CN 1520302
                                 20040811
                                             CN 2002-812881
                                                                     20020626
                                             JP 2003-506479
     JP-2004535429
                          T2
                                 20041125
                                                                     20020626
    US 2003130242
                                             US 2003-337506
                                                                     20030107
                          Α1
                                 20030710
     US 6680309
                          B2
                                 20040120
PRIORITY APPLN. INFO.:
                                             US 1996-781910
                                                                  A3 19961230
                                             US 1998-596149
                                                                  A2 19980223
                                             US 1993-119895
                                                                  A2 19930910
                                             US 1994-265438
                                                                  A2 19940624
                                             US 1995-415488
                                                                  A2 19950403
                                             US 1995-486387
                                                                  A2 19950607
                                             US 2001-891814
                                                                  A2 20010626
                                             WO 2002-US20475
                                                                     20020626
                         MARPAT 136:210551
```

OTHER SOURCE(S):

Methods use hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia. Patients with advanced androgen-independent prostate cancer were treated with $1\alpha, 24$ -dihydroxyvitamin D2.

114977-28-5, Docetaxel IT

> RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministration with cytotoxic; hypocalcemic vitamin D analogs for treating hyperproliferative diseases)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

CAPLUS COPYRIGHT 2006 ACS on STN L12 ANSWER 25 OF 55 ACCESSION NUMBER:

1996:533912 CAPLUS

DOCUMENT NUMBER: 125:185194

TITLE: AUTHOR(S): Treatment of patients with liver metastases

Fumoleau, P.

CORPORATE SOURCE:

Center Regionale de Lutte Contre le Cancer,

Nantes-Atlantique, Herblain, 44805, Fr.

SOURCE:

Anti-Cancer Drugs (1996), 7(Suppl. 2,

Management of Advanced Breast Cancer: Patient Needs,

Challenges and New Treatment Options), 21-23 CODEN: ANTDEV; ISSN: 0959-4973

Rapid Science Publishers

PUBLISHER: DOCUMENT TYPE:

Journal

LANGUAGE:

English

The presence of liver metastases is a very poor prognostic factor for patients with metastatic breast cancer. Liver metastases are generally less responsive to chemotherapy than metastases in other sites, and patients with liver lesions have a shorter survival duration than patients with other sites of disease. The results from 5 multicenter phase II studies of docetaxel as a first-line treatment for metastatic breast cancer were analyzed with regard to the presence or absence of liver lesions, which were found in 39% of the 209 patients involved. Response rates to docetaxel, 100 or 75 mg/m2, were maintained in the presence of liver lesions and the median survival across all five studies was 16.4 mo for all patients and 14.7 mo for patients with liver lesions. Similarly, when results from 129 patients given docetaxel as a second-line treatment were analyzed, the response rates and survival durations were not reduced in the 57% of patients who had liver lesions. The presence of liver metastases does not reduce the probability or duration of response to docetaxel as a first- or second-line treatment for advanced breast cancer.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of patients with liver metastases)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 26 OF 55

MEDLINE on STN

ACCESSION NUMBER:

2000024224 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 10560434

TITLE:

A case of multiple liver metastases from breast cancer

successfully treated with intra-arterial administration of

docetaxel.

Maeda Y; Nishida M; Takao T; Harada K; Mori N; Tamesa T; AUTHOR:

Somura H; Tangoku A; Oka M; Konishi T

CORPORATE SOURCE: Dept. of Surgery II, Yamaguchi University School of

Medicine.

Gan to kagaku ryoho. Cancer & chemotherapy, (1999 SOURCE:

Oct) Vol. 26, No. 12, pp. 1951-4.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY:

Japan

DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

Japanese

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199911

ENTRY DATE:

Entered STN: 13 Jan 2000

Last Updated on STN: 13 Jan 2000

Entered Medline: 26 Nov 1999

Docetaxel is an excellent agent with a high antitumor effect for AB the treatment of advanced/recurrent breast cancer. A 55-year-old female with metastatic liver tumors from breast cancer showed a remarkable response to intra-arterial administration of docetaxel (20 mg/week, or 40 mg/2 weeks). Since CT and MRI imaging revealed multiple metastases in the liver, intra-arterial chemotherapy was selected. No critical side effect was found during this chemotherapy. A CT scan 3 months after chemotherapy showed a partial response. We conclude that this intra-arterial chemotherapy using docetaxel will be safe and useful for liver metastases from breast cancer.

L12 ANSWER 27 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1998:564267 CAPLUS

DOCUMENT NUMBER:

129:197984

TITLE:

Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

INVENTOR(S):

Nielsen, Loretta; Horowitz, Jo Ann; Maneval, Daniel C.; Demers, G. William; Rybak, Mary Ellen; Resnick,

Gene

PATENT ASSIGNEE(S):

Canji, Inc., USA

SOURCE:

PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
	A2 19980820 A3 19981126	WO 1998-US3514	19980217 <
DK, EE, KP, KR, NO, NZ,	ES, FI, GB, GE, GH, KZ, LC, LK, LR, LS,	BG, BR, BY, CA, CH, CN GM, GW, HU, ID, IL, IS LT, LU, LV, MD, MG, MK SE, SG, SI, SK, SL, TJ	, JP, KE, KG, , MN, MW, MX,
FR, GB,		UG, ZW, AT, BE, CH, DE NL, PT, SE, BF, BJ, CF TG	
AU 737621	A1 19980908 B2 20010823	CA 1998-2282683 AU 1998-64380	19980217 < 19980217 <
EP 969720 R: AT, BE, IE, FI		EP 1998-910038 GB, GR, IT, LI, LU, NL	

NZ	337283	Α	20010223	NZ	1998-337283		19980217	
HU	200004326	A2	20010228	HU	2000-4326		19980217	
JP	2001511815	T2	20010814	JP	1998-536033	•	19980217	
BR	9807418	A	20020122	BR	1998-7418		19980217	
US	2003060434	A1	20030327	US	1999-311772		19990513	
NO	9903943	Α	19991015	NO	1999-3943		19990817	<
US	2003064949	A1	20030403	US	2002-86294		20020228	
US	2004235736	A1	20041125	US	2004-824058		20040413	
US	2005142112	A1	20050630	US	2004-823932		20040413	
PRIORITY	APPLN. INFO.:			US	1997-38065P	P	19970218	
				US	1997-801285	Α	19970218	
				US	1997-801681	A	19970218	
_				US	1997-801755	A	19970218	
				US	1997-801765	Α	19970218	
				US	1997-47834P	P	19970528	
				US	1998-24932	B1	19980217	
				WO	1998-US3514	W	19980217	
				US	1999-311772	B3	19990513	

In one embodiment, the invention provides methods of treating mammalian AΒ cancer or hyperproliferative cells, the method comprising contacting the cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting the cells with at least one adjunctive anticancer agent. The invention also provides for a pharmacol. composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, as well as a kit for the treatment of mammalian cancer or hyperproliferative cells.

IT 114977-28-5, Taxotere

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tumor suppressor gene therapy-chemotherapy combination for treatment of neoplasms and hyperproliferative cells)

RN114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 28 OF 55 ACCESSION NUMBER: 2001066728

MEDLINE on STN

DOCUMENT NUMBER:

MEDLINE PubMed ID: 10907946

TITLE:

Phase II study of docetaxel in patients with

liver metastases from breast cancer. UK study group.

Coleman R E; Howell A; Eggleton S P; Maling S J; Miles D W AUTHOR:

Weston Park Hospital NHS Trust, Sheffield, UK. CORPORATE SOURCE:

Annals of oncology : official journal of the European SOURCE:

Society for Medical Oncology / ESMO, (2000 May)

Vol. 11, No. 5, pp. 541-6.

Journal code: 9007735. ISSN: 0923-7534.

PUB. COUNTRY: DOCUMENT TYPE: Netherlands (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

200012

ENTRY DATE:

Entered STN: 22 Mar 2001

Last Updated on STN: 22 Mar 2001 Entered Medline: 28 Dec 2000

AB BACKGROUND: Previous phase II studies of docetaxel have

indicated that hepatic metastases from breast cancer respond well to

first-line treatment with docetaxel. The objective of this

prospective, open label phase II study therefore was specifically to

evaluate the activity and safety of docetaxel in this

indication. PATIENTS AND METHODS: The study recruited 47 women (mean age

50 years, range 33-66 years) with hepatic metastases from breast cancer. who fulfilled the eligibility criteria. After premedication with steroids, patients received a one-hour intravenous infusion of

docetaxel 100 mg/m2 at three-weekly intervals for up to eight cycles. Response to treatment during medication was assessed after three, six and where appropriate, eight cycles and every three month follow-up

thereafter, until disease progression or death. RESULTS: The best overall response rate (ORR) for evaluable patients was 64.3% (95% CI: 48.0-78.5%). In terms of the primary efficacy parameters, the ORR at the sixth cycle of treatment was 62% (95% CI: 45%-80%) with 17% complete responses. The median duration of response was 139 days (95% CI: 111-216 days) and the median survival duration calculated on an intent-to-treat basis was 335

days (227-568 days, 95% CI). One (2%) toxic death was reported. CONCLUSIONS: Docetaxel is a highly effective cytotoxic agent in the treatment of patients with liver metastases from breast cancer.

L12 ANSWER 29 OF 55 MEDLINE on STN ACCESSION NUMBER: 1998056505 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 9446016

TITLE:

[Docetaxel (taxotere) for therapy of breast

carcinoma. Highest effectiveness with moderate side

effects].

Docetaxel (Taxotere) zur Therapie des

Mammakarzinoms. Hochste Wirksamkeit bei moderaten

Nebenwirkungen.

AUTHOR:

von Minckwitz G; Costa S D

CORPORATE SOURCE:

Klinik fur Gynakologie und Geburtshilfe, Johann Wolfgang

Goethe-Universitat Frankfurt.. minckwitz@em.uni-

frankfurt.de

SOURCE:

Medizinische Klinik (Munich, Germany: 1983), (1997

Sep 15) Vol. 92 Suppl 4, pp. 4-9. Ref: 16 Journal code: 8303501. ISSN: 0723-5003.

PUB. COUNTRY: GERMANY: Germany, Federal Republic of DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

German

FILE SEGMENT:

Priority Journals.

ENTRY MONTH:

199801

ENTRY DATE:

Entered STN: 6 Feb 1998

General Review; (REVIEW)

Last Updated on STN: 6 Feb 1998 Entered Medline: 27 Jan 1998

AB CLINICAL RESULTS: Docetaxel is a taxan which has proven high efficacy in the treatment of breast cancer. The results are consistent throughout all phases of clinical evaluation. High response rates have been observed especially for women after failure of anthracyclins or with liver metastases. Response rates are superior to doxorubicin, while the extent of the side effects is comparable. CONCLUSION: Due to the different toxicity profile a combination of docetaxel and anthracyclins is feasible and has already been demonstrated in early clinical trials. The role of the combinatory treatments in first line or adjuvant setting is currently under investigation.

L12 ANSWER 30 OF 55 MEDLINE ON STN ACCESSION NUMBER: 96351131 MEDLINE DOCUMENT NUMBER: PubMed ID: 8745348

TITLE: Docetaxel: a new defence in the management of

breast cancer.

AUTHOR: Piccart M

CORPORATE SOURCE: Department of Chemotherapy, Institut Jules Bordet,

Brussels, Belgium.

SOURCE: Anti-cancer drugs, (1995 Jul) Vol. 6 Suppl 4, pp.

7-11. Ref: 12

Journal code: 9100823. ISSN: 0959-4973.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199610

ENTRY DATE: Entered STN: 25 Oct 1996

Last Updated on STN: 25 Oct 1996 Entered Medline: 16 Oct 1996

The results of nine phase II trials of docetaxel in the first-AB and second-line treatment of patients with advanced breast cancer are summarized. All 316 patients included in this report received docetaxel at a dose of 100 mg/m2 administered over 1 h every 3 weeks on an outpatient basis. One hundred and fifty-four patients received docetaxel as first-line therapy for advanced disease, half of whom had received prior adjuvant chemotherapy (finished at least 1 year previously). An overall response rate of 59% (95% CI: 51-67) was achieved in these patients, with a median duration of response of 8.3 months and a median time to progression of 4.9 months. Similar results were seen in a subgroup of 68 patients with liver metastases. Among the 162 patients given docetaxel as second-line therapy, 134 had strictly defined anthracycline-resistant disease; 73 had liver metastases. The combined overall response rate for anthracycline-resistant patients in two US studies was 48% (95% CI: 37-59) while that in a multicenter French study was 29% (95% CI: 18-44). The median duration of response in each case was 6.3 and 5.5 months, respectively, with an overall median survival duration of 11 and 10 months, respectively. Among patients with liver metastases, second-line treatment with docetaxel achieved an overall response rate of 32%, a median duration of response of 7.8 months and a median survival duration of 9 months. These results for docetaxel as both first- and second-line therapy are comparable with those achieved with doxorubicin and are particularly promising in patients with liver metastases and anthracycline-resistant disease.

L12 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:736476 CAPLUS

DOCUMENT NUMBER: 131:346535

TITLE: Use of neomycin for treating angiogenesis-related

diseases

INVENTOR(S): Hu, Guo-Fu; Vallee, Bert L.

PATENT ASSIGNEE(S): The Endowment for Research In Human Biology, Inc., USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
PATENT NO.
                               DATE
                                           APPLICATION NO.
                                                                  DATE
                        KIND
                               -----
                                           ______
     -----
                               19991118
                                           WO 1999-US10269
                                                                 19990511 <--
    WO 9958126
                         A1
        W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
            DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
            JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
            MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
            TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
            MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
            ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
            CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2331620
                         AΑ
                               19991118 CA 1999-2331620
                                                                  19990511 <--
                               19991129
                                           AU 1999-39804
    AU 9939804
                         A1
                                                                  19990511 <--
                               20010321 + EP 1999-922915
    EP 1083896
                         A1
                                                                  19990511
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI
                                           US 2000-700436
    US 6482802
                         B1
                               20021119
                                                                  20001109
                                                               P
PRIORITY APPLN. INFO.:
                                           US 1998-84921P
                                                                 19980511
                                           WO 1999-US10269
                                                              W 19990511
```

AB The present invention is directed to using neomycin or an analog thereof as a therapeutic agent to treat angiogenesis-related diseases, which are characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-angiogenic agent or an anti-neoplastic agent. The present invention is further directed to a method for screening neomycin analogs having anti-angiogenic activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases. A dose of 20 ng neomycin/embryo or higher completely inhibited angiogenin-induced angiogenesis in the chorioallantoic membrane (CAM) assay. Neomycin inhibits angiogenin-induced angiogenesis mainly through inhibition of nuclear translocation of angiogenin.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

RN 114977-28-5 CAPLUS

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 32 OF 55 MEDLINE ON STN
ACCESSION NUMBER: 1999314769 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10408850

TITLE: Phase II study of docetaxel in patients with

metastatic pancreatic cancer: a Japanese cooperative study.

Cooperative Group of Docetaxel for Pancreatic

Cancer in Japan.

AUTHOR: Okada S; Sakata Y; Matsuno S; Kurihara M; Sasaki Y; Ohashi

Y; Taguchi T

CORPORATE SOURCE: Department of Internal Medicine, National Cancer Center

Hospital, Tokyo, Japan.

SOURCE: British journal of cancer, (1999 May) Vol. 80,

No. 3-4, pp. 438-43.

Journal code: 0370635. ISSN: 0007-0920.

PUB. COUNTRY: SCOTLAND: United Kingdom

DOCUMENT TYPE: (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199907

ENTRY DATE: Entered STN: 27 Jul 1999

Last Updated on STN: 27 Jul 1999 Entered Medline: 15 Jul 1999

AΒ Docetaxel has been reported to show promising anti-tumour activity in pancreatic ductal cancer (PC). This study was conducted to evaluate the activity and toxicity of moderate-dose (60 mg m(-2)) docetaxel in Japanese chemo-naive patients with measurable metastatic PC. The patients had a performance status of 0-2. received docetaxel intravenously over a 1- to 2-h period without any premedication for hypersensitivity reactions. This treatment was repeated every 3-4 weeks with dose adjustments based on the toxic effects observed. Twenty-one patients were eligible and treated with docetaxel. The median number of courses was 2 (range, 1-4). None of the patients achieved an objective response; seven showed no change and 13 showed progressive disease. In one patient, the response was not assessable because of early death. The median survival time for all patients was 118 days. The main grade 3-4 toxicities by patient were leucocytopenia (67%) and neutropenia (86%). Other grade 3-4 toxicities included anaemia (10%), thrombocytopenia (5%), nausea/vomiting (29%), anorexia (29%), GOT/GPT increase (10%), alkaline phosphatase increase (14%), malaise/fatigue (33%) and alopecia (24%). In conclusion, docetaxel, administered on this schedule, did not show significant anti-tumour activity in patients with metastatic PC.

CAPLUS COPYRIGHT 2006 ACS on STN L12 ANSWER 33 OF 55 2000:824124 CAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 134:506 Treatment of refractory human tumors with epidermal TITLE: growth factor receptor antagonists Waksal, Harlan W. INVENTOR(S): Imclone Systems Incorporated, USA PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 31 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ _____ ______ WO 2000-US11756 WO 2000069459 A1 20001123 20000501 <--W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2373815 AA 20001123 CA 2000-2373815 20000501 <--BR 2000010524 Α 20020528 BR 2000-10524 20000501 EP 2000-928671 EP 1218032 A1 20020703 20000501 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL HU 200201480 HU 2002-1480 A2 20020828 20000501 EE 200100603 20030217 EE 2001-603 Α 20000501 **T**2 JP 2003520195 20030702 JP 2000-617919 20000501 AU 782994 B2 20050915 AU 2000-46871 20000501 CN 1720994 CN 2005-10055865 Α 20060118 20000501 US 2002012663 **A1** 20020131 US 2001-840146 20010424 NO 2001005546 Α NO 2001-5546 20020114 20011113 ZA 2001009347 Α 20030213 ZA 2001-9347 20011113 BG 106110 BG 2001-106110 Α 20020430 20011114 20030821 US 2001-996954 US 2003157104 A1 20011130 A1 20050526 US 2005112120 US 2004-18950 20041220 PRIORITY APPLN. INFO.: US 1999-312284 A 19990514 US 1999-374028 A 19990813 CN 2000-810321 A3 20000501 WO 2000-US11756 W 20000501 US 2001-840146 A1 20010424 A method of inhibiting the growth of refractory tumors that are stimulated AB by a ligand of epidermal growth factor in human patients comprises treating the human patients with an effective amount of an epidermal growth factor receptor antagonist, e.g. a monoclonal antibody. TT 114977-28-5, Docetaxel RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (EGF receptor antagonists for treatment of refractory human tumors) 114977-28-5 CAPLUS RN CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI)

INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:454255 CAPLUS

DOCUMENT NUMBER: 131:92524

TITLE: Therapeutic liposome-encapsulated immunomodulators

INVENTOR(S): Spitler, Lynn E.; Fidler, Issaiah J.

PATENT ASSIGNEE(S): Jenner Biotherapies, Inc., USA

SOURCE: PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	TENT	NO. KIND					DATE	E APPLICATION NO.							DATE			
WO	9935	162			A1	-	1999	 0715		 WO 1	 999-1	US27:	- <i></i> 2		1	9990	 106 ·	<
	W:	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DΕ,	
		DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	
		ΚE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	
		MW,	MX,	NO,	ΝZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	
		TR,	TT,	UA,	UG,	UZ,	VN,	ΥU,	ZW,	AM,	ΑZ,	BY,	KG,	KZ,	MD,	RU,	ΤJ,	TM
	RW:	GH,	GM,	ΚE,	LS,	MW,	SD,	SZ,	ŪĠ,	ZW,	ΑT,	ΒE,	CH,	CY,	DE,	DK,	ES,	
		FI,	FR,	GB,	GR,	ΙE,	ΙT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	
		CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG							
AU	9922	141			A1		1999	0726		AU 1	999-	2214	1		1	9990	106 •	<
US	2003	0179	76		A1		2003	0123	•	US 2	001-	76454	46		2	0010	117	
US	2004	1465	52		A1		2004	0729		US 2	003-	7056:	18		2	0031	110	
PRIORIT	Y APP	LN.	INFO	. :						US 1	998-	7071	7 P		P 1	9980:	107	
									•	US 1	999-:	2260	75		B1 1	9990:	106	
									•	WO 1	999-1	JS27:	2	1	W 1	9990:	106	
3.D ml-											001-					0010		

The present invention relates to the use of novel compns. of lipopeptides that are immunomodulators encapsulated as liposomes or free-form for the treatment of neoplasia and in reducing chemotherapeutically induced cellular pathol., including mucositis. These lipopeptides may be administered alone or in combination with a second antineoplastic agent. E.g., a synthetic JBT 3002 lipopeptide entrapped in phosphatidylcholine/phosphatidylserine liposomes is shown to be a potent activator of tumoricidal properties of murine macrophages by a mechanism that differs from that of lipopolysaccharides. These data highly support the in vivo use of multilamellar liposome-encapsulated JBT 3002 to enhance host resistance to infections and cancer.

IT 114977-28-5, Taxotere

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination with; free or liposome-encapsulated lipopeptide immunomodulators for tumor treatment and reduction of antitumor adverse effects)

RN 114977-28-5 CAPLUS

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

MEDLINE on STN L12 ANSWER 35 OF 55 ACCESSION NUMBER: 97356889 MEDLINE DOCUMENT NUMBER: PubMed ID: 9213325

TITLE: Docetaxel combined with vinorelbine: phase I

results and new study designs.

AUTHOR: Fumoleau P; Fety R; Delecroix V; Perrocheau G; Azli N

CORPORATE SOURCE: Medical Oncology Department, Centre Rene Gauducheau, CRLCC

Nantes-Atlantique, Nantes-St Herblain, France.

SOURCE: Oncology (Williston Park, N.Y.), (1997 Jun) Vol.

> 11, No. 6 Suppl 6, pp. 29-31. Journal code: 8712059. ISSN: 0890-9091.

PUB. COUNTRY: United States DOCUMENT TYPE:

(CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE I) Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199709

ENTRY DATE: Entered STN: 16 Sep 1997

> Last Updated on STN: 16 Sep 1997 Entered Medline: 2 Sep 1997

AB This was a phase I dose-finding and pharmacokinetic study of vinorelbine (Navelbine) and docetaxel (Taxotere) as first-line chemotherapy for metastatic breast cancer. Vinorelbine dose, 20 or 22.5 mg/m2, on days 1 and 5, was followed on day 1 by docetaxel every 21 days, in doses increasing from 60 to 100 mg/m2. Two maximum tolerated doses were reached, the first at 75 mg/m2 of docetaxel and 22.5 mg/m2 of vinorelbine, and the second at 100 mg/m2 of docetaxel and 20 mg/m2 of vinorelbine. Symptomatic peripheral neuropathy was not observed.

The recommended doses for phase II studies are 75 to 85 mg/m2 of docetaxel on day 1 and 20 mg/m2 of vinorelbine on days 1 and 5, every 3 weeks. The treatment regimen, which included 3-day corticosteroid prophylaxis, resulted in only mild fluid retention. Responses were seen at all dose levels, with an 80% overall response rate at the higher recommended dose; the overall response rate for patients at all dose levels was 66%. A high rate of response, including a complete response, was observed in patients with liver metastases.

L12 ANSWER 36 OF 55 MEDLINE on STN ACCESSION NUMBER: 96150144 MEDLINE DOCUMENT NUMBER: PubMed ID: 8546908

A late phase II study of RP56976 (docetaxel) in TITLE:

patients with advanced or recurrent breast cancer.

Adachi I; Watanabe T; Takashima S; Narabayashi M; Horikoshi AUTHOR:

N; Aoyama H; Taguchi T

CORPORATE SOURCE: Department of Medical Oncology, National Cancer Center

Hospital, Tokyo, Japan.

SOURCE: British journal of cancer, (1996 Jan) Vol. 73,

No. 2, pp. 210-6.

Journal code: 0370635. ISSN: 0007-0920.

PUB. COUNTRY: SCOTLAND: United Kingdom

(CLINICAL TRIAL) DOCUMENT TYPE:

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199602

ENTRY DATE: Entered STN: 6 Mar 1996

> Last Updated on STN: 6 Feb 1998 Entered Medline: 16 Feb 1996

AB A late phase II clinical trial of RP56976 (docetaxel), derived from Taxus baccata was performed to evaluate anti-tumour activity, time to progression and clinical toxicity in patients with advanced or recurrent breast cancer. The patients, between 15 and 80 years old with performance status (PS) of 0-2, received at least two cycles of docetaxel 60 mg m-2 intravenously at 3-4 week intervals. Of the 81 patients enrolled, the 72 eligible for the study were given a total of 327 cycles, with a median of four cycles each. Five patients obtained a complete response (CR) and 27 a partial response (PR); the response rate (RR) was 44.4% (95% confidence interval 32.7-56.6%). A relatively high RR of 9/28 (32.1%) was observed in patients who had received prior chemotherapy involving anthracyclines. The dose-limiting toxicity was grade 3-4 leucocytopenia or neutropenia, found in 78.9% and 85.9% patients respectively. Other severe (grade > 3) toxicities included alopecia (38%), anorexia (18.3%), nausea/vomiting (11.3%), and fatigue (9.9%). Hypersensitivity reactions, oedema and skin toxicity were not severe and were reversible. therapy-related death occurred 10 days after the initial dose was given. These findings indicate that docetaxel has potent activity against metastatic breast cancer, and that the dose of 60 mg m-2 is safe.

L12 ANSWER 37 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:123598 CAPLUS

DOCUMENT NUMBER: 136:161350

TITLE: Method of inhibiting angiogenesis associated with

malignant and neoplastic cells using active vitamin D

analogs

INVENTOR(S): Bishop, Charles W.; Mazess, Richard B.

PATENT ASSIGNEE(S): Bone Care International, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S.

Ser. No. 596,149.

CODEN: USXXCO

DOCUMENT TYPE:

Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 20 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002019375 US 6573256	A1 B2	20020214	US 2001-891805	20010626
US 5763429	A	19980609	US 1996-781910	19961230 <
US 6537982 PRIORITY APPLN. INFO.:	B1	20030325	US 1998-596149 US 1996-781910	19980223 A3 19961230
				A2 19980223 A2 19930910
		•		A2 19940624
				A2 19950403 A2 19950607

OTHER SOURCE(S): MARPAT 136:161350

AB Methods are disclosed which use active vitamin D analogs for the inhibition of angiogenesis associated with malignant and neoplastic cells. Methods comprise the application of an effective amount of a hypocalcemic hydroxyvitamin D compound to inhibit the angiogenesis of malignant cells, induce the apoptosis of malignant cells, and regress the growth of tumor cells.

IT 114977-28-5, Docetaxel

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydroxyvitamin D compds. for inhibition of tumor-associated angiogenesis, and use with other agents)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 38 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2002:72803 CAPLUS

DOCUMENT NUMBER:

136:113175

TITLE:

Method of treating malignancy-associated hypercalcemia

using active vitamin D analogs

INVENTOR (S):

Bishop, Charles W.; Mazess, Richard B.

PATENT ASSIGNEE(S):

Bone Care International, Inc., USA

SOURCE:

U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S.

5,763,429. CODEN: USXXCO DOCUMENT TYPE: Patent LANGUAGE: English 20

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	TENT 1	NO.			KIN		DATE				ICAT				D	ATE		
	2002		65		A 1		2002	0124			001-				2	0010	626	
	6566				B2		2003	0520						19961230 <				
	5763																	<
	2451						2003											
	2003									WO 2	002-	US20	320		2	0020	626	
WO	2003																	
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	ВB,	ВG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
		CO,	CR,	.CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	ΗU,	ID,	IL,	IN,	ıs,	JP,	KΕ,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	NZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,	
		UA,	UG,	UZ,	VN,	YU,	ZA,	ZM,	ZW									
	RW:	GH,	GM,	KE,	LS,	MW	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,	AZ,	BY,	
							TM,											
			-	-	•	-	NL,						-			-		
					•		NE,				,	,	,	,	,	,	,	
ED	1416						2004				002-	7479	79		2	0020	626	
- 11							ES,											
	к.						RO,						шо,	мш,	JE,	MC,	ΕΙ,	
CN	1520	201	JΙ,	ш.,	лv,	гт,	2004	0011	CI,	CITIO	002-i	0120	71		2	0020	626	
	2004	20 E 4 .	2.0		шэ Т		2004	1125		TD 2	002-	C 1 2 0	/ <u>1</u>		2			
																0020		
	20032				AI		2003	1100										
PRIORIT	Y APP	⊔N	INFO	. :							996-				A2 1:			
											993-				A2 1			
											994 - :				A2 1:			
											995-4				A2 1			
											995-4				A2 1			
											998-				A3 1			
								•		US 2	001-	8917	63	i	A 2	0010	626	
										WO 2	002-1	JS20	320	1	W 2	0020	626	
OTHED CO	OTTDOE	/c) .			MADI	ידיעכ	136.	1121	75								•	

OTHER SOURCE(S): MARPAT 136:113175

Methods utilizing active vitamin D analogs for the treatment of malignancy-associated hypercalcemia. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to alleviate hypercalcemia, lower serum parathyroid hormone related protein (PTHrP) levels. The hypocalcemic vitamin D compds. can be coadministered with a cytotoxic agent.

114977-28-5, Docetaxel IT

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method of treating malignancy-associated hypercalcemia using active vitamin D analogs coadministered with cytotoxic agents)

RN 114977-28-5 CAPLUS

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2001:507531 CAPLUS

DOCUMENT NUMBER:

135:107247

TITLE:

Preparation of 3-heteroarylidenyl-2-indolinone

compounds for modulating protein kinase activity and

for use in cancer chemotherapy

INVENTOR(S):

Langecker, Peter J.; Shawver, Laura K.; Tang, Peng C.;

Sun, Li

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 93 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	TENT	NO.			KINI)	DATE	,				ION			D.	ATE		
						-									-			
WO	2001	0492	87		A1		2001	0712		WO 2	000-	US18	058		2	0000	630	
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	ВA,	BB,	ВG,	BR,	BY,	CA,	CH,	CN,	CR,	
		CU,	CZ,	DΕ,	DK,	DM,	DZ,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	GM,	HR,	ΗU,	
		ID,	ΙL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	
		LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	
		SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZW
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	
												SN,						
WO	2000														1	9991	230 -	<
	W:	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
												HU,						
				-	-			-	-	-		LU,	•		•		•	
												SG,						
							VN,			•	•	•	•	•	•	•	•	
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	
				-			-	-		-		NL,		-	-	-	-	
	•	CG,	CI,	CM,	GA.	GN.	GW,	ML,	MR.	NE.	SN.	TD,	TG	•	•	•	•	
US	2003														1	9991:	230	
	1259											94333						
EP	1259	234																
	R:	AT,	BE,	CH,	DE.	DK.	ES.	FR.	GB,	GR,	IT.	LI,	LU.	NL.	SE.	MC.	PT.	
							RO,					•	•	•	•	•	•	
JP	2003			-					•		001-	5496	55		2	0000	530	
US	2003	1911	52		A1		2003	1009		US 20	002-	30748	33		2	0021	202	
PRIORITY												47623				9991		
												US312				99912		•
		•										56954		_		0000		
												1143						
								•			_			-				

OTHER SOURCE(S):

MARPAT 135:107247

$$R^4$$
 $C-R^3$
 R^5
 R^6
 R^7
 R^1

Ι

The present invention relates to 3-heteroarylidenyl-2-indolinone compds. AB [I; R1 = H, alkyl; R2 = O, S; R3 = H; R4 , R5, R6, R7 = H, alkyl, alkoxy, aryl, aryloxy, alkaryloxy, halo, trihalomethyl, S(O)R, SO2NRR', SO3R, SR, NO2, NRR', OH, cyano, COR, O2CR, (CH2)nCO2R, CONRR'; A = a five membered heteroaryl selected from (un) substituted thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, etc.; n = 0-3; R, R' = H, alkyl, aryl] or physiol. acceptable salts or prodrugs thereof are prepared These compds. modulate the enzymic activity of protein kinases such as receptor protein tyrosine kinase, cellular tyrosine kinase, and serine threonine kinase and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. Furthermore, these compds. are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer. In a cellular-based assay for inhibiting the receptor phosphorylation, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2indolinone (II) inhibited Flk-1-autophosphorylation with IC50 of .apprx.1 μM. II in vitro inhibited proliferation of endothelial cells induced by VEGF with IC50 of .apprx.0.07 µM. Although II in vitro had no direct inhibitory effect on a variety of tumor cell lines at concentration up

to

 $50~\mu\text{M},$ it in vivo demonstrated a significant suppression of tumor growth against a broad spectrum of tumor types s.c. implanted into immunocompromised mice and whose growth are driven by various growth factors such as PDGF, EGF, and Her2.

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for cancer chemotherapy in combination with heteroarylidenylindolinone derivative; preparation of 3-heteroarylidenyl-2-indolinone compds. for modulating protein kinase activity for cancer chemotherapy)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 40 OF 55 MEDLINE ON STN ACCESSION NUMBER: 2000024226 MEDLINE DOCUMENT NUMBER: PubMed ID: 10560436

TITLE: A case of hepatic arterial infusion chemotherapy with

docetaxel for liver metastasis from breast cancer.

AUTHOR: Kim S J; Maeura Y; Ueda N; Saito M; Matsunaga S

CORPORATE SOURCE: Senri Hoken Medical Center, Dept. of Surgery, Shinsenri

Hospital.

SOURCE: Gan to kagaku ryoho. Cancer & chemotherapy, (1999)

Oct) Vol. 26, No. 12, pp. 1959-62.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY: Japan

DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199911

ENTRY DATE: Entered STN: 13 Jan 2000

Last Updated on STN: 13 Jan 2000 Entered Medline: 26 Nov 1999

AB We experienced a case of hepatic arterial infusion chemotherapy using docetaxel for liver metastasis, which showed no response to CEF therapy, from breast cancer. A 63-year-old woman had undergone modified radical mastectomy for right breast cancer (T2aN1bM0: Stage II) in October, 1995. Six-cycle CMF therapy and toremifene citrate (40 mg/day) were administered as adjuvant therapy, but multiple recurrent tumors in liver, lung, and local site were detected in February 1997. Six-cycle CEF therapy was given for recurrent disease and there was a complete response for lung and local recurrence, but no change in liver metastasis. Chemoendocrine therapies using 5'-DFUR or CMitF in addition to TAM and fadrozole hydrochloride hydrate had developed progressive disease for liver metastasis. A catheter and port kit were operatively inserted and implanted in March 1998. Hepatic arterial infusion of docetaxel (30-40 mg/body/month, one hour administration) was repeated 4 times, once in our clinic. Leukopenia, general fatigue and fever, which were mild and did not require any treatment, appeared as side effects. This treatment reduced multiple liver metastatic sites on abdominal CT finding and was thought to be a partial response. However, the patient had multiple brain metastasis and died on August 2, 1998. While docetaxel, even by systemic administration, has a 36-77% response rate for liver metastasis, arterial infusion might have a good response and mild side effect with a lower dose than by intravenous administration.

L12 ANSWER 41 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2001:161407 CAPLUS

DOCUMENT NUMBER:

134:202681

TITLE:

Dietary supplementation with, and methods for, administration of a yeast-derived selenium product,

and use in cancer chemotherapy

INVENTOR(S):

Hsia, Houn Simon; Yang, Ping; Arnold, Michael

PATENT ASSIGNEE(S):

Viva America Marketing Corporation, USA U.S., 9 pp., Cont.-in-part of U.S. 6,140,107.

SOURCE: CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6197295	B1	20010306	US 1999-303993	19990503
US 6140107	Α	20001031	US 1996-719572	19960925 <
US 6368643	B1	20020409	US 1999-298114	19990423
US 2001043925	A1	20011122	US 2001-801124	20010305
US 6576233	B2	20030610		
PRIORITY APPLN. INFO.:			US 1996-719572	A2 19960925
			US 1997-802773	B2 19970221
•		•	US 1998-15758	A2 19980129
			US 1998-82939P	P 19980424
			US 1999-303993	A3 19990503

ЪВ The invention solves the need for nontoxic forms of selenium which is an essential part of the human diet. The invention provides dried-yeast products containing selenium, as well as a method of producing the dried yeast products. The method uses selenium having high biol. activity but low toxicity. The invention also provides nutritional supplements containing the selenium-containing dried yeast products and methods of administering these products and supplements to improve human health. The invention also provides a practically nontoxic yeast selenium product having increased intracellular selenium concns., as well as methods to reduce tumor cell growth by administration of a selenium yeast product comprising yeast Saccharomyces boulardii sequela PY31 (ATCC 74366) in combination with chemotherapeutic agents.

TT 114977-28-5, Taxotere

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(dietary supplementation with yeast-derived selenium product, and use in cancer chemotherapy)

RN 114977-28-5 CAPLUS

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 42 OF 55 MEDLINE ON STN
ACCESSION NUMBER: 2001191709 MEDLINE

DOCUMENT NUMBER: PubMed ID: 11124653

TITLE: Chemotherapy-induced noncardiogenic pulmonary edema related

to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.

AUTHOR: Briasoulis E; Froudarakis M; Milionis H J; Peponis I;

Constantopoulos S; Pavlidis N

CORPORATE SOURCE: Department of Medical Oncology, Ioannina University

Hospital, Ioannina, Greece.. ebriasou@otenet.gr

SOURCE: Respiration; international review of thoracic diseases,

(2000) Vol. 67, No. 6, pp. 680-3.

Journal code: 0137356. ISSN: 0025-7931.

PUB. COUNTRY: Switzerland DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200104

ENTRY DATE: Entered STN: 10 Apr 2001

Last Updated on STN: 10 Apr 2001

Entered Medline: 5 Apr 2001

AB Several cancer therapeutic agents have been associated with pulmonary toxicity. Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema (NPE) while on treatment with gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor (G-CSF) support. Gemcitabine, a deoxycytidine analogue, is reported to produce mild self-limiting and only occasionally severe pulmonary toxicity. microtubule stabilizer docetaxel has been associated with water retention complications. The combination of these two agents has shown promising activity in several solid tumors and is in a phase of clinical development with prophylactic G-CSF in most of the trials due to the high rate of dose-limiting neutropenia observed with this combination. In our case pulmonary toxicity resolved rapidly following the administration of corticosteroids. A possible deleterious synergy of the compounds involved in this case is discussed and the medical literature on NPE related to cancer therapy is shortly reviewed. We conclude that NPE should always be considered in patients with respiratory function deterioration while on therapy with the gemcitabine-docetaxel combination and G-CSF. Corticosteroids can provide maximum benefit if started early upon diagnosis coupled with withdrawal of the causative drugs. Copyright 2000 S. Karger AG, Basel

ACCESSION NUMBER: 1999197818 MEDLINE DOCUMENT NUMBER: PubMed ID: 10097745

A late phase II clinical study of RP56976 (TITLE:

docetaxel) in patients with advanced or recurrent

gastric cancer: a cooperative study group trial (group B). Mai M; Sakata Y; Kanamaru R; Kurihara M; Suminaga M; Ota J;

AUTHOR:

Hirabayashi N; Taguchi T; Furue H

CORPORATE SOURCE: Dept. of Surgery, Cancer Research Institute, Kanazawa

University.

Gan to kagaku ryoho. Cancer & chemotherapy, (1999 SOURCE:

Mar) Vol. 26, No. 4, pp. 487-96.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY: Japan

(CLINICAL TRIAL) DOCUMENT TYPE:

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199904

ENTRY DATE: Entered STN: 13 Apr 1999

Last Updated on STN: 13 Apr 1999

Entered Medline: 1 Apr 1999

AB A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer was performed to evaluate the anti-tumor activity and clinical toxicity as a multicenter cooperative trial. Docetaxel was administered intravenously at a dose of 60 mg/m2 every 3-4 weeks. Of 72 patients enrolled, 63 patients were eligible and 59 patients were evaluable for response. The anti-tumor effects obtained complete response (CR) in one patient partial response (PR) in 13, minor response (MR) in 3, no change (NC) in 20, and progressing disease (PD) in 22 patients. The overall response rate in 59 patients was 23.7% (14/59). For 14 CR or PR cases, a response appeared 10 to 107 days (median 33.5 days) and 1 to 8 (median 2) times of dosing after the initial administration. The response rate was 9.5% in the primary tumor, 31.3% livers, 50.0% abdominal tumor, and 24.1% lymph nodes, respectively. The major adverse reactions were gastrointestinal symptoms including nausea/vomiting, anorexia, fatigue, alopecia and fever. Leukocytopenia and neutrocytopenia were also observed with a high incidence, but they recovered after 8 days from the nadir. The results show that docetaxel is an effective anti-tumor agent for advanced or recurrent gastric cancer. It is necessary to conduct another clinical trial by concomitant administration with other anti-tumor agents.

L12 ANSWER 44 OF 55 MEDLINE on STN ACCESSION NUMBER: 1999014548 MEDLINE DOCUMENT NUMBER: PubMed ID: 9797814

TITLE: Late phase II clinical study of RP56976 (docetaxel

) in patients with advanced/recurrent gastric cancer: a

Japanese Cooperative Study Group trial (group A).

AUTHOR: Taguchi T; Sakata Y; Kanamaru R; Kurihara M; Suminaga M; Ota J; Hirabayashi N

Japan Society for Cancer Chemotherapy, Aomori Prefectural

Central Hospital. SOURCE: Gan to kagaku ryoho. Cancer & chemotherapy, (1998)

Oct) Vol. 25, No. 12, pp. 1915-24.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY: Japan

CORPORATE SOURCE:

DOCUMENT TYPE:

(CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals ENTRY MONTH:

199811

ENTRY DATE:

Entered STN: 6 Jan 1999

Last Updated on STN: 6 Jan 1999 Entered Medline: 4 Nov 1998

A late phase II clinical study of RP56976 (docetaxel) was AB

conducted in patients with advanced/recurrent gastric cancer as a

multicenter cooperative trial. Docetaxel was administered intravenously at a dose of 60 mg/m2 every 3-4 weeks. Of the 76 patients enrolled, 66 patients were eligible and 59 patients were evaluable for response. One patient showed complete response (CR), 13 patients partial response (PR), 1 patient minor response (MR), 19 patients no change (NC) and 25 patients had progressive disease (PD). The overall response rate in 59 evaluable patients was 23.7% (95% CI = 13.6-36.6%). The primary tumor showed a 4.3% (1/23) response, while the metastatic lesions in the abdomen, pelvic mass, lung, liver, and lymph nodes showed response rates of 62.5% (5/8), 33.3% (1/3), 33.3% (1/3), 14.8% (4/27), and 13.9% (5/26), respectively. About hematological toxicity, severe (Grade 3 or more) leukopenia was observed in 36 patients (56.3%) and neutropenia in 52 patients (81.3%). Other major toxicity (Grade 3 or more) included nausea/vomiting in 11 patients (17.2%), anorexia in 9 patients (14.1%), fatigue in 5 patients (7.8%), and alopecia in 7 patients (10.9%), all

which were tolerable. The results show that docetaxel is an effective anticancer agent for advanced/recurrent gastric cancer.

L12 ANSWER 45 OF 55 MEDLINE on STN

ACCESSION NUMBER:

2000464139 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 11016005

TITLE:

A case of effective chemotherapy using CAF followed by

docetaxel for advanced breast cancer.

AUTHOR:

Kokufu I; Taniguchi H; Kim Y H; Fukuda K; Yamamoto M; Yano

T; Yamada K; Kitano H; Fukuda H

CORPORATE SOURCE:

Dept. of Surgery, Itami City Hospital.

SOURCE:

Gan to kagaku ryoho. Cancer & chemotherapy, (2000

Sep) Vol. 27, No. 10, pp. 1577-80.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY:

Japan

DOCUMENT TYPE:

(CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

Japanese

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

200010

ENTRY DATE:

Entered STN: 19 Oct 2000

Last Updated on STN: 19 Oct 2000 Entered Medline: 10 Oct 2000

AΒ A huge mass measuring 13 x 12 cm and wide cutaneous edema were detected in the right breast of a 51-year-old woman. Under a diagnosis of locally advanced breast cancer (T4bN2M1, stage IV) with liver metastases, we attempted sequential neoadjuvant chemotherapy. After three courses of CAF therapy (cyclophosphamide, doxorubicin (DXR), 5-FU), the primary tumor was decreased by 56% and the liver metastases had disappeared. A minor pathologic response was observed. Subsequently, three courses of docetaxel (TXT) administration were carried out. The primary tumor was then decreased by 75% and the axillary metastases had disappeared. Histopathological examination showed gross viable tumor cells in the residual tumor and positive axillary lymph nodes. The only toxic effect was nausea (grade 1) and no major adverse effects were observed. Neoadjuvant chemotherapy with sequential DXR followed by TXT is a useful treatment for locally advanced breast cancer.

L12 ANSWER 46 OF 55

MEDLINE on STN

ACCESSION NUMBER:

1999430325 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 10500538

TITLE:

A case of recurrent breast cancer successfully treated with

docetaxel.

AUTHOR: Koshizuka K; Hada M; Muto S; Hagiwara J; Nakagomi H; Takano

K; Kamiya K; Tada Y

CORPORATE SOURCE: Second Dept. of Surgery, Yamanashi Medical University.

SOURCE: Gan to kagaku ryoho. Cancer & chemotherapy, (1999

Sep) Vol. 26, No. 10, pp. 1479-81.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY: Japan

DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199909

ENTRY DATE: Entered STN: 12 Oct 1999

Last Updated on STN: 12 Oct 1999 Entered Medline: 30 Sep 1999

AB A 53-year-old female underwent mastectomy for left breast cancer in April, 1993. She was given oral tamoxifen but this had to be discontinued due to its side effects. In March, 1998, she developed bone and lung metastases, in spite of treatment with combination chemotherapy (CEF). We thus treated here with docetaxel 90 mg three times and 40 mg six times. After the chemotherapy, she achieved complete remissions of the lung metastases and a decrease in serum CEA, CA 15-3, NCC-ST439, and BCA225. Adverse reactions to docetaxel were grade 2 alopecia, grade 4 neutropenia, dysgeusia, and fluid retention. All were tolerable. This new agent may play an important future role in chemotherapy for recurrent breast cancer.

L12 ANSWER 47 OF 55 MEDLINE ON STN ACCESSION NUMBER: 1998233482 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9571974

TITLE: Breast cancer with liver metastasis responsive to

docetaxel: case report.

AUTHOR: Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa

Y

CORPORATE SOURCE:

SOURCE:

Dept. of Surgery, Wakayama Medical College Kihoku Hospital.

Gan to kagaku ryoho. Cancer & chemotherapy, (1998

Apr) Vol. 25, No. 5, pp. 743-6.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY:

Japan

DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199805

ENTRY DATE: Entered STN: 14 May 1998

Last Updated on STN: 14 May 1998

Entered Medline: 7 May 1998

AB A 59-year-old female underwent mastectomy for right breast cancer in November 1992. She received tamoxifen and anthracycline-containing

November 1992. She received tamoxifen and anthracycline-containing chemotherapy as adjuvant therapy. In and after September 1994, she developed loco-regional recurrences five times in total, each of which was treated with surgery and conventional combination chemotherapy. In April 1997, she developed liver metastasis, which was refractory to biochemical modulation therapy (low-dose cisplatin + 5-FU). We, therefore, treated her six times with docetaxel 80 mg, which resulted in partial response of the liver metastasis and brought about a marked decrease in serum CA15-3 levels. Adverse effects of docetaxel were grade 3 alopecia and leucocytopenia. She has been well without re-growth of the liver metastasis for over five months.

L12 ANSWER 48 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1998:259786 BIOSIS DOCUMENT NUMBER: PREV199800259786

TITLE: Antitumour effect of docetaxel in malignant

diseases.

AUTHOR(S): Eckhardt, Sandor [Reprint author]

CORPORATE SOURCE: Rath Gyorgy u. 7-9, 1122 Budapest, Hungary SOURCE: Orvosi Hetilap, (April 12, 1998) Vol. 139, No.

15, pp. 867-872. print.

CODEN: ORHEAG. ISSN: 0030-6002.

DOCUMENT TYPE:

Article

General Review; (Literature Review)

LANGUAGE:

Hungarian

ENTRY DATE:

Entered STN: 9 Jun 1998

Last Updated on STN: 12 Aug 1998

AB In recent years numerous molecular biological discoveries enlightened the various steps of the neoplastic transformation. Based on new targets, this development made it possible to synthetize new tumour inhibitory substances. Among them taxanes capable to block depolymerization of tubulin - which is an essential molecule in cell division - play an important role. Docetaxel (Taxotere) belongs to this group and is an active drug in the treatment of breast cancer. Moreover, platinum-resistant tumours may also respond to the therapy. It is important to note that even visceral (hepatic) metastases may express chemosensitivity. Results of combination chemotherapy seem to be also promising. The antitumour effect of Taxotere in NSCLC and other malignant neoplasms In under investigation. The toxicity of Taxotere may be successfully reduced by premedication of steroids. The necessary protective measures render the Taxotere therapy safe and of being perspectivistic.

L12 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1999:325975 CAPLUS

DOCUMENT NUMBER:

130:357177

TITLE:

Detoxication of active pharmaceutical substances using

cyclodextrin oligomers

INVENTOR(S):

Moser, Joerg G.

PATENT ASSIGNEE(S):

Germany

SOURCE:

DOT Total

PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent German

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	TENT	NO.					DATE		APPLICATION NO.						DATE		
															-		
WO	9924	474			A1		1999	0520	1	WO 1:	998-1	EP72:	29		1:	9981	111 <
	W:	AL,	AU,	BA,	BB,	BG,	BR,	CA,	CN,	CU,	CZ,	EE,	GE,	HR,	HU,	ID,	IL,
		IS,	JP,	ΚP,	KR,	LC,	LK,	LR,	LS,	LT,	LV,	MG,	MK,	MN,	MX,	NO,	NZ,
		PL,	RO,	SG,	SI,	SK,	SL,	TR,	TT,	UA,	US,	UΖ,	VN,	YU,	AM,	AZ,	BY,
		KG,	ΚZ,	MD,	RU,	TJ,	TM										
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	ES,
							IT,										
							MR,					•	-	•	•	•	•
AU	9916							-	-	-		1669	4		1:	9981	111 <
EP	1045	863			A1		2000	1025	1	EP 19	998-	9611	84		1:	9981	111 <
EP	1045	863			B1		2003	0402									
	R:	AT,	BE,	CH,	DE,	ES,	FR,	GB,	IT,	LI,	NL						
JP	2001	5229	01		T2	·	2001	1120	٠,	JP 20	000-	52048	82		1:	9981	111
AT	2361	95			E		2003	0415	1	AT 1:	998-	96118	84		1:	9981	111
	6642						2003									0000	
PRIORITY	APP	LN.	INFO	. :								1974					
]	DE 19	998-	19822	2416		A 1	9980	519
									_			EP722		_		9981	
			_										-				-

AB Cyclodextrin oligomers with 2 cyclodextrins connected via a spacer B on the secondary side [CD-X-A-X-B-X-A-X-CD; CD = cyclodextrin; X = bond, NH,

O, S, C(O); A = bond, C2-4 aliphatic residue; B = rigid, preferably hydrophilic residue] form strongly hydrophilic inclusion compds. with pharmaceutical agents and thereby prevent toxic side effects of drugs on nontarget cells by inhibiting their uptake into the cells. The drugs can be targeted to specific tissue sites by attachment of affinity groups such as antibodies to the cyclodextrin residues, and the drug can be released at the target site by destruction of the cyclodextrin residues (e.g. with cyclodextrinase from Klebsiella oxytoca). Provided the cyclodextrins are connected on their secondary sides, their cavities will face each other; the distance between them is determined by the choice of spacer, and is preferably 0.8-1.8 nm. Thus, β -cyclodextrin was condensed with 4,4'-methylenebis(benzenesulfonyl chloride) and the product reacted with diaminopropane to form β -6(A-D)-diamidopropanediaminocyclodextrin (I). Sep., 2-monotosyl- β -cyclodextrin reacted with 3-mercaptopropionic acid to form \(\beta\)-(2)cyclodextrin-(3-thiopropionic acid) (II). Reaction of II with carbonyldiimidazole, Nhydroxysuccinimide, and a 2.5-fold molar excess of I produced a cyclodextrin trimer. Nude mice bearing OAT SCLC cell tumors were treated with biotinylated monoclonal antibody ICO 25 i.p., followed 24 h later by NeutrAvidin i.p., and after an addnl. 48 h by a biotinylcadaverine-labeled CD dimer-paclitaxel complex. Growth of the tumors was inhibited without occurrence of side effects.

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2006 ACS on STN L12 ANSWER 50 OF 55

1998:213711 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 128:289570

TITLE: Pharmacokinetics of anticancer agents in patients with

impaired liver function

AUTHOR(S): Donelli, M. G.; Zucchetti, M.; Munzone, E.; D'incalci,

M.; Crosignani, A.

Dipartimento di Oncologia, Istituto di Ricerche CORPORATE SOURCE:

Farmacologiche Mario Negri, Milan, 20157, Italy

SOURCE: European Journal of Cancer (1998), 34(1),

33-46

CODEN: EJCAEL; ISSN: 0959-8049

PUBLISHER: Elsevier Science Ltd. DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

A review with 95 refs. This report reviews published information on the clin. pharmacokinetics of antitumor agents in patients with liver dysfunction, associated with primary liver disease or liver metastases. Information was available for anthracyclines and their related compds., antimetabolites, cyclophosphamide, vinca alkaloids, taxanes and epipodophyllotoxins. Changes in the pharmacokinetic profile or metabolism in , patients with mild or severe hepatobiliary dysfunction are described and the relationships between serum levels, parameters employed for measuring hepatic function and toxic or therapeutic effects are examined Current knowledge of the pharmacokinetics of antineoplastic agents in liver disease is far from complete, mostly obtained in small nos. of non-homogeneous patients often presenting only moderate liver dysfunction, and empirical guidelines for dose assessment are still largely applied in clin. practice. Because of the complex pathophysiol. mechanisms of liver insufficiency in cancer patients, there is still doubt whether endogenous markers are useful. Although caution in treating cancer patients with liver insufficiency is compulsory, for most compds. there seems no need to recommend dose redns. for moderate impairment. However, for the tubulin acting agents, vincristine, vinblastine and possibly for paclitaxel and docetaxel, there is strong evidence that dose adjustment is mandatory in order to avoid excessive neutropenia and neurotoxicity.

REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L12 ANSWER 51 OF 55 MEDLINE on STN ACCESSION NUMBER: 2000390579 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 10895201

TITLE:

Preliminary results of multicenter phase II trial of

docetaxel (Taxotere) in combination with

doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.

AUTHOR:

Muthalib A; Darwis I; Prayogo N; Sutjipto

CORPORATE SOURCE:

Dharmais National Cancer Center/School of Medicine,

University of Indonesia, Jakarta.

SOURCE:

Gan to kagaku ryoho. Cancer & chemotherapy, (2000

May) Vol. 27 Suppl 2, pp. 498-504.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY:

Japan

DOCUMENT TYPE:

(CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE:

English FILE SEGMENT:

Priority Journals

ENTRY MONTH:

200008

ENTRY DATE:

Entered STN: 18 Aug 2000

Last Updated on STN: 18 Aug 2000 Entered Medline: 10 Aug 2000

AB RATIONALE: Docetaxel and doxorubicin have produced a high degree of activity in previously untreated/treated patients with metastatic breast cancer (MBC). The efficacy of Taxotere (T) single agent as 2nd line chemotherapy is well established in large randomized phase III studies. OBJECTIVE: The objective of this study is to confirm the efficacy and safety of a combination of Taxotere with doxorubicin as 1st line chemotherapy in Indonesian MBC patients. TREATMENT AND METHOD: Eighteen patients age < or = 70 years with advanced or metastatic breast cancer (MBC) with no prior taxane chemotherapy or prior cumulative doxorubicin (D) of no more than 250 mg/m2 and no heart disease were enrolled in this phase II study of D (50 mg/m2) IV bolus followed one hour later by Taxotere (T) 60 mg/m2 IV infusion over 1 hour every 3 weeks for 6 cycles treatments. A 3-day oral corticosteroid premedication was administered starting one day before the infusion of each cycle. Left ventricular ejection fraction (LVEF) was evaluated at baseline and after cycle 6. PATIENTS CHARACTERISTICS: 18 patients (pts) have been treated with 108 cycles administered. Median age was 46 years (31-58), WHO PS 0 = 50%, 1 = 50% and number of organs involved were: 2 (72%), 3 (22%) and 4 (6%). RESULTS: After 3 cycles, partial (PR) and no change (NC) responses occurred in 15 pts (83.3%) and 3 pts (16.7%). The best overall response after 6 cycles, including complete (CR) and partial (PR) responses, occurred in 13 pts (72.2%) including 3 CRs and 10 PRs. Two patients with extensive liver metastases at the baseline had a complete disappearance after 6 cycles. No patients developed congestive heart failure (CHF). Grade 3/4 hematological toxicities included leukopenia in 18 pts (100%), febrile neutropenia in 6 pts (33%), leukopenia with infection in 2 pts (11%), leukopenia with fever in 1 pt (5.5%), and anemia in 6 pts (33.3%). Nonhematological toxicities grade 3/4 included alopecia (61%), asthenia (4.6%), nausea/vomiting (2.7%), pain (2.7%), stomatitis (2.7%), and diarrhoea (0.9%). Leukopenia was generally of short duration, occurred mainly during the first and second cycle, and did not require any dose reduction. There was one death due to progressive disease after six cycles of treatment. CONCLUSION: Taxotere--doxorubicin combination is very active in the first-line treatment of MBC, seems to be especially effective in patients with liver metastases, and is associated with a manageable toxicity profile.

L12 ANSWER 52 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:89699 BIOSIS DOCUMENT NUMBER: PREV200100089699

TITLE: Phase I study of weekly docetaxel in combination

with capecitabine in patients with solid malignancies.

Villalona-Calero, M. A. [Reprint author]; Shapiro, C.

[Penrint author]: Otterson, G. A. [Reprint author]: Hauc

[Reprint author]; Otterson, G. A. [Reprint author]; Hauger, M. [Reprint author]; Kraut, E. [Reprint author]; Clinton, S. [Reprint author]; Shah, M. [Reprint author]; Stanek, M.

[Reprint author]; Monk, J. P. [Reprint author]

CORPORATE SOURCE: Arthur James Cancer Center and R Solove Research Institute,

Ohio State University, Columbus, OH, USA

SOURCE: Breast Cancer Research and Treatment, (November,

2000) Vol. 64, No. 1, pp. 125. print.

Meeting Info.: 23rd Annual San Antonio Breast Cancer Symposium. San antonio, Texas, USA. December 06-09, 2000. Cancer Therapy and Research Center Research Foundation.

CODEN: BCTRD6. ISSN: 0167-6806.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

AUTHOR (S):

ENTRY DATE: Entered STN: 14 Feb 2001

Last Updated on STN: 12 Feb 2002

L12 ANSWER 53 OF 55 MEDLINE ON STN ACCESSION NUMBER: 2000339901 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10885392

TITLE: Metastasectomy as a cytoreductive strategy for treatment of

isolated pulmonary and hepatic metastases from breast

cancer.

AUTHOR: Bathe O F; Kaklamanos I G; Moffat F L; Boggs J; Franceschi

D; Livingstone A S

CORPORATE SOURCE: Department of Surgery, University of Miami, FL 33136, USA...

bathe@worldnet.att.net

SOURCE: Surgical oncology, (1999 Jul) Vol. 8, No. 1, pp.

35-42. Ref: 45

Journal code: 9208188. ISSN: 0960-7404.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200007

ENTRY DATE: Entered STN: 28 Jul 2000

Last Updated on STN: 28 Jul 2000 Entered Medline: 20 Jul 2000

AB The authors sought to examine the utility of resection in conjunction with adjuvant chemotherapy for treatment of metastases from breast cancer isolated to the liver or lungs. Limitations of regional therapy were examined and potential agents for systemic therapy were reviewed. As resection of metastases is a controversial therapeutic approach, no clinical trials are available for review. Rather, evidence for a potential role for surgery rests on retrospective studies of small series of patients. Technical advances have rendered resection of liver and lung metastases safe. Long-term results as reported by other investigators support the role of metastasectomy in selected patients. The site of failure following ablation of liver metastases is usually in the liver. Following resection of lung metastases, nonpulmonary and disseminated recurrences are most common. Adjuvant therapy with docetaxel or any other agent or combination with significant activity against visceral metastases might potentiate long-term results.

L12 ANSWER 54 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:77815 BIOSIS

DOCUMENT NUMBER: PREV200100077815

TITLE: A phase II trial of escalated dose docetaxel

(TXT) with G-CSF support in patients (pts) with advanced

breast cancer.

AUTHOR(S): Mitchell, P. [Reprint author]; Basser, R.; Harris, M.

[Reprint author]; Ng, S.; Gibbs, P. [Reprint author]; Chipman, M. [Reprint author]; Grigg, A.; Jeffrey, A.; James, R.; Gargano, J.; Riva, A.; Appia, F.; Green, M.

CORPORATE SOURCE: Medical Oncology, Austin and Repatriation Medical Centre, Heidelberg West, VIC, Australia

SOURCE: Breast Cancer Research and Treatment, (November,

2000) Vol. 64, No. 1, pp. 88. print.

Meeting Info.: 23rd Annual San Antonio Breast Cancer Symposium. San antonio, Texas, USA. December 06-09, 2000. Cancer Therapy and Research Center Research Foundation.

CODEN: BCTRD6. ISSN: 0167-6806.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 7 Feb 2001

Last Updated on STN: 12 Feb 2002

L12 ANSWER 55 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on

 \mathtt{STN}

ACCESSION NUMBER: 2001:132253 BIOSIS DOCUMENT NUMBER: PREV200100132253

TITLE: Close correlation of paraneoplastic hyperfibrinolysis with

relapse and remission of anaplastic small cell carcinoma: A

case report.

AUTHOR(S): Kegel, T. [Reprint author]; Kellner, O. [Reprint author];

Grothey, A. [Reprint author]; Wolf, H.-H. [Reprint author];

Voigt, W. [Reprint author]; Dorligshaw, O. [Reprint

author]; Schmoll, H.-J. [Reprint author]

CORPORATE SOURCE: Dept. of Hematology/Oncology, University of Halle, Halle,

Germany

SOURCE: Onkologie, (October, 2000) Vol. 23, No.

Sonderheft 7, pp. 184. print.

Meeting Info.: Annual Meeting of the German and Austrian Society for Hematology and Oncology. Graz, Austria. October

21-25, 2000.

CODEN: ONKOD2. ISSN: 0378-584X.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 14 Mar 2001

Last Updated on STN: 15 Feb 2002



```
L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
```

RN 114977-28-5 REGISTRY

ED Entered STN: 25 Jun 1988

Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)- α -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydró-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-ylester, [2aR-[2a α ,4 β ,4a β ,6 β ,9 α (α R*, β S*),11 α ,12 α ,12a α ,12b α]]-

OTHER NAMES:

CN Docetaxel

CN Docetaxol

CN N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol

CN RP 56976

CN Taxotere

FS STEREOSEARCH

DR 216252-50-5

MF C43 H53 N O14

CI COM

SR CA

STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3431 REFERENCES IN FILE CA (1907 TO DATE)

132 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

3480 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/083565

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:35:31 ON 06 DEC 2006

=> file caplus medline biosis embase COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:35:51 ON 06 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:35:51 ON 06 DEC 2006

FILE 'BIOSIS' ENTERED AT 12:35:51 ON 06 DEC 2006 Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:35:51 ON 06 DEC 2006 Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s docetaxol or docetaxel or txotere or rp 56976 or 114977-28-5
L1 20746 DOCETAXOL OR DOCETAXEL OR TXOTERE OR RP 56976 OR 114977-28-5

=> s docetaxol or docetaxel or txotere or rp 56976 or 114977-28-5/rn

'RN' IS NOT A VALID FIELD CODE

'RN' IS NOT A VALID FIELD CODE

'RN' IS NOT A VALID FIELD CODE

L2 18876 DOCETAXOL OR DOCETAXEL OR TXOTERE OR RP 56976 OR 114977-28-5/RN

=> s (hepatocellular or hepatic or liver or hepato) (w) (cancer or neoplasm or neoplastic or tumor or tumour or cancerous)

L3 183161 (HEPATOCELLULAR OR HEPATIC OR LIVER OR HEPATO) (W) (CANCER OR NEOPLASM OR NEOPLASTIC OR TUMOR OR TUMOUR OR CANCEROUS)

=> s 12 and 13

L4 434 L2 AND L3

=> dup rem 14

PROCESSING COMPLETED FOR L4

L5 403 DUP REM L4 (31 DUPLICATES REMOVED)

=> focus

PROCESSING COMPLETED FOR L5

L6 403 FOCUS L5 1-

=> s (hepatocellular or hepatic or liver or hepato) (w) (cancer or neoplasm or neoplastic or tumor or tumour or cancerous or carcinoma or carci?)

L7 231795 (HEPATOCELLULAR OR HEPATIC OR LIVER OR HEPATO) (W) (CANCER OR NEOPLASM OR NEOPLASTIC OR TUMOR OR TUMOUR OR CANCEROUS OR CARCIN OMA OR CARCI?)

.=> s 12 and 137

L37 NOT FOUND

The L-number entered could not be found. To see the definition of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

Welcome to STN International!

```
Welcome to STN International!
                               Enter x:
LOGINID:SSSPTA1616BSK
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
                      Welcome to STN International
                  Web Page URLs for STN Seminar Schedule - N. America
NEWS
                  "Ask CAS" for self-help around the clock
NEWS
                  INSPEC enhanced with 1898-1968 archive
NEWS
         AUG 09
                  ADISCTI Reloaded and Enhanced
NEWS
         AUG 28
                  CA(SM)/CAplus(SM) Austrian patent law changes
         AUG 30
NEWS
                  CA/CAplus enhanced with more pre-1907 records
NEWS
      6
         SEP 11
                  CA/CAplus fields enhanced with simultaneous left and right
         SEP 21
NEWS
                  truncation
                  CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 8
          SEP 25
                  CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS
     9
         SEP 25
                  CAS REGISTRY (SM) updated with amino acid codes for pyrrolysine
 NEWS 10
          SEP 25
                  CEABA-VTB classification code fields reloaded with new
 NEWS 11
         SEP 28
                  classification scheme
                  LOGOFF HOLD duration extended to 120 minutes
         OCT 19
NEWS 12
                  E-mail format enhanced
 NEWS 13
         OCT 19
                  Option to turn off MARPAT highlighting enhancements available
         OCT 23
 NEWS 14
                  CAS Registry Number crossover limit increased to 300,000 in
         OCT 23
 NEWS 15
                  multiple databases
                  The Derwent World Patents Index suite of databases on STN
          OCT 23
NEWS 16
                  has been enhanced and reloaded
                  CHEMLIST enhanced with new search and display field
          OCT 30
NEWS 17
                  JAPIO enhanced with IPC 8 features and functionality
         NOV 03
 NEWS 18
                  CA/CAplus F-Term thesaurus enhanced
         NOV 10
 NEWS 19
                  STN Express with Discover! free maintenance release Version
 NEWS 20
         NOV 10
                  8.01c now available
                  CA/CAplus pre-1967 chemical substance index entries enhanced
 NEWS 21
         NOV 13
                  with preparation role
                  CAS Registry Number crossover limit increased to 300,000 in
         NOV 20
 NEWS 22
                  additional databases
                  CA/CAplus to MARPAT accession number crossover limit increased
         NOV 20
 NEWS 23
                  to 50,000
                  CA/CAplus patent kind codes will be updated
         NOV 20
 NEWS 24
                  CAS REGISTRY updated with new ambiguity codes
 NEWS 25
         DEC 01
              NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
NEWS EXPRESS
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
               STN Operating Hours Plus Help Desk Availability
NEWS HOURS
               Welcome Banner and News Items
NEWS LOGIN
               For general information regarding STN implementation of IPC 8
NEWS IPC8
              X.25 communication option no longer available
NEWS X25
```

Enter x:

Enter NEWS followed by the item number or name to see news on that specific topic.

=> s 12 and 17 469 L2 AND L7 L8 => dup rem 18 PROCESSING COMPLETED FOR L8 420 DUP REM L8 (49 DUPLICATES REMOVED) => focus PROCESSING COMPLETED FOR L9 420 FOCUS L9 1-=> s 110 and pd<=2000 2 FILES SEARCHED... 55 L10 AND PD<=2000 => focus PROCESSING COMPLETED FOR L11 55 FOCUS L11 1-=> d ibib abs hitstr 1-55 L12 ANSWER 1 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN 2000:650912 CAPLUS ACCESSION NUMBER: 134:141449 DOCUMENT NUMBER: Comparison of 2-methoxyestradiol-induced, TITLE: docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species Lin, Heng-Liang; Liu, Tsung-Yun; Chau, Gar-Yang; Lui, AUTHOR (S): Wing-Yiu; Chi, Chin-Wen Institute of Pharmacology, National Yang-Ming CORPORATE SOURCE: University, Taipei, Taiwan Cancer (New York) (2000), 89(5), 983-994 SOURCE: CODEN: CANCAR; ISSN: 0008-543X John Wiley & Sons, Inc. PUBLISHER: Journal DOCUMENT TYPE: English LANGUAGE: Previously, the authors observed that paclitaxel treatment of hepatoma cells AB resulted in differential cytotoxicity. Whether other antimicrotubule agents (docetaxel and 2-methoxyestradiol) are more effective than paclitaxel is not clear. Moreover, whether the modulation of reactive oxygen species (ROS) is involved in the drug-induced growth inhibition of hepatoma cells is not known. The authors examined the effects of 2-methoxyestradiol, paclitaxel, and docetaxel on HepG2, Hep3B, HA22T/VGH, and Hepal-6 hepatoma cell lines. The parameters examined included cell viability, cell membrane permeability, cell cycle distribution, DNA fragmentation, and ROS generation. Docetaxel and paclitaxel inhibited the growth of hepatoma cells at submicromolar concns., whereas that of 2-methoxyestradiol was within a micromolar range. This drug-induced growth inhibition was cell cycle dependent. 2-Methoxyestradiol-treated (10-50 $\mu M)$ cells resulted in G2/M block prior to apoptosis. High dose (0.1 µM) docetaxel- and paclitaxel-treated cells resulted in a G2/M arrest followed by generation of polyploidy or apoptosis; however, low dose (0.01 μM) treatment induced apoptosis without G2/M arrest. The low dose effect was more significant in docetaxel-treated cells than in paclitaxel-treated cells. Although these antimicrotubule agents increased the formation of ROS, antioxidant treatment did not block drug-induced cell cycle and growth inhibition effects. The current results suggest that the growth inhibition of hepatoma cells induced by 2-methoxyestradiol, paclitaxel, and docetaxel was mediated through G2/M-phase arrest, caspase activation, and DNA fragmentation.

drug-induced apoptosis was independent of ROS formation.

Docetaxel was more effective than paclitaxel in killing hepatoma

cells. The potential of using 2-methoxyestradiol and docetaxel for the treatment of patients with hepatoma is worthy of further study. 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(2-methoxyestradiol-, docetaxel-, and paclitaxel-induced apoptosis in hepatoma cells)

RN 114977-28-5 CAPLUS

IT

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:126569 CAPLUS 132:175461

DOCUMENT NUMBER: TITLE:

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825

heavily pretreated advanced breast cancer patients

AUTHOR (S):

Alexandre, J.; Bleuzen, P.; Bonneterre, J.; Sutherland, W.; Misset, J. L.; Guastalla, J.-P.; Viens, P.; Faivre, S.; Chahine, A.; Spielman, M.; Bensmaine, A.; Marty, M.; Mahjoubi, M.; Cvitkovic, E.

CORPORATE SOURCE:

Paul Brousse Hospital and Institut Gustave Roussy,

Villejuif, 94804, Fr.

SOURCE:

Journal of Clinical Oncology (2000), 18(3),

562-573

CODEN: JCONDN; ISSN: 0732-183X Lippincott Williams & Wilkins

PUBLISHER: DOCUMENT TYPE:

Journal English

LANGUAGE: English

AB Purpose: To identify predictive factors for efficacy and safety in advanced breast cancer (ABC) patients treated in the French compassionate-use docetaxel program. Patients and Methods: A total of 825 ABC patients treated with docetaxel (100 mg/m2 every 3 wk) were source-reviewed and analyzed for prognostic factors associated with overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), febrile neutropenia, mucositis, and severe fluid retention syndrome by univariate and multivariate anal. Results: The ORR was 22.9% (95% confidence interval, 20.2% to 26.2%). The median TTF and

OS were 4.0 and 9.8 mo, resp. By multivariate anal., secondary anthracycline-resistant disease was significantly associated (P < .05) with lower ORR and shorter TTF and OS, whereas anthracycline-refractory disease was associated with shorter OS. Poor performance status was associated with lower ORR, shorter TTF, and shorter OS. Liver dysfunction (transaminase levels > 1.5 times the upper limit of normal [ULN] and alkaline phosphatase [AP] level > three times ULN) and time since first relapse less than 24 mo were associated with shorter TTF and OS. Other significant correlations included the following: elevated CA 15-3 serum level with lower ORR; more than two involved sites, and minor transaminase and AP level abnormalities with shorter OS; and no previous chemotherapy for ABC with shorter TTF. According to multivariate anal., ORR, TTF, and OS were not decreased in patients with liver metastases but without liver dysfunction. Docetaxel activity was maintained in heavily pretreated ABC patients and in those with liver metastasis; docetaxel must be used cautiously, however, in patients with liver dysfunction in whom high morbidity risk necessitates strict adherence to dose-adaptation

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (factors predicting for efficacy and safety of docetaxel in pretreated humans with advanced breast cancer)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:60933 CAPLUS

DOCUMENT NUMBER: 132

132:102535

TITLE:

A Phase I study of gemcitabine and docetaxel

in patients with metastatic solid tumors

AUTHOR(S): Ryan, David P.; Lynch, Thomas J.; Grossbard, Michael

L.; Seiden, Michael V.; Fuchs, Charles S.; Grenon, Nina; Baccala, Paul; Berg, Deborah; Finkelstein,

Dianne; Mayer, Robert J.; Clark, Jeffrey W.

CORPORATE SOURCE: Gastrointestinal Cancer Clinic, Dana-Farber/Partners

CancerCare, Boston, MA, 02114, USA

SOURCE: Cancer (New York) (2000), 88(1), 180-185

CODEN: CANCAR; ISSN: 0008-543X

PUBLISHER:

John Wiley & Sons, Inc.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. Patients with metastatic solid tumors were treated with docetaxel , 60 mg/m2, on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and 15 and underwent dose adjustment in cohorts of 3-6 patients. At the maximum tolerated dose, 11 addnl. patients were enrolled. Twenty-six patients received 85 cycles of therapy. At the first dose level, the planned gemcitabine dose on Days 1, 8, and 15 was 800 mg/m2. Two of the 6 patients treated at this dose level experienced dose-limiting toxicities (DLTs) requiring the reduction of gemcitabine to 600 mg/m2 per dose and the administration of ciprofloxacin, 500 mg orally twice daily, on Days 8-18. At the second dose level the first 3 patients experienced no DLTs and the dose of gemcitabine was increased to 700 mg/m2. Two of the 6 patients treated at the 700 mg/m2 dose level experienced DLTs. Eleven addnl. patients were enrolled at the recommended Phase II dose of gemcitabine (600 mg/m2). At this dose level, Grade 3/4 (according the National Cancer Institute's common toxicity criteria) neutropenia and thrombocytopenia occurred in 12.5% and 2.1% of cycles, resp. Grade 3 and 4 nonhematol. toxicities were uncommon. Three of seven evaluable patients with pancreatic carcinoma had evidence of significant antineoplastic activity (three partial responses). In addition, two complete responses (one patient with gastric carcinoma and one patient with ovarian carcinoma) and one partial response (patient with hepatocellular carcinoma) were noted in patients with other solid tumors. The regimen comprised of docetaxel, 60 mg/m2, on Day 1 and gemcitabine, 600 mg/m2, on Days 1, 8, and 15 with ciprofloxacin on Days 8-18 every 28 days is safe, well tolerated, and active.

IT 114977-28-5, Docetaxel

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gemcitabine and docetaxel in human patients with metastatic solid tumors)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

```
1999:641123 CAPLUS
ACCESSION NUMBER:
                         132:117128
DOCUMENT NUMBER:
                         Efficacy and safety of docetaxel (Taxotere)
TITLE:
                         in heavily pretreated advanced breast cancer patients;
                         the French compassionate use program experience
                         Bonneterre, J.; Spielman, M.; Guastalla, J. -P.;
AUTHOR (S):
                         Marty, M.; Viens, P.; Chollet, P.; Roche, H.;
                         Fumoleau, P.; Mauriac, L.; Bourgeois, H.; Namer, M.;
                         Bergerat, J. P.; Misset, J. -L.; Trandafir, L.;
                         Mahjoubi, M.
                         Centre Oscar Lambret, Lille, 59020, Fr.
CORPORATE SOURCE:
                         European Journal of Cancer (1999), 35(10),
SOURCE:
                         1431-1439
                         CODEN: EJCAEL; ISSN: 0959-8049
                         Elsevier Science Ltd.
PUBLISHER:
                         Journal
DOCUMENT TYPE:
                         English
LANGUAGE:
     The aim was to assess retrospectively doceaxel safety and efficacy in
     advanced breast cancer patients in a French compassionate use program.
     Patients had received >1 prior chemotherapy regimen for advanced disease,
     were either anthracycline-resistant (that is progressed within 6 mo after
     anthracycline-based chemotherapy) or had received the maximum cumulative
           The recommended docetaxel dose was 100 mg/m2/cycle (75
     mq/m2) prior palliative chemotherapy lines. The most frequent severe
     toxicity, febrile neutropenia (reported in 223/870 (25.6%) patients
     evaluable for safety), caused 10 deaths, 6 of these being patients with
     severe liver impairment before inclusion. Fluid retention syndrome and
     other common non-Hematol. toxicities were well tolerated. 3.1% (28/889) of
     all patients and 11.4% of those with liver dysfunction, died from
     treatment-related causes. The overall response rate in 825 assessable
     patients was 22.9% (95% confidence interval (CI): 20.2-26.2%). Median
     time to treatment failure was 4 mo (95% CI: 3.6-4.3) and median survival
     was 9.8 mo (95% CI: 8.8-10.7). This report on the largest series of
     unselected advanced breast cancer patients treated with docetaxel
     , supports previous phase II studies, confirming docetaxel's
     utility in patients relapsing after failing anthracycline-containing
     palliative chemotherapy.
     114977-28-5, Docetaxel
TΤ
     RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
     effector, except adverse); BSU (Biological study, unclassified); THU
    (Therapeutic use); BIOL (Biological study); USES (Uses)
        (efficacy and safety of docetaxel in heavily pretreated
        advanced breast cancer patients)
     114977-28-5 CAPLUS
RN
     Benzenepropanoic acid, \beta-[[(1,1-dimethylethoxy)carbonyl]amino]-
CN
     \alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
     (benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11-
     trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI)
     INDEX NAME)
```

L12 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:790283 CAPLUS

DOCUMENT NUMBER: TITLE:

133:344606 Combined pharmaceuticals comprising anthracycline

derivatives

INVENTOR(S):

Geroni, Maria Cristina; Ripamonti, Marina; Caruso,

Michele; Suarato, Antonino

PATENT ASSIGNEE(S):

Pharmacia & Upjohn S.p.A., Italy

SOURCE:

PCT Int. Appl., 23 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT NO.					KIN	ND DATE			i	APP	LI	CAT	ION :	NO.		D	ATE		
WO WO	2000	0660: 0660:	93 93		A2 A3	-	2000 2001	1109 0125	1							2	00004	404	<
	W:	AE.	AL.	AM.	AT.	AU,	ΑZ,	BA,	BB,	BG	; , :	BR,	BY,	CA,	CH,	CN,	CR,	CU,	,
		CZ.	DE.	DK,	DM,	EE,	ES,	FI,	GB,	GD	΄, ι	GE,	GH,	GM,	HR,	HU,	ID,	IL,	,
		IN.	ıs.	JP,	KE.	KG,	KP,	KR,	KZ,	LC	.,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	
	•	MD.	MG.	MK.	MN.	MW.	MX,	NO,	NZ,	PL	, .	PT,	RO,	RU,	SD,	SE,	SG,	SI,	,
		SK.	SL.	TJ.	TM.	TR.	TT,	TZ,	UA,	UG	; , 1	US,	UZ,	VN,	YU,	ZA,	ZW		
	RW:	GH.	GM.	KE.	LS.	MW.	SD,	SL,	SZ,	TZ	, i	ŪĠ,	ZW,	AT,	BE,	CH,	CY,	DE,	,
	2000.0	DK.	ES.	FI.	FR.	GB,	GR,	IE,	IT,	LU	J, 1	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	,
			CT.	CM.	GA.	GN.	GW.	ML.	MR.	NE	Ι,	SN,	TD,	TG					
EP	1173	-	,	,	A2		2002	0123		ΕP	20	00-	9251	58		2	0000	404	
	1173	187			B1		2003	0806						•					
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR	٤,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,	,
		TE	Q T	T.T	T.V	FT	RΩ												
JР	2002	5431	12		T2		2002	1217		JP	20	00-	6149	78		2	0000	404	
EP	1323	423			A1		2003	0702		EΡ	20	03-	7577	6		2	0000	404	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR	٤,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	,
		TE.	SI.	LT.	LV.	FI.	RO.	MK.	CY,	AL									
ΑT	2465	0.7			E		2003	0815		AΤ	20	00-	9251	58		2	0000	404	
PT	1173	187	,		T		2003	1031	:	PΤ	20	00-	9251	58		2	0000	404	
ES	1173 2204	572			Т3		2004	0501	;	ES	20	00-	9251	58		2	0000	404	
CN	1507	869			Α		2004	0630	(CN	20	03-	1011	4911		2	0000	404	
CN	1535	688			Α		2004	1013						4909					
CN	1853				Α		2006	1101		CN	20	06-	1005	9701		2	0000	404	
CN	1853	642			A		2006	1101	(CN	20	06-	1005	9703		2	0000	404	
TW	1853 2228	63			В1		2004	1101						6805					
	6537						2003							92					
	1045						2006	0428	, 1	ΗK	20	02-	1070	29		2	0020	926	

US 2003087839 US 6586428	A1 B2	20030508 20030701	US 2002-284144		20021031
PRIORITY APPLN. INFO.:			GB 1999-9925	A	19990429
FRIORITI ALIZATI			CN 2000-806897	A	20000404
			CN 2003-1011490	9 A3	20000404
			CN 2003-1011491	1 A3	20000404
			EP 2000-925158	A3	20000404
			WO 2000-EP2923	W	20000404
			US 2001-926392	A1	20011025

The present invention relates to combined pharmaceuticals comprising a AΒ morpholinylanthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inhibitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful in anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer. At doses 5.9 and 7,7 mg/kg cis-platin administered alone and 0.05 mg/kg PNU-152243 (morpholinylanthracycline) administered alone, the increase in lifespan values was 33, 33 and 50%. Sequential administration of these drugs showed a therapeutic advantage of the combination in comparison with each drug administered alone.

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combined pharmaceuticals comprising anthracycline derivs.)

RN 114977-28-5 CAPLUS

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

2000:456927 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

133:84243

Method of using a cyclooxygenase-2 inhibitor and one TITLE:

or more antineoplastic agents as a combination therapy

in the treatment of neoplasia

McKearn, John P.; Gordon, Gary; Cunningham, James J.; INVENTOR(S):

Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

L.

G.D. Searle and Co., USA PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 236 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

		KIND	DATE	APPLICATION NO.	DATE
	WO 2000038730 WO 2000038730	A2	20000706	WO 1999-US30693	
	W: AE. AL.	AM. AT. AU	, AZ, BA, BB	, BG, BR, BY, CA, C	CH, CN, CR, CU,
	CZ. DE.	DK, DM, EE	, ES, FI, GB	, GD, GE, GH, GM, H	IR, HU, ID, IL,
	IN, IS,	JP, KE, KG	, KP, KR, KZ	, LC, LK, LR, LS, I	T, LU, LV, MA,
	MD, MG,	MK, MN, MW	, MX, NO, NZ	, PL, PT, RO, RU, S	SD, SE, SG, SI,
	SK, SL,	TJ, TM, TR	, TT, TZ, UA	, UG, US, UZ, VN, Y	U, ZA, ZW
	RW: GH, GM,	KE, LS, MW	, SD, SL, SZ	, TZ, UG, ZW, AT, E	SE, CH, CY, DE,
	DK, ES,	FI, FR, GB	, GR, IE, IT	, LU, MC, NL, PT, S	SE, BF, BJ, CF,
		CM, GA, GN	, GW, ML, MR	, NE, SN, TD, TG	10001000
	CA 2356606	AA	20000706	CA 1999-2356606 AU 2000-23805	19991222 <
	AU 2000023805	A5	20000731	AU 2000-23805	19991222 <
		В2	20060112	TD 1000 067543	10001222
		A2		EP 1999-967543	19991222
	EP 1140192	B1	20060405	on to it iii N	II CE MC DT
	R: AT, BE,	CH, DE, DK	, ES, FR, GB	, GR, IT, LI, LU, N	10, 35, MC, PI,
		LT, LV, FI		TR 2001-200102499	19991222
	TR 200102499	T2	20011221	DD 1000-16518	19991222
	BR 9916518	A NO	20020129	BR 1999-16518 HU 2001-4814	
	TD 2002533416	H2	20020425	HU 2001-4814 JP 2000-590681	19991222
	EP 1522313	A1	20021000	EP 2004-26577	19991222
	R: AT, BE,	CH DE DK	ES FR GB	, GR, IT, LI, LU, N	IL. SE. MC. PT.
	IE, FI,		, 20, 111, 0-	, 20, 22, 22, 2	
	AT 322290	E	20060415	AT 1999-967543	19991222
	ZA 2001005055	Ā	20020920	ZA 2001-5055	20010620
		A	20020107	ZA 2001-5120	20010621
	NO 2001003155	A	20010822	NO 2001-3155	20010622
	US 2003119895	A Al	20030626	US 2002-150546	20020516
	US 2003203956	A1	20031030	US 2002-212523	20020805
	AU 2004210578	A1	20041007	AU 2004-210578	20040910
	US 2005037090	A1	20050217	US 2004-945422	20040920
PRIO	RITY APPLN. INFO.	:	1	US 1998-113786P	
				US 1999-385214	A 19990827
				AU 2000-25936 EP 1999-968939	A3 19991222
	•			EP 1999-968939 WO 1999-US30693	A3 19991222
				US 2001-857873	
AB	Methods are prov	idea to tr	eat or preve	ent neoplasia disord se-2 inhibitor and a	en antineonlastic
		ion of a c	ycrooxygenas	se-2 limitation and a	an ancincopiascie
TO	agent. 114977-28-5, Doc	etavel			
IT	DI PAC (Piologi	cal activi	ty or effect	or, except adverse	. BSU (Biological
	etudy unclassif	ied). THI	(Therapeutic	use); BIOL (Biolog	gical study); USES
	(Uses)	100,, 1110	(Inolupouolo	. 220, , 2202 (220=1)	1
	(cvc]ooxvgena	se-2 inhib	itor-antineo	plastic agent comb	ination for
	neoplasia tre				
RN	114977-28-5 CAP	LUS			
CN	Benzenepropanoic	acid. β-[[(1,1-dimeth	ylethoxy)carbonyl]a	amino]-
	α -hvdroxv-, (2aR	4S,4S,6R	,9S,11S,12S,	12aR, 12bS) - 12b - (ace	etyloxy) -12 -
	(benzovloxy) -2a,	3,4,4a,5,6	,9,10,11,12,	12a, 12b-dodecahydro	0-4,6,11-
	trihydroxy-4a,8,	13,13-tetr	amethyl-5-ox	co-7,11-methano-1H-	
	cyclodeca[3,4]be	nz[1,2-b]o	xet-9-yl est	er, $(\alpha R, \beta S)$ - $(9CI)$	(CA
	INDEX NAME)				•

L12 ANSWER 7 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456915 CAPLUS

DOCUMENT NUMBER:

133:84242

TITLE:

Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination

therapy in the treatment of neoplasia

INVENTOR(S):

McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

PATENT ASSIGNEE(S):

SOURCE:

G.D. Searle and Co., USA

PCT Int. Appl., 277 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 21

PA'	rent 1	NO.			KIND DATE					ICAT				D2	ATE		
WO	2000	 0387 0387	18 18		A2	200 200	00706 01109							19	9991:	222	<
	W:	AE,	AL,	AM,	AT,	AU, AZ	, BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,	
		CZ,	DE,	DK,	DM,	EE, ES	, FI,	GB,	GD,	GΕ,	GH,	GM,	HR,	ΗU,	ID,	IL,	
		IN,	IS,	JP,	KΕ,	KG, KF	, KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	
		MD,	MG,	MK,	MN,	MW, MX	, NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	
		SK,	SL,	ТJ,	TM,	TR, TI	TZ,	UA,	UG,	US,	UΖ,	VN,	YU,	ZA,	ZW		
	RW:	GH,	GM,	KE,	LS,	MW, SI	, SL,	SZ,	TZ,	UG,	ZW,	AΤ,	BE,	CH,	CY,	DE,	
		DK,	ES,	FI,	FR,	GB, GR	, IE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	
		CG,	CI,	CM,	GΑ,	GN, GW	, ML,	MR,	ΝE,	SN,	TD,	TG					
CA	2356	929			AA	200	00706		CA 1	999-	2356	929		1:	9991	222	<
AU	A 2356929 J 2000027135				A5	200	00/31		AU Z	000-	Z: / I 3	o '			J J J I .	222	<
EP	P 1140182				A2	20011010 EP 1999-968941 DK, ES, FR, GB, GR, IT, LI, LU, NL							1:	9991	222		
	R:	ΑT,	BE,	CH,	DE,	DK, ES	, FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FI, RC)										
TR	2001	0249	9		T2	200	11221		TR 2	001-	2001	0249	9	1:	9991	222	
JP	2002	5334	06		T2	200	21008		JP 2	000-	5906	69		1	999T.	222	
EP	1522	313			A1	200	50413		EP 2	004-	2657	7		1:	9991	222	
	R:	ΑT,	ΒE,	CH,	DE,	DK, ES	, FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	FI,	RO,	CY												
AT	3222	90			E	200	60415		AT 1	999-	9675	43		1:	9991	222	
ZA	2001	0050	55		Α	200	20920		ZA 2	001-	5055			2	0010	620	
ZA	2001	0051	20		Α	200	20107			001-							
	6858					200	50222		US 2	001-	8579	95		2	0011	005	
ΑU	AU 2004210578				A1	20041007			AU 2	004-	2105	78		2	0040	910	
US	US 2005058725				A1	200	50317		US 2	004-	9450	02		2	0040	920	
US 6916800				B2	200	50712											
[ORIT	RITY APPLN. INFO.:							•	US 1	998-	1137	86P		P 1	9981	223	

US 1999-385214 A 19990827 AU 2000-25936 A3 19991222 EP 1999-968939 A3 19991222 WO 1999-US30699 W 19991222 US 2001-857995 A1 20011005

AB Methods are provided for the prevention and treatment of neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(matrix metalloproteinase inhibitor and antineoplastic agent as combination therapy in neoplasia treatment)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456866 CAPLUS

DOCUMENT NUMBER:

133:84239

TITLE:

Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the

treatment of neoplasia

INVENTOR(S):

McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

т.

PATENT ASSIGNEE(S):

G.D. Searle and Co., USA

SOURCE:

PCT Int. Appl., 220 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

21

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038665	A2	20000706	WO 1999-US30670	19991222 <
WO 2000038665 W: AE, AL, AM, CZ, DE, DK,	A3 AT, AU DM, EE	20001116 , AZ, BA, BB , ES, FI, GB	, BG, BR, BY, CA, CH, , GD, GE, GH, GM, HR,	CN, CR, CU, HU, ID, IL,

```
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, MI, MD, NE, CN, TD, TC
                 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                                                         19991222 <--
                                          20000706
                                                          CA 1999-2356462
                                  AA
      CA 2356462
                                                          AU 2000-25926
                                                                                         19991222 <--
                                  A5
                                          20000731
      AU 2000025926
                                                          EP 1999-968529
                                                                                         19991222
                                          20011010
                                  A2
      EP 1140193
                AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                 IE, SI, LT, LV,
                                     FI, RO
                                                          TR 2001-200102499
                                                                                         19991222
                                  T2
                                          20011221
      TR 200102499
                                  Т2
                                          20021008
                                                          JP 2000-590619
                                                                                         19991222
      JP 2002533387
                                                          EP 2004-26577
                                                                                         19991222
                                  A1
                                          20050413
      EP 1522313
                 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                 IE, FI, RO, CY
                                                          AT 1999-967543
                                                                                         19991222
                                          20060415
                                  Ε
      AT 322290
                                          20020920
                                                          ZA 2001-5055
                                                                                         20010620
                                  Α
      ZA 2001005055
                                                                                         20010621
                                          20020107
                                                          ZA 2001-5120
                                  Α
      ZA 2001005120
                                                                                         20011005
                                          20'041221
                                                          US 2001-857994
                                  B1
      US 6833373
                                                                                         20040610
                                                          US 2004-865414
                                          20041125.
      US 2004234624
                                  A1
                                                                                         20040910
                                                          AU 2004-210578
                                  A1
                                          20041007
      AU 2004210578
                                                          US 1998-113786P
                                                                                     P
                                                                                         19981223
PRIORITY APPLN. INFO.:
                                                          US 1999-385214
                                                                                     Α
                                                                                         19990827
                                                          AU 2000-25936
                                                                                     A3 19991222
                                                          EP 1999-968939
                                                                                     A3 19991222
                                                          WO 1999-US30670
                                                                                         19991222
                                                                                     A1 20011005
                                                          US 2001-857994
      The present invention provides methods to treat or prevent neoplasia
AB
```

AB The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(integrin antagonist-antineoplastic agent combination for neoplasia treatment)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

2000:368032 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

133:26843

TITLE:

Methods and compositions for diagnosis and treatment

of cancer based on the transcription factor ets2

Papas, Takis S.; Watson, Dennis K. INVENTOR(S):

PATENT ASSIGNEE(S):

Musc Foundation for Research Development, USA; Papas,

Tula Christy

SOURCE:

PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	TENT NO.	KIN	D DATE	APPLICATION NO.	DATE
	2000030590	A2		WO 1999-US27805	19991123 <
WO	2000030590 W: AU, CA,	A3 JP, US	20000817		
			DE, DK, ES,	FI, FR, GB, GR, IE,	IT, LU, MC, NL,
CA	2351627	AA	20000602	CA 1999-2351627	19991123 <
AU	2000024740	A5	20000613	AU 2000-24740	19991123 <
EP	1133575	A2	20010919	EP 1999-968046	19991123
		CH, DE,	DK, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, MC, PT,
	IE, FI				
JР	2002530102	T2	20020917	JP 2000-583475	19991123
US	2002081601	A1	20020627	US 2001-841963	20010425
·US	2004047845	A1	20040311	US 2001-841960	20010425
PRIORIT	Y APPLN. INFO	.:		US 1998-109850P WO 1999-US27805	P 19981125 W 19991123

The present invention relates to methods for treating and preventing AB cancer by modifying the expression of ets2 gene expression or the activity of the gene product. The invention also relates to sensitizing cancer cells to chemotherapeutic or radiotherapeutic agents. Ets2 gene expression and/or activity of the gene product can be modulated using antisense ets2 nucleic acids and/or modified ets2 proteins. The present invention also provides pharmaceutical compns. which comprise antisense ets2 nucleic acid, and nucleic acid that encode modified ets2 proteins and/or modified ets2 proteins.

114977-28-5, Docetaxel IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(diagnosis and treatment of cancer based on the transcription factor ets2)

114977-28-5 CAPLUS RN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456950 CAPLUS

DOCUMENT NUMBER:

133:84244

TITLE:

Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the

treatment of neoplasia

INVENTOR(S):

McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

PATENT ASSIGNEE(S):

SOURCE:

G.D. Searle and Co., USA

PCT Int. Appl., 348 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 21

PAT	rent 1			KIND DATE								D	ATE					
															-			
										WO 1	999-	US30	692		1	9991	222 <-	-
WO	2000																	
	W:	ΑE,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	ВG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,	
		CZ,	DE,	DK,	DM,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	
								KR,										
		MD,	MG,	MK,	MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	
		SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	ŪĠ,	US,	UΖ,	VN,	YU,	ZA,	ZW		
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	\$Z,	TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	DE,	
		DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	
		CC	CT	CM	CΔ	CN	GW	MT.	MR	NE.	SN.	TD.	TG					
CA	2356	302	•	_	AΆ		2000	0706		CA 1	999-	2356	302		1	9991	222 <-	-
AU	2000	A5		2000	0731		AU 2	000-	2210	4 ·		. 1	9991	222 <-	-			
	1140																	
																	PT,	
		IE.	SI.	LT.	LV.	FI.	RO											
TR	2001	0249	9 .		T2	•	2001	1221		TR 2	001-	2001	0249	9	1	9991	222	
JP	2002	5334	22		T2		2002	1008		JP 2	000-	5907	34		1	9991	222	
EP	1522	313			A1		2005	0413		EP 2	004-	2657	7		1	9991	222	
	R:	AT.	BE.	CH.	DE.	DK.	ES.	FR,	GB.	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			FI,			,		•	•		•	•		•				
ΔΨ	3222		•	•			2006	0415		AT 1	999-	9675	43		1	9991	222	
											001-							
7.0	2001	0051	20		A		2002	0107			001-							
אַנַ	ZA 2001005055 ZA 2001005120 AU 2004210578				A1		2004	1007			004-							
	IORITY APPLN. INFO.:				••-						998-							
RIORII	TORITI APPEN. INFO.:										999-					9990		
											000-					9991		
											999-					9991		
									F		,,,	,,,,,	-					

AB Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor, an integrin antagonist and an antineoplastic agent.

IT 114977-28-5, Docetaxel RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclooxygenase-2 inhibitor and integrin antagonist in combination for neoplasia treatment)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:456916 CAPLUS

DOCUMENT NUMBER:

133:68929

TITLE:

Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia McKearn, John P.; Gordon, Gary; Cunningham, James J.;

INVENTOR(S):

Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.

PATENT ASSIGNEE(S):

G.D. Searle and Co., USA PCT Int. Appl., 358 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

21

PA	PATENT NO.					KIND DATE				APPL	ICAT:	ION I	NO.		D	ATE		
						-									-		- 	
WO	2000	0387	19		A1		2000	0706	,	WO 1	999-1	US30	700		19	9991:	222 <-	-
	W:	AE,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,	-
		CZ,	DE,	DK,	DM,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	
		IN.	ıs.	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	
		MD.	MG.	MK.	MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	
		SK.	SL.	TJ.	TM.	TR.	TT,	TZ,	UA,	ŪĠ,	US,	UZ,	VN,	YU,	ZA,	ZW		
	RW:						SD,										DE,	
		DK.	ES.	FI.	FR.	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	
							GW,											

CA	2356402	AA	20000706	CA 1999-2356402	19991222 <
AU	2000027136	A5	20000731	AU 2000-27136	19991222 <
EP	1140183	A1	20011010	EP 1999-968942	19991222
		, DE,	DK, ES, FR,	GB, GR, IT, LI, LU, NL,	SE, MC, PT,
	IE, SI, LI				
TR			20011221	TR 2001-200102499	19991222
JP	2002533407	Т2	20021008	JP 2000-590670	19991222
EP	1522313	A1	20050413	EP 2004-26577	19991222
	R: AT, BE, CH	, DE,	DK, ES, FR,	GB, GR, IT, LI, LU, NL,	SE, MC, PT,
	IE, FI, RO				
AT	322290	E	20060415	AT 1999-967543	19991222
ZA	2001005055	Α	20020920	ZA 2001-5055	20010620
ZA	2001005120	Α	20020107	ZA 2001-5120	20010621
AU	2004210578	A1	20041007	AU 2004-210578	20040910
PRIORITY	APPLN. INFO.:			US 1998-113786P	P 19981223
				US 1999-385214	A 19990827
				AU 2000-25936	A3 19991222
				EP 1999-968939	A3 19991222
				WO 1999-US30700	W 19991222
35 34-1				wort roomlagia digorder	e in a mammal

AB Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor, an integrin antagonist, and an antineoplastic agent.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(matrix metalloproteinase inhibitor and integrin antagonist in neoplasia treatment)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 20

2000:441655 CAPLUS

DOCUMENT NUMBER:

133:68922

TITLE:

Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination

therapy in the treatment of neoplasia

INVENTOR(S): McKearn, John P.; Gordon, Gary; Cunningham, James J.;

Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime

L.

PATENT ASSIGNEE(S):

G.D. Searle and Co., USA

PCT Int. Appl., 437 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

SOURCE:

Patent English

LANGUAGE: Engangle FAMILY ACC. NUM. COUNT: 21

PATENT INFORMATION:

```
DATE
                               KIND
                                       DATE
                                                      APPLICATION NO.
      PATENT NO.
                               _ - - -
                                        ____
                                                      ______
                                                                                   _____
      _____
                                                                                   19991222 <--
      WO 2000037107
                               A2
                                        20000629
                                                      WO 1999-US30776
                                        20010201
      WO 2000037107
                               A3
           W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
          W: AE, AL, AM, AI, AU, AZ, BA, BB, BG, BR, BI, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      CA 2356426
                                AA
                                        20000629
                                                      CA 1999-2356426
                                                                                   19991222 <--
      AU 2000025936
                                Α5
                                        20000712
                                                      AU 2000-25936
                                                                                   19991222 <--
                                                      EP 1999-968540
                                                                                   19991222
      EP 1140194
                                A2
                                        20011010
           R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, SI, LT, LV, FI, RO
                                                      TR 2001-200102499
                                                                                    19991222
      TR 200102499
                                T2
                                        20011221
                                        20020102
                                                      BR 1999-16536
                                                                                    19991222
                                Α
      BR 9916536
                                                      HU 2001-4747
                                                                                    19991222
      HU 200104747
                                A2
                                        20020429
                                                      JP 2000-589217
                                                                                    19991222
                                T2
                                        20021002
      JP 2002532563
                                                      EP 2004-26577
                                                                                   19991222
                               A1
                                        20050413
      EP 1522313
               AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, FI, RO, CY
                                                      AT 1999-967543
                                                                                    19991222
      AT 322290
                                Е
                                        20060415
                                Α
                                        20020920
                                                       ZA 2001-5055
                                                                                   20010620
      ZA 2001005055
                                Α
                                        20020107
                                                       ZA 2001-5120
                                                                                   20010621
      ZA 2001005120
                                                      NO 2001-3156
                                                                                   20010622
      NO 2001003156
                                Α
                                        20010823
                                                       AU 2004-210578
                                                                                    20040910
      AU 2004210578
                                A1
                                        20041007
                                                                               P 19981223
                                                       US 1998-113786P
PRIORITY APPLN. INFO.:
                                                                               A 19990827
                                                       US 1999-385214
                                                                               A3 19991222
                                                       AU 2000-25936
                                                       EP 1999-968939
                                                                                A3 19991222
                                                       WO 1999-US30776
                                                                               W 19991222
      Methods are provided to treat or prevent neoplasia disorders in a mammal
AΒ
      using a combination of a cyclooxygenase-2 inhibitor, a matrix
      metalloproteinase inhibitor and an antineoplastic agent.
      114977-28-5, Docetaxel
IT
      RL: BAC (Biological activity or effector, except adverse); BSU (Biological
      study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
      (Uses)
          (cyclooxygenase-2 inhibitor and matrix metalloproteinase inhibitor in
          combination therapy for neoplasia treatment)
```

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-

trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI)

α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-

INDEX NAME)

114977-28-5 CAPLUS

RN

CN

L12 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1997:400101 CAPLUS

DOCUMENT NUMBER:

127:23742

TITLE:

Method, compositions and kits for increasing the oral

bioavailability of pharmaceutical agents

INVENTOR (S):

Broder, Samuel; Duchin, Kenneth L.; Selim, Sami

Baker Norton Pharmaceuticals, Inc., USA

SOURCE:

PCT Int. Appl., 136 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT ASSIGNEE(S):

PATENT NO. KIND DATE APPLICATION NO. DATE WO 9715269 A2 19970501 WO 1996-IB1485 19961024 <- WO 9715269 A3 19970731 W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,	
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,	· -
GB, GE, HU, IL, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,	
MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,	
MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,	
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,	
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,	
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,	
MR, NE, SN, TD, TG	
US 5968972 A 19991019 US 1996-608776 19960229 <	
TIC 6245805 B1 20010612 US 1996-733142 19961016	
AU 9712056 A1 19970515 AU 1997-12056 19961024 <-	
AU 698142 B2 19981022	
EP 794794 A1 19970917 EP 1996-943268 19961024 <-	
EP 794794 B1 20051207	
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL,	
PT, SE	
JP 10509741	
JP 3361102 B2 20030107	
BR 9607066 A 20021210 BR 1996-7066 19961024 RU 2217135 C2 20031127 RU 1997-112888 19961024	
RU 2217135 C2 20031127 RU 1997-112888 19961024	
PL 188281 B1 20050131 PL 1996-321791 19961024	
AT 311903 E 20051215 AT 1996-943268 19961024	
ZA 9609001 A 19970617 ZA 1996-9001 19961025 <	
NO 9702968 A 19970723 NO 1997-2968 19970625 <	
NO 321091 B1 20060313	
HK 1001960 A1 20060127 HK 1998-101042 19980211	
AU 2002035584 A5 20020606 AU 2002-35584 20020422	
AU 784159 B2 20060216	
PRIORITY APPLN. INFO.: US 1995-7071P P 19951026	
US 1996-608776 A 19960229	

US 1996-733142 A 19961016 WO 1996-IB1485 W 19961024 AU 1998-71300 A3 19980422

A method of increasing the bioavailability upon oral administration of a AB pharmacol. active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F, or ketoconazole). The oral bioavailability-enhancing agents are known to be MDR (P-glycoprotein) inhibitors. The enhancing agent may be administered orally from 0.5-24 h prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent, or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailabilityenhancing agents and target agents kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (target; increasing oral bioavailability of pharmaceutical agents)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:799989 CAPLUS

DOCUMENT NUMBER: 130:43304

TITLE: Method and compositions for administering taxanes

orally to human patients using a cyclosporin to

enhance bioavailability

INVENTOR(S): Broder, Samuel; Duchin, Kenneth L.; Selim, Sami

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

```
APPLICATION NO.
                                                                        DATE
                                  DATE
     PATENT NO.
                          KIND
                                               _____
                           ----
                                               WO 1998-US7776
                                                                        19980422 <--
                                  19981203
                           A1
     WO 9853811
         W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, UG, UZ, VN, YU, ZW
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, ML, MR, NE, SN, TD, TG
                                                                        19980422 <--
                                               CA 1998-2290446
                                  19981203
     CA 2290446
                            AA
                                               AU 1998-71300
                                                                        19980422 <--
                                  19981230
     AU 9871300
                            A1
                                               EP 1998-918361
                                                                        19980422 <--
                                  20000426
                            A1
     EP 994706
                                  20051102
                            В1
     EP 994706
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, RO
                                                                        19980422 <--
                                               BR 1998-9694
                                  20001003
     BR 9809694
                            Α
                                               JP 1999-500663
                                                                        19980422
                                  20020108
                            T2
     JP 2002500667
                                  20021128
                                               HU 2000-3546
                                                                        19980422
                            A2
     HU 200003546
                           C2
                                  20030527
                                               RU 1999-128033
                                                                        19980422
     RU 2205005
                                                                        19980422
                           Α
                                  20030630
                                               NZ 1998-516026
     NZ 516026
                                                                        19980422
                                               CN 2004-10030478
     CN 1550231
                           Α
                                  20041201
                                               AT 1998-918361
                                                                        19980422
                           Ε
                                  20051115
     AT 308365
                                                                        19980422
                                               ES 1998-918361
     ES 2247690
                           Т3
                                  20060301
                                                                        19980520 <--
                                               ZA 1998-4268
                           Α
                                  19990623
     ZA 9804268
                                                                        20000920'
                           A1
                                  20060106
                                               HK 2000-105943
     HK 1026637
                                                                        20020422
                                               AU 2002-35584
     AU 2002035584
                                  20020606
                           Α5
     AU 784159
                                  20060216
                           B2
                                               US 1997-863513
                                                                     A 19970527
PRIORITY APPLN. INFO.:
                                                                     A3 19980422
                                               AU 1998-71300
                                                                     A1 19980422
                                               NZ 1998-501127
                                                                     W 19980422
                                               WO 1998-US7776
     Taxane antineoplastic agents which have heretofore exhibited poor or
AΒ
     non-existent oral bioavailability are administered orally to human
     patients suffering from taxane-responsive disease conditions and made
     sufficiently bioavailable to achieve therapeutic blood levels. In a
     preferred embodiment, the taxane, preferably paclitaxel, is
     co-administered to the patient with an oral cyclosporin enhancing agent,
     preferably cyclosporin A. By one preferred method, a dose of oral
     enhancer is administered about 0.5-72 h before the taxane and a second
     dose of the enhancer and administered immediately before, together with or
     immediately after the taxane. A method of treating human patients
     suffering from taxane-responsive disease conditions is also provided, as
     well as a method for providing such treatment while preventing or reducing
     hypersensitivity and allergic reactions without the need for
     pre-medication.
     114977-28-5, Docetaxel
IT
     RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
     effector, except adverse); BSU (Biological study, unclassified); THU
     (Therapeutic use); BIOL (Biological study); USES (Uses)
         (method and compns. for administering taxanes orally to human patients
        using a cyclosporin to enhance bioavailability)
     114977-28-5 CAPLUS
RN
     Benzenepropanoic acid, \beta-[[(1,1-dimethylethoxy)carbonyl]amino]-
CN
     \alpha-hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-
     (benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11-
     trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (\alpha R, \beta S)- (9CI)
     INDEX NAME)
```

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS 1 REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1999:215571 CAPLUS

DOCUMENT NUMBER:

130:247032

TITLE:

Fused imidazole derivatives for improving oral

bioavailability of pharmaceutical agents

INVENTOR(S):

Snoeck, Henricus Johannes Matheus Janssen Pharmaceutica N.V., Belg.

PATENT ASSIGNEE(S):

PCT Int. Appl., 45 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

P	ATENT	NO.			KIND DATE				APPL	ICAT	ION I	NO.		D/	ATE			
															19	9809	910 <-	_
													-				-	
W		3871								DD.	DV	C A	CH	CINT	CII	CZ	חפ	
	W	AL,	AM,	AT,	ΑU,	AZ,	, BA,	BB,	BG,	BK,	ы,	CA,	Cn,	CN,	CO,	C2,	עם,	
		DK,	EE,	ES,	FΙ,	GB,	GE,	GH,	GM,	HR,	HU,	ID,	ДШ,	IS,	JP,	KE,	NG,	
		KΡ,	KR,	KZ,	LC,	LK	, LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MX,	
		NO,	NZ,	PL,	PT,	RO.	, RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	
							, YU,											
	RI	: GH,	GM.	KE,	LS,	MW	, SD,	SZ,	ŪĠ,	ZW,	AT,	ΒE,	CH,	CY,	DE,	DK,	ES,	
		FI.	FR.	GB.	GR.	IE	, IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	
		CM	GA,	GN	GW	MT.	, MR,	NE.	SN.	TD.	TG							
λΙ	т аа	1460	011,	011,	Δ1		1999	0405	,	ΔΙΙ 1	999-	1146	0		19	9980	910 <-	_
A.	J JJ.	1726			7.7		2000	0628		RD 1	998-	9542	- 68:		19	9980	910 <-	_
		1726					2003			UL 1		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
E.										CD	TT	T.T	T.TT	NT.	SE	рт	TE	
	R	AT,						FR,	GD,	GR,	11,	DI,	шо,	, ш,	UL,	,	10,	
		•	-	-	FI,					^			0.4		7.	2000	210	
		15167					2001									9960	910	
J	P 37'	75780 3104			B2		2006	0517							<u>.</u>			
A.	r 23:	104			E	•	2003	0315	٠.	AT 1	998-	9542	68		19	9980		
		8527															917 <-	-
US	3 654	4979			В1		2003	0408		US 2	000-	50874	48		20	0000	315	
PRIORI											997-							
										WO 1	998-	EP57	51	1	W 19	9980	910	
OTHER S	SOUR	CE(S):			MAR	PAT	130:	2470	32									

GΙ

$$\mathbb{Q}A^{2} \circ \mathbb{Q}A^{2} \circ \mathbb{Q}$$

Compds. I [dotted line = optional bond; n = 1, 2; R1 = H, halo, formyl, (substituted) C1-4 alkyl, etc.; R2 = H, halo, C1-4 alkyl, hydroxy-C1-4 alkyl, etc.; R3 = H, C1-4 alkyl, C1-4 alkyloxy; R4 = H, halo, C1-4 alkyl, C1-4 alkyloxy, halo-C1-4 alkyl; Z = CH2, CH2CH2, CH=CH, CH(OH)CH2, OCH2, C(O)CH2, C(=NOH)CH2; AB = bivalent radical; A1 = direct bond, (substituted) C1-6 alkanediyl, C1-6 alkanediyl-oxy-C1-6 alkanediyl, carbonyl, C1-6 alkanediylcarbonyl, (substituted) C1-6 alkanediyloxy; A2 = direct bond, C1-6 alkanediyl; Q = aryll, and N-oxide forms, pharmaceutically acceptable addition salts, and stereochem. isomeric forms thereof, are used for the manufacture of a medicine for improving the bioavailability of a second pharmaceutical agent which is co-administered orally to a warm-blooded animal. The second pharmaceutical agent is e.g. an antitumor agent. Preparation of compds. of the invention, and intermediates thereto, is described.

IT 114977-28-5, Docetaxel RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fused imidazole derivs., and preparation thereof, for improving oral bioavailability of pharmaceutical agents)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 1998:65802 CAPLUS

DOCUMENT NUMBER: 128:123804

```
Down-regulation of DNA repair to enhance sensitivity
TITLE:
                                     to p53-mediated suppression in cancer therapy
                                     Gjerset, Ruth A.
INVENTOR(S):
                                     Sidney Kimmel Cancer Center, USA; Gjerset, Ruth A.
PATENT ASSIGNEE(S):
                                     PCT Int. Appl., 88 pp.
SOURCE:
                                     CODEN: PIXXD2
                                     Patent
DOCUMENT TYPE:
                                    English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                              DATE
                                                                APPLICATION NO.
                                                                                                  DATE
                                    KIND
       PATENT NO.
                                                                 ______
       _______
                                               19980115
                                                                WO 1997-US12542
                                                                                                  19970702 <--
                                      A1
       WO 9801123
            W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, CN, ML, MB, NE, SN, TD, TG
                   GN, ML, MR, NE, SN, TD, TG
                                               20000425
                                                                US 1996-675887
                                                                                                   19960705 <--
       US 6054467
                                      Α
                                                                                                  19970702 <--
                                      AA
                                               19980115
                                                                CA 1997-2259960
       CA 2259960
                                                                AU 1997-36705
                                                                                                   19970702 <--
                                      A1
                                               19980202
       AU 9736705
                                      B2
                                               20000914
       AU 724212
                                                                EP 1997-933543
                                                                                                   19970702 <--
                                      A1
                                               19990428
       EP 910357
                                               20030604
                                      B1
       EP 910357
             R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                   IE, FI
```

WO 1997-US12542 W 19970702
US 2000-556440 B1 20000424

AB The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis in cancer cells following treatment with inhibitors of DNA repair in combination with p53 gene therapy. Treatment of glioblastoma and breast tumor cells with inhibitors of DNA repair induced growth suppression that was a result of p53-mediated apoptosis. Thus it appears that inhibitors of DNA repair in combination with p53 gene therapy is involved in restoration of p53-mediated apoptosis.

20001205

20030615

20050505

T2

E

A1

IT 114977-28-5, Taxotere

JP 2000516207

US 2005095226

PRIORITY APPLN. INFO.:

AT 241973

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

JP 1998-505400

AT 1997-933543

US 2004-842718

US 1996-675887

19970702 <--

19970702

20040510

A2 19960705

(down-regulation of DNA repair to enhance sensitivity to p53-mediated suppression in cancer therapy)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

8

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER:

L12 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN 1999:405000 CAPLUS

DOCUMENT NUMBER:

REFERENCE COUNT:

131:43591

TITLE:

Combination therapy of cancer with anti-ErbB2

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

antibodies

INVENTOR(S):

Shak, Steven; Paton, Virginia E.

PATENT ASSIGNEE(S):

Genentech, Inc., USA PCT Int. Appl., 42 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

1

FAMILY ACC. NUM. COUNT:

PA	TENT	NO.			KIND DATE		j	APPI	LICAT	ION I	NO.		D	ATE				
WO	9931	140			A1		1999	0624	. 1	WO :	1998-	US26:	266		1			
	W:	ΑL,	AM,	ΑT,	AU,	ΑZ,	ΒA,	BB,	ВG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
		DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	, HR,	ΗU,	ID,	IL,	IS,	JP,	KE,	
		KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	, LU,	LV,	MD,	MG,	MK,	MN,	MW,	
		MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE	, SG,	SI,	ŠK,	SL,	TJ,	TM,	TR,	
							YU,											
	RW:	GH,	GM,	ΚE,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DΕ,	DK,	ES,	
		FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	
		CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	, TG							
ZA	9811	162			Α		2000	0607	,	ZA :	1998-	1116	2		1	9981	207	<
CA	2311	409			AA		TAAA	0624	,	CA.	1998-	2311·	409		1	9901 .	210	<
	9919				A1		1999	0705		AU :	1999-	1908	1		1	9981	210	<
EP	1037	926			A1		2000	0927	:	EP :	L998-	9638	40		. 1	9981	210	<
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
							RO											
TR	2000	0168	9		T2		2001	0122	'	TR 2	-000	2000	0168	9	1	9981	210	
CN	1281	468			Α		2001	0124	(CN 3	1998-	8120	97		1	9981	210	
BR	1281 9815	363			Α		2001	1016	1	BR 1	L998-	1536	3		1	9981	210	
JP	2002	5083	97		T2		2002	0319		JP 2	-000	5390	62		1	9981	210	
CN	1820	734			Α		2006	0823	(2006-							
NZ	5045	97			Α		2003	0530	' 1	NZ 2	2000-	5045	97		2	0000	517	
NO	2000	00299					2000]	NO 2	-000	2957			2	0000	609	<
US	2003	14788	34		A1		2003	0807	1	US 2	2003-	3568	24		· 2	0030	203	
	2004																	
US	2003	17023	34		A1		2003	0911	1	US 2	2003 -	4069	25		2	00304	404	
US	2005	00292	28		A1		2005	0106			2004 -					0040		
PRIORITY	APP	LN. 3	INFO	. :							1997-							
											L998-							
									1	US 1	1998-	2086	49	i	A3 1	99812	210	

A3 19981210 US 1998-209023 W 19981210 WO 1998-US26266

The authors disclose the treatment of disorders characterized by the AB overexpression of ErbB2. More specifically, human patients are treated with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline (e.g., doxorubicin or epirubicin). Preferably, the chemotherapeutic agent is Taxol.

114977-28-5 IT

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (in combination cancer therapy with anti-erbB-2 receptor antibodies)

114977-28-5 CAPLUS RN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) INDEX NAME)

Absolute stereochemistry.

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS 6 REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2006 ACS on STN L12 ANSWER 18 OF 55

ACCESSION NUMBER:

2000:911036 CAPLUS

DOCUMENT NUMBER:

134:76383

TITLE:

Oral pharmaceutical compositions containing taxanes Gutierrez-Rocca, Jose C.; Cacace, Janice L.; Selim,

INVENTOR(S):

Sami; Testman, Robert; Rutledge, J. Michael

Baker Norton Pharmaceuticals, Inc., USA

SOURCE:

PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT ASSIGNEE(S):

PATENT	NO.			KIN	D :	DATE		1	APPL	ICAT	ION 1	NO.		D	ATE	
					-											 518 <
WO 200	000782	247		A1		2000	1228		MO T	999-	US13	52 I		13	77700	210 <
· W:	AE,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,
	DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,
		KE,														
	MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	·SL,	ΤJ,
		TR,														
RV	: GH,															
	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	ĽU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,
	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG					

CA	2371	924			AA	2000	1228	CA	1999-	2371924		19990	0618	<
AU	9946	955			A1	2001	0109	AU	1999-	46955		19990	0618	
	7740				В2	2004	0617							
	9917				Α	2002	0709	BR	1999-	17403		19990	618	
	1221				A 1	2002	0717	EP	1999-	930408		19990	618	
	R:	AT,	BE,	CH,	DE,	DK, ES,	FR,	GB, GF	R, IT,	LI, LU,	NL,	SE, MC	PT,	
				RO,										
JР	2003			•	T2	2003	0121	JP	2001-	504316		19990	0618	
HU	2003	0083	6		A2	2003	0828	' HU	2003-	836		19990	0618	
	5162				Α	2004	0625	NZ	1999-	516279		19990	618	
	22362	-			C2	2004	0920	RU	2002-	100703		19990	618	
	1479				A1	2004	1124	ĘΡ	2004-	77062		19990	618	
	R:	AT.	BE,	CH,	DE,	DK, ES,	FR,	GB, GF	R, IT,	LI, LU,	NL,	SE, MC,	PT,	
				RO,						•				
RIORIT	Y APPI	-	INFO					EP	1999-	930408	A:	3 19990	618	
								WO	1999-1	US13821	W	19990	618	

Pharmaceutical compns. for oral administration to mammalian subjects AB comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, the carrier having an HLB value of at least about The compns. may also comprise 0-70% of a viscosity-reducing co-solubilizer. The compns. may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a 2-part drug wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compns. are also disclosed, whereby the compns. can be administered alone or in association with an oral bioavailability enhancing agent. A formulation containing Tween 80 at 18 mg/kg and paclitaxel gave an absolute bioavailability of 54% which was >15% for i.v. drug.

IT 114977-28-5, Docetaxel RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (oral pharmaceuticals containing taxanes)

114977-28-5 CAPLUS RN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) INDEX NAME)

Absolute stereochemistry.

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS 1 REFERENCE COUNT: RECORD, ALL CITATIONS AVAILABLE IN THE RE FORMAT ACCESSION NUMBER:

2005:1210172 CAPLUS

DOCUMENT NUMBER:

143:466194

TITLE:

Oral pharmaceutical compositions containing taxanes and methods of cancer therapy employing the same Gutierrez-Rocca, Jose C.; Cacace, Janice L.; Selim,

US 1996-733142

US 1997-863513

US 1998-55818

AU 1998-71300 NZ 1998-501127 A2 19961016

B2 19970527

A3 19980406

A3 19980422

A1 19980422

INVENTOR (S):

Sami; Testman, Robert; Rutledge, J. Michael

PATENT ASSIGNEE(S): SOURCE:

Baker Norton Pharmaceuticals, Inc., USA U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 863,513,

abandoned. CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6964946	B1	20051115	US 1998-55818	19980406
US 5968972	A	19991019	US 1996-608776	19960229 <-
US 6245805	B1	20010612	US 1996-733142	19961016
ZA 9609001	A	19970617	ZA 1996-9001	19961025 <-
NZ 516026	Α	20030630	NZ 1998-516026	19980422
AU 2002035584	A5	20020606	AU 2002-35584	20020422
AU 784159	B2	20060216	•	
US 2005267201	A1	20051201	US 2005-165896	20050624
PRIORITY APPLN. INFO.:			US 1995-7071P P	19951026
			US 1996-608776 A	2 19960229

The present invention relates to pharmaceutical compns. for oral AΒ administration to mammalian subjects comprising a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compns. may also comprise 0-70% of a viscosity-reducing co-solubilizer. The compns. may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compns. are also disclosed, whereby the compns. can be administered alone or in association with an oral bioavailability enhancing agent.

114977-28-5, Docetaxel IT

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral pharmaceutical compns. containing taxanes and methods of cancer therapy employing same)

114977-28-5 CAPLUS RN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:191189 CAPLUS

DOCUMENT NUMBER:

132:227475

TITLE:

Treatment of oncologic tumors with an injectable formulation of a Golgi apparatus disturbing agent

INVENTOR(S): Singh, Saira Sayed

PATENT ASSIGNEE(S):

Oncopharmaceutical, Inc., USA

SOURCE:

PCT Int. Appl., 32 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PAT	ENT 1	NO.			KINI)	DATE			API	PLIC	CAT	ION :	NO.		Ι	ATE		
	WO	2000					-	2000	0323		WO	199	99-T	JS21	312	-	1	9990	915	<
			AU, AT, PT,	BE,			DE,	DK,	ES,	FI,	FF	₹, 0	GΒ,	GR,	IE,	IT,	LU,	MC,	NL,	,
	CA	2344	316			AA		2000	0323		CA	199	99-2	2344	316		1	9990	915	<
	ΑU	9959	253			A1		2000	0403		ΑU	199	99-9	5925	3		1	.9990	915	<
	ΕP	1114	144			A1		2001	0711		ΕP	199	99-9	9469	55		1	.9990	915	
		R:	AT, IE,		CH,	DE,	DK,	ES,	FR,	GB,	GF	٦, ٦	IT,	LI,	LU,	NL,	SE,	MC,	PT,	,
	US	6287	•			В1		2001	0911	1	US	199	99-3	3973	90		1	9990	915	
	JР	2002	5252	68		T2		2002	0813		JΡ	200	00-5	5702	93		1	9990	915	
	US	2002	0127	03		A1		2002	0131		US	200	01-9	9121	15		2	20010	723	
	US	6497	904			B2		2002	1224											
PRIOR	ITY	APP	LN.	INFO	. :						US	199	98-:	1004	79P]	P 1	.9980	916	
											US	199	99-3	3973	90	1	A1 1	9990	915	
											WO	199	99-T	JS21	312	7	<i>N</i> 1	9990	915	

AB Novel pharmaceutical formulations for treating a cellular proliferative disease are provided comprising: a therapeutically effective amount of a Golgi apparatus disturbing agent; a biocompatible carrier; and a solvent. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A (BFA) and the biocompatible carrier is a polymer such as chitin or chitosan. Methods of treating cellular proliferative diseases using the pharmaceutical formulations are also described. Nude mice bearing human epithelial (KB-1) tumors were treated with a BFA/chitin/dimethylacetamide composition

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as addnl. pharmacol. agent; treatment of oncol. tumors with injectable formulation of golgi apparatus disturbing agent).

114977-28-5 CAPLUS RNCN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2006 ACS on STN L12 ANSWER 21 OF 55

ACCESSION NUMBER:

2000:456819 CAPLUS

DOCUMENT NUMBER:

133:84238

TITLE:

3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in

cancer chemotherapy

INVENTOR(S):

Langecker, Peter J.; Shawver, Laura Kay; Tang, Peng

Cho; Sun, Li

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2

PA'	TENT :	NO.			KIN	D	DATE				ICAT				D?	ATE		
						-										- -		
WO	2000	0385	19		A1		2000	0706		WO 1	999-	US31:	232		. 19	99912	230 <-	-
	W:	AL,	AM,	ΑT,	ΑŪ,	ΑZ,	ВA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
		DK,	EE,	ES,	FI,	GB,	GD,	GΕ,	GH,	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	
		KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	
		MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	
							VN,											
	RW:	GH,	GM,	ΚE,	LS,	MW,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZW,	ΑT,	BE,	CH,	CY,	DE,	
		DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	
		CG,	CI,	CM,	GA,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG					
CA	2357										.999-:						230 <-	-
	9916										.999-					99912	230	
EP	1139															99912		
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	ΝL,	SE,	MC,	PT,	
					LV,													
JР	2002	5333	60		T2		2002	1008		JP 2	000-	5904	34			99912		
AU	7609	64			B2		2003	0522	: .	AU 2	000-	2221	5			99912		
WO	2001	0492	87		A1		2001	0712		WO 2	000-	US180	058		20	00006	530	

```
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                                                   EP 2000-943334
                                                                                                                               20000630
                                                            20021127
                                                 A1
         EP 1259234
                                                            20060816
         EP 1259234
                                                 В1
                       AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                        IE, SI, LT, LV, FI, RO, MK, CY, AL
                                                            20031125
                                                                                   JP 2001-549655
                                                                                                                               20000630
                                                 T2
         JP 2003535038
                                                                                                                               20000630
                                                 Ε
                                                            20060915
                                                                                   AT 2000-943334
         AT 336245
                                                                                                                               20021202
                                                            20031009
                                                                                   US 2002-307483
         US 2003191162
                                                 A1
                                                                                                                         P
                                                                                                                               19981231
                                                                                   US 1998-114313P
PRIORITY APPLN. INFO .:
                                                                                                                               19991230
                                                                                   US 1999-476232
                                                                                                                         Α
                                                                                   WO 1999-US31232
                                                                                                                         W
                                                                                                                               19991230
                                                                                   US 2000-569545
                                                                                                                         Α
                                                                                                                               20000512
                                                                                   WO 2000-US18058
                                                                                                                         W
                                                                                                                               20000630
```

OTHER SOURCE(S): MARPAT 133:84238

AB 3-Heteroarylidenyl-2-indolinone compds. are provided that modulate the enzymic activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase-related cellular disorders, e.g. cancer. Furthermore, these compds. are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(heteroarylidenylindolinone derivs. for modulating protein kinase activity and in cancer chemotherapy)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2000:880923 CAPLUS

DOCUMENT NUMBER:

134:37055

TITLE:

Methods and compositions using FGF inhibitors and agonists for modulating cell proliferation and cell

death

INVENTOR(S):

Au, Jessie L. S.; Wientjes, M. Guillaume

PATENT ASSIGNEE(S):

USA

SOURCE:

PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PA									APPLICATION NO.						D	ATE	
		0746	34												2	0000	605 <
WO	2000 W:	AE, CZ, IL, MA,	AL, DE, IN, MD,	AM, DK, IS, MG,	AT, DM, JP,	AU, DZ, KE,	AZ, EE, KG,	BA, ES, KP,	BB, FI, KR,	GB, KZ,	GD, LC,	GE, LK,	GH, LR,	GM, LS,	HR, LT,	CR, HU, LU, SD,	ID, LV,
	RW:	GH, DE,	DK,	KE, ES, CI,	FI, CM,	FR, GA,	GB, GN,	GR, GW,	IE, ML,	IT, MR,	LU, NE,	MC, SN,	NL, TD,	PT, TG	SE,	CH, BF,	ВJ,
	2377				AΑ		2000	1214	1	CA 2	000-	2377	385		2	0000	605 <
EP	1206	234			A2		2002	0522		EP 2	000-	9434:	29		2	0000	605
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	${f AL}$						MC,	
JP	2003	5033	13		T2		2003	0128		JP 2	001-	5011	71		2	0000	605
US	6599	912			В1		2003	0729		US 2	000-	5875	59		2	0000	605
AU	7804	54			B2		2005	0324		AU 2	000-	5790	3		2	0000	605
US	2004	0100	01		A1		2004	0115	•	US 2	003-	4640	18		2	0030	618
PRIORIT	Y APP	LN.	INFO	.:												9990	
											999-					9991	
																9991	
																0000	
											000-					0000	
										WO 2	000-	US40	TO3		w 2	0000	6 05

- Methods and compns. for modulating the FGF effect on the sensitivity of AΒ malignant and normal cells to anticancer agents are provided. particular, methods and compns. for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compns. include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promote apoptosis and/or necrosis, an interferon, an interleukin, a tumor necrosis factor, and radiation. In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes administering to the subject an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent. FGF gene expression-based methods for diagnosis of proliferative disorders are also disclosed.
- 114977-28-5, Taxotere IT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(FGF inhibitors and agonists for modulating cell proliferation and cell death)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2000:824125 CAPLUS

DOCUMENT NUMBER:

134:4050

TITLE:

Treatment with anti-erbB2 antibodies

INVENTOR(S):
PATENT ASSIGNEE(S):

Cohen, Robert L.

SOURCE:

Genentech, Inc., USA PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PA	PATENT NO.					KIND DATE			APPLICATION NO.					Di -	ATE	-
WO	2000	0694	60		A1	200								2	0000	509 <
	W:	ΑE,	AG,	AL,	AM,	AT, AU	, AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,
		CU,	CZ,	DE,	DK,	DM, DZ	, EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,
•		ID,	ΙL,	IN,	IS,	JP, KE	, KG,	KP,	KR,	KZ,	LC,	LK,	ĿR,	LS,	LT,	LU,
		LV,	MA,	MD,	MG,	MK, MN	, MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,
		SG,	SI,	SK,	SL,	TJ, TM	, TR,	TT,	TZ,	UA,	ŪĠ,	UΖ,	VN,	ΥU,	ZA,	ZW,
		AM,	ΑZ,	BY,	KG,	KZ, MD	, RU,	ТJ,	TM							
	RW:	GH,	GM,	KE,	LS,	MW, SD	, SL,	SZ,	TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	DE,
		DK,	ES,	FI,	FR,	GB, GR	, IE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,
		CG,	CI,	CM,	GA,	GN, GW	, ML,	MR,	ΝE,	SN,	TD,	TG				
CA	2374	085			AA	200	01123	C	:A 20	000-2	2374	085		2	0000!	509 <
EP	1187	632			A1	200	20320	E	EP 20	200-9	9289	16		2	0000	509
	R:	AT,	BE,	CH,	DE,	DK, ES	, FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FI, RO										
· JP	2002	5442	38		T2	200	21224	Ĵ	TP 20	000-6	5179:	20		2	0000	509
AU	7823	25			B2	200	50721	P	U 20	000~4	1708	0		20	0000!	509
US	2003	1702	35		A1	200	30911	τ	JS 20	003-4	1295	19		20	0030	505
PRIORIT	Y APP	LN.	INFO	. :				τ	JS 19	999-3	1340	85P]	P 19	9990!	514
								υ	JS 20	2-000	56832	22	7	A1 2	0000!	509
								W	10 20	J-00C	JS12!	552	1	N 20	0000!	509

AB A method treating a human patient to or diagnosed with a tumor in which erbB2 protein is expressed comprising the following steps, performed sequentially: (a) treating the patient with a therapeutically effective amount of an anti-erbB2 antibody; (b) surgically removing the tumor, and then (c) treating the patient with a therapeutically effective amount of an anti-erbB2 antibody or of a chemotherapeutic agent.

IT 114977-28-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cancer treatment with anti-erbB2 antibodies)

RN 114977-28-5 CAPLUS

CN Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 24 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2002:158387 CAPLUS

DOCUMENT NUMBER:

136:210551

TITLE:

Method of treating hyperproliferative diseases using

active vitamin D analogues

INVENTOR(S):

Bishop, Charles W.; Mazess, Richard B.

PATENT ASSIGNEE(S):

Bone Care International, Inc., USA

SOURCE:

U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S.

Ser. No. 596,149.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

20

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002025950	A1	20020228	US 2001-891814	20010626
US 6503893	B2	20030107		
US 5763429	A	19980609	US 1996-781910	19961230 <
US 6537982	B1	20030325	US 1998-596149	19980223
US 2002128240	A1	20020912	US 2001-995911	20011128
CA 2450942	AA	20030103 .	CA 2002-2450942	20020626
WO 2003000023	A2	20030103	WO 2002-US20475	20020626
WO 2003000023	A3	20030731		
ህ. አው አር እነ	7 7 7 7 7 7	ר אוז איז איז	A RR RG RR RV RZ	CA. CH. CN.

```
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
                PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
                UA, UG, UZ, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
                GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
                GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                       20040421
                                                      EP 2002-756332
                                                                                   20020626
                                A2
      EP 1408983
               AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, FI, CY, TR
                                        20040811
                                                      CN 2002-812881
                                                                                   20020626
      CN 1520302
                                Α
                                                      JP 2003-506479
                                                                                   20020626
                                T2
                                        20041125
      JP 2004535429
                                                      US 2003-337506
                                                                                   20030107
                                        20030710
      US 2003130242
                                A1
                                        20040120
                                B2
      US 6680309
                                                      US 1996-781910
                                                                                A3 19961230
PRIORITY APPLN. INFO .:
                                                      US 1998-596149
                                                                                A2 19980223
                                                                                A2 19930910
                                                      US 1993-119895
                                                                                A2 19940624
                                                      US 1994-265438
                                                                                A2 19950403
                                                      US 1995-415488
                                                                                A2 19950607
                                                      US 1995-486387
                                                      US 2001-891814
                                                                                A2 20010626
                                                      WO 2002-US20475
                                                                                W 20020626
                               MARPAT 136:210551
OTHER SOURCE(S):
```

Methods use hypocalcemic vitamin D analogs to inhibit the AΒ hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia. Patients with advanced androgen-independent prostate cancer were treated with $1\alpha, 24$ -dihydroxyvitamin D2.

114977-28-5, Docetaxel IT

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministration with cytotoxic; hypocalcemic vitamin D analogs for treating hyperproliferative diseases)

114977-28-5 CAPLUS RN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) INDEX NAME)

Absolute stereochemistry.

CAPLUS COPYRIGHT 2006 ACS on STN L12 ANSWER 25 OF 55

ACCESSION NUMBER:

1996:533912 CAPLUS

DOCUMENT NUMBER:

125:185194

TITLE:

Treatment of patients with liver metastases

Fumoleau, P.

AUTHOR(S):
CORPORATE SOURCE:

Center Regionale de Lutte Contre le Cancer,

Nantes-Atlantique, Herblain, 44805, Fr.

SOURCE:

Anti-Cancer Drugs (1996), 7(Suppl. 2,

Management of Advanced Breast Cancer: Patient Needs,

Challenges and New Treatment Options), 21-23

CODEN: ANTDEV; ISSN: 0959-4973

PUBLISHER:

Rapid Science Publishers

DOCUMENT TYPE:

Journal

LANGUAGE:

English

The presence of liver metastases is a very poor prognostic factor for patients with metastatic breast cancer. Liver metastases are generally less responsive to chemotherapy than metastases in other sites, and patients with liver lesions have a shorter survival duration than patients with other sites of disease. The results from 5 multicenter phase II studies of docetaxel as a first-line treatment for metastatic breast cancer were analyzed with regard to the presence or absence of liver lesions, which were found in 39% of the 209 patients involved. Response rates to docetaxel, 100 or 75 mg/m2, were maintained in the presence of liver lesions and the median survival across all five studies was 16.4 mo for all patients and 14.7 mo for patients with liver lesions. Similarly, when results from 129 patients given docetaxel as a second-line treatment were analyzed, the response rates and survival durations were not reduced in the 57% of patients who had liver lesions. The presence of liver metastases does not reduce the probability or duration of response to docetaxel as a first- or second-line treatment for advanced breast cancer.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of patients with liver metastases)

RN 114977-28-5 CAPLUS

Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 26 OF 55

MEDLINE on STN

ACCESSION NUMBER:

2000024224 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 10560434

TITLE:

A case of multiple liver metastases from breast cancer

successfully treated with intra-arterial administration of

docetaxel.

Maeda Y; Nishida M; Takao T; Harada K; Mori N; Tamesa T; AUTHOR:

Somura H; Tangoku A; Oka M; Konishi T Dept. of Surgery II, Yamaguchi University School of CORPORATE SOURCE:

Medicine.

Gan to kagaku ryoho. Cancer & chemotherapy, (1999 SOURCE:

Oct) Vol. 26, No. 12, pp. 1951-4.

Journal code: 7810034. ISSN: 0385-0684.

Japan PUB. COUNTRY:

(CASE REPORTS) DOCUMENT TYPE:

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

Japanese

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199911

ENTRY DATE:

Entered STN: 13 Jan 2000

Last Updated on STN: 13 Jan 2000 Entered Medline: 26 Nov 1999

Docetaxel is an excellent agent with a high antitumor effect for AB the treatment of advanced/recurrent breast cancer. A 55-year-old female with metastatic liver tumors from breast cancer showed. a remarkable response to intra-arterial administration of docetaxel (20 mg/week, or 40 mg/2 weeks). Since CT and MRI imaging revealed multiple metastases in the liver, intra-arterial chemotherapy was selected. No critical side effect was found during this chemotherapy. A CT scan 3 months after chemotherapy showed a partial response. We conclude that this intra-arterial chemotherapy using docetaxel will be safe and useful for liver metastases from breast cancer.

L12 ANSWER 27 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1998:564267 CAPLUS

DOCUMENT NUMBER:

129:197984

TITLE:

Combined tumor suppressor gene therapy and

chemotherapy in the treatment of neoplasms

INVENTOR(S):

Nielsen, Loretta; Horowitz, Jo Ann; Maneval, Daniel C.; Demers, G. William; Rybak, Mary Ellen; Resnick,

Gene

PATENT ASSIGNEE(S):

Canji, Inc., USA

SOURCE:

PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	rent 1				KIN	o :	DATE		i	APPL:	[CAT	ION I	NO .		D	ATE		
WO	9835 9835	554					 1998: 1998:		Ī	WO 1	998-1	JS35:	14		1	99802	217 <-	-
WO		AL,	ΔM						BG.	BR.	BY.	CA.	CH.	CN,	CU,	CZ,	DE,	
	".						GE,											
							LR,											
		NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	
		UA,	UG,	US,	UZ,	VN,	YU,	ZW										
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	DE,	DK,	ES,	FI,	
		FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	
		GA,	GN,	ML,	MR,	ΝE,	·SN,	TD,	TG									
CA	2282	683			AA		1998	0820	(CA 19	998-2	2282	583		19	99802	217 <-	-
ΑU	9864	380			A1		1998	0908	i	AU 19	998-6	64380	כ	-	19	9980	217 <-	- .
ΑU	7376	21			B2	:	2001	0823				•						
ΕP	9697	20			A2		2000	0112	1	EP 19	998-	9100	38		19	99802	217 <-	-
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		TE.																

IE, FI

	25222	A	20010223	MZ	1998-337283		19980217	
	337283			_	=			
HU 2	200004326	A2	20010228	HU	2000-4326		19980217	
JP 2	2001511815	T2	20010814	JP	1998-536033		19980217	
BR 9	807418	Α	20020122	BR	1998-7418		19980217	
US 2	2003060434	A1	20030327	US	1999-311772		19990513	
NO 9	9903943	Α	19991015	NO	1999-3943		19990817	<
	2003064949	A1	20030403	US	2002-86294		20020228	
	2004235736	A1	20041125	US	2004-824058		20040413	
US 2	2005142112	A1	20050630	US	2004-823932		20040413	
PRIORITY	APPLN. INFO.:			US	1997-38065P	P	19970218	
				US	1997-801285	A	19970218	
			•	US	1997-801681	A	19970218	
				US	1997-801755	Α	19970218	
				US	1997-801765	Α	19970218	
				US	1997-47834P	P	19970528	
				US	1998-24932	В1	19980217	•
				WO	1998-US3514	W	19980217	
				US	1999-311772	В3	19990513	

AB In one embodiment, the invention provides methods of treating mammalian cancer or hyperproliferative cells, the method comprising contacting the cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting the cells with at least one adjunctive anticancer agent. The invention also provides for a pharmacol. composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, as well as a kit for the treatment of mammalian cancer or hyperproliferative cells.

IT 114977-28-5, Taxotere

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tumor suppressor gene therapy-chemotherapy combination for treatment of neoplasms and hyperproliferative cells)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 28 OF 55 MEDLINE on STN
ACCESSION NUMBER: 2001066728 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10907946

TITLE:

Phase II study of docetaxel in patients with

liver metastases from breast cancer. UK study group.

AUTHOR:

SOURCE:

Coleman R E; Howell A; Eggleton S P; Maling S J; Miles D W

CORPORATE SOURCE: West

Weston Park Hospital NHS Trust, Sheffield, UK.

Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, (2000 May)

Vol. 11, No. 5, pp. 541-6.

Journal code: 9007735, ISSN: 0923-7534.

PUB. COUNTRY:

Netherlands

DOCUMENT TYPE: (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

200012

ENTRY DATE:

Entered STN: 22 Mar 2001

Last Updated on STN: 22 Mar 2001

Entered Medline: 28 Dec 2000

AB BACKGROUND: Previous phase II studies of docetaxel have

indicated that hepatic metastases from breast cancer respond well to

first-line treatment with docetaxel. The objective of this

prospective, open label phase II study therefore was specifically to

evaluate the activity and safety of docetaxel in this

indication. PATIENTS AND METHODS: The study recruited 47 women (mean age 50 years, range 33-66 years) with hepatic metastases from breast cancer

who fulfilled the eligibility criteria. After premedication with steroids, patients received a one-hour intravenous infusion of docetaxel 100 mg/m2 at three-weekly intervals for up to eight

cycles. Response to treatment during medication was assessed after three, six and where appropriate, eight cycles and every three month follow-up thereafter, until disease progression or death. RESULTS: The best overall response rate (ORR) for evaluable patients was 64.3% (95% CI: 48.0-78.5%).

In terms of the primary efficacy parameters, the ORR at the sixth cycle of treatment was 62% (95% CI: 45%-80%) with 17% complete responses. The median duration of response was 139 days (95% CI: 111-216 days) and the median survival duration calculated on an intent-to-treat basis was 335 days (227-568 days, 95% CI). One (2%) toxic death was reported.

CONCLUSIONS: Docetaxel is a highly effective cytotoxic agent in the treatment of patients with liver metastases from breast cancer.

MEDLINE

L12 ANSWER 29 OF 55

MEDLINE on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

PubMed ID: 9446016

TITLE:

[Docetaxel (taxotere) for therapy of breast

carcinoma. Highest effectiveness with moderate side

effects].

1998056505

Docetaxel (Taxotere) zur Therapie des

Mammakarzinoms. Hochste Wirksamkeit bei moderaten

Nebenwirkungen.

AUTHOR:

von Minckwitz G; Costa S D

CORPORATE SOURCE:

Klinik fur Gynakologie und Geburtshilfe, Johann Wolfgang

Goethe-Universitat Frankfurt.. minckwitz@em.uni-

frankfurt.de

SOURCE:

Medizinische Klinik (Munich, Germany: 1983), (1997

Sep 15) Vol. 92 Suppl 4, pp. 4-9. Ref: 16 Journal code: 8303501. ISSN: 0723-5003.

PUB. COUNTRY: DOCUMENT TYPE:

GERMANY: Germany, Federal Republic of Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE:

German

FILE SEGMENT: Priority Journals

ENTRY MONTH:

199801

ENTRY DATE:

Entered STN: 6 Feb 1998

Last Updated on STN: 6 Feb 1998 Entered Medline: 27 Jan 1998 CLINICAL RESULTS: Docetaxel is a taxan which has proven high efficacy in the treatment of breast cancer. The results are consistent throughout all phases of clinical evaluation. High response rates have been observed especially for women after failure of anthracyclins or with liver metastases. Response rates are superior to doxorubicin, while the extent of the side effects is comparable. CONCLUSION: Due to the different toxicity profile a combination of docetaxel and anthracyclins is feasible and has already been demonstrated in early clinical trials. The role of the combinatory treatments in first line or adjuvant setting is currently under investigation.

L12 ANSWER 30 OF 55 MEDLINE ON STN ACCESSION NUMBER: 96351131 MEDLINE DOCUMENT NUMBER: PubMed ID: 8745348

TITLE: Docetaxel: a new defence in the management of

breast cancer.

AUTHOR: Piccart M

CORPORATE SOURCE: Department of Chemotherapy, Institut Jules Bordet,

Brussels, Belgium.

SOURCE: Anti-cancer drugs, (1995 Jul) Vol. 6 Suppl 4, pp.

7-11. Ref: 12...

Journal code: 9100823. ISSN: 0959-4973.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199610

ENTRY DATE: Entered STN: 25 Oct 1996

Last Updated on STN: 25 Oct 1996 Entered Medline: 16 Oct 1996

The results of nine phase II trials of docetaxel in the first-ΑB and second-line treatment of patients with advanced breast cancer are summarized. All 316 patients included in this report received docetaxel at a dose of 100 mg/m2 administered over 1 h every 3 weeks on an outpatient basis. One hundred and fifty-four patients received docetaxel as first-line therapy for advanced disease, half of whom had received prior adjuvant chemotherapy (finished at least 1 year previously). An overall response rate of 59% (95% CI: 51-67) was achieved in these patients, with a median duration of response of 8.3 months and a median time to progression of 4.9 months. Similar results were seen in a subgroup of 68 patients with liver metastases. Among the 162 patients given docetaxel as second-line therapy, 134 had strictly defined anthracycline-resistant disease; 73 had liver metastases. The combined overall response rate for anthracycline-resistant patients in two US studies was 48% (95% CI: 37-59) while that in a multicenter French study was 29% (95% CI: 18-44). The median duration of response in each case was 6.3 and 5.5 months, respectively, with an overall median survival duration of 11 and 10 months, respectively. Among patients with liver metastases, second-line treatment with docetaxel achieved an overall response rate of 32%, a median duration of response of 7.8 months and a median survival duration of 9 months. These results for docetaxel as both first- and second-line therapy are comparable with those achieved with doxorubicin and are particularly promising in patients with liver metastases and anthracycline-resistant disease.

L12 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:736476 CAPLUS

DOCUMENT NUMBER: 131:346535

TITLE: Use of neomycin for treating angiogenesis-related

diseases

INVENTOR(S): Hu, Guo-Fu; Vallee, Bert L.

PATENT ASSIGNEE(S): The Endowment for Research In Human Biology, Inc., USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

PE: Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
DATE
                                                           APPLICATION NO.
                                 KIND
                                           DATE
      PATENT NO.
                                                           -----
                                 _ - - -
                                                           WO 1999-US10269
                                                                                           19990511 <---
                                           19991118
                                  A1
      WO 9958126
           W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
                DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
                 MD, RU, TJ, TM
           RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
                 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                                                           19990511 <--
                                                           CA 1999-2331620
                                  AA
                                           19991118
      CA 2331620
                                                                                           19990511 <--
                                                           AU 1999-39804
                                  A1
                                           19991129
      AU 9939804
                                                           EP. 1999-922915 ...
                                                                                           19990511
                                           20010321
                                  A1
      EP 1083896
           R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                 IE, FI
                                                                                           20001109
                                   B1
                                           20021119
                                                           US 2000-700436
      US 6482802
                                                                                       P
                                                                                           19980511
                                                            US 1998-84921P
PRIORITY APPLN. INFO.:
                                                                                           19990511
                                                                                       W
                                                            WO 1999-US10269
```

The present invention is directed to using neomycin or an analog thereof as a therapeutic agent to treat angiogenesis-related diseases, which are characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-angiogenic agent or an anti-neoplastic agent. The present invention is further directed to a method for screening neomycin analogs having anti-angiogenic activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases. A dose of 20 ng neomycin/embryo or higher completely inhibited angiogenin-induced angiogenesis in the chorioallantoic membrane (CAM) assay. Neomycin inhibits angiogenin-induced angiogenesis mainly through inhibition of nuclear translocation of angiogenin.

IT 114977-28-5, Docetaxel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

RN 114977-28-5 CAPLUS

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 32 OF 55 MEDLINE ON STN
ACCESSION NUMBER: 1999314769 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10408850

TITLE: Phase II study of docetaxel in patients with

metastatic pancreatic cancer: a Japanese cooperative study.

Cooperative Group of Docetaxel for Pancreatic

Cancer in Japan.

AUTHOR: Okada S; Sakata Y; Matsuno S; Kurihara M; Sasaki Y; Ohashi

Y; Taguchi T

CORPORATE SOURCE: Department of Internal Medicine, National Cancer Center

Hospital, Tokyo, Japan.

SOURCE: British journal of cancer, (1999 May) Vol. 80,

No. 3-4, pp. 438-43.

Journal code: 0370635. ISSN: 0007-0920.

PUB. COUNTRY: SCOTLAND: United Kingdom

DOCUMENT TYPE: (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199907

ENTRY DATE: Entered STN: 27 Jul 1999

Last Updated on STN: 27 Jul 1999 Entered Medline: 15 Jul 1999

Docetaxel has been reported to show promising anti-tumour AB activity in pancreatic ductal cancer (PC). This study was conducted to evaluate the activity and toxicity of moderate-dose (60 mg m(-2)) docetaxel in Japanese chemo-naive patients with measurable metastatic PC. The patients had a performance status of 0-2. received docetaxel intravenously over a 1- to 2-h period without any premedication for hypersensitivity reactions. This treatment was repeated every 3-4 weeks with dose adjustments based on the toxic effects observed. Twenty-one patients were eligible and treated with The median number of courses was 2 (range, 1-4). docetaxel. of the patients achieved an objective response; seven showed no change and 13 showed progressive disease. In one patient, the response was not assessable because of early death. The median survival time for all patients was 118 days. The main grade 3-4 toxicities by patient were leucocytopenia (67%) and neutropenia (86%). Other grade 3-4 toxicities included anaemia (10%), thrombocytopenia (5%), nausea/vomiting (29%), anorexia (29%), GOT/GPT increase (10%), alkaline phosphatase increase (14%), malaise/fatigue (33%) and alopecia (24%). In conclusion, docetaxel, administered on this schedule, did not show significant anti-tumour activity in patients with metastatic PC.

L12 ANSWER 33 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2000:824124 CAPLUS 134:506 DOCUMENT NUMBER: Treatment of refractory human tumors with epidermal TITLE: growth factor receptor antagonists Waksal, Harlan W. INVENTOR(S): Imclone Systems Incorporated, USA PATENT ASSIGNEE(S): PCT Int. Appl., 31 pp. SOURCE: CODEN: PIXXD2 Patent DOCUMENT TYPE: English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: DATE APPLICATION NO. DATE KIND PATENT NO. ______ _____ ----_____ 20001123 WO 2000-US11756 20000501 <--WO 2000069459 **A**1 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 20001123 CA 2000-2373815 20000501 <--AA CA 2373815 20020528 BR 2000-10524 20000501 BR 2000010524 Α 20020703 EP 2000-928671 20000501 EP 1218032 **A1** R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL A2 20020828 HU 2002-1480 20000501 HU 200201480 20030217 EE 2001-603 20000501 EE 200100603 Α 20030702 JP 2000-617919 20000501 T2 JP 2003520195 B2 20050915 AU 2000-46871 20000501 AU 782994 20060118 CN 2005-10055865 20000501 CN 1720994 Α 20020131 US 2001-840146 20010424 A1 US 2002012663 Α 20020114 NO 2001-5546 20011113 NO 2001005546 Α 20030213 ZA 2001-9347 20011113 ZA 2001009347 20020430 BG 2001-106110 20011114 Α BG 106110 A1 20030821 US 2001-996954 20011130 US 2003157104 20050526 US 2004-18950 20041220 US 2005112120 A1 US 1999-312284 A 19990514 PRIORITY APPLN. INFO.: US 1999-374028 A 19990813 CN 2000-810321 A3 20000501 WO 2000-US11756 W 20000501 , US 2001-840146 A1 20010424 A method of inhibiting the growth of refractory tumors that are stimulated AB by a ligand of epidermal growth factor in human patients comprises treating the human patients with an effective amount of an epidermal growth factor receptor antagonist, e.g. a monoclonal antibody. IT 114977-28-5, Docetaxel RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (EGF receptor antagonists for treatment of refractory human tumors) RN114977-28-5 CAPLUS Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-

(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-

trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R,\beta S)$ - (9CI)

INDEX NAME)

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS 3 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2006 ACS on STN L12 ANSWER 34 OF 55

ACCESSION NUMBER:

1999:454255 CAPLUS

DOCUMENT NUMBER:

131:92524

TITLE:

Therapeutic liposome-encapsulated immunomodulators

Spitler, Lynn E.; Fidler, Issaiah J.

INVENTOR(S): PATENT ASSIGNEE(S):

Jenner Biotherapies, Inc., USA

SOURCE:

PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO.					KIND DATE				APPL:	ICAT	ION 1		DATE				
WO	WO 9935162				A1 19990715			WO 1999-US272						19990106 <			<	
	W:	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
		DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	
		KE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	
							PT,											
							VN,											TM
	RW:						SD,											
							IT,					SE,	BF,	ВJ,	CF,	CG,	CI,	
		CM,	GΑ,	GN,	GW,		MR,											
AU	9922	141			A1		1999									9990		<
US	2003	0179	76		A1		2003	0123	1	US 2	001-	76454	46		_	0010		
US	2004	1465	52		A1		2004	0729	1	US 2	003-	7056	18 ·			0031		
PRIORITY	APP	LN.	INFO	. :								7071				9980		
												2260				9990:		
									1	WO 1	999-	US27	2		-	9990		
												76454	46		A1 2	0010		

The present invention relates to the use of novel compns. of lipopeptides AB that are immunomodulators encapsulated as liposomes or free-form for the treatment of neoplasia and in reducing chemotherapeutically induced cellular pathol., including mucositis. These lipopeptides may be administered alone or in combination with a second antineoplastic agent. E.g., a synthetic JBT 3002 lipopeptide entrapped in phosphatidylcholine/phosphatidylserine liposomes is shown to be a potent activator of tumoricidal properties of murine macrophages by a mechanism that differs from that of lipopolysaccharides. These data highly support the in vivo use of multilamellar liposome-encapsulated JBT 3002 to enhance host resistance to infections and cancer.

IT 114977-28-5, Taxotere RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination with; free or liposome-encapsulated lipopeptide

immunomodulators for tumor treatment and reduction of antitumor adverse effects)

CAPLUS 114977-28-5 RN

CN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

MEDLINE on STN L12 ANSWER 35 OF 55 97356889 MEDLINE ACCESSION NUMBER: PubMed ID: 9213325 DOCUMENT NUMBER:

Docetaxel combined with vinorelbine: phase I TITLE:

results and new study designs.

Fumoleau P; Fety R; Delecroix V; Perrocheau G; Azli N AUTHOR: CORPORATE SOURCE:

Medical Oncology Department, Centre Rene Gauducheau, CRLCC Nantes-Atlantique, Nantes-St Herblain, France.

Oncology (Williston Park, N.Y.), (1997 Jun) Vol.

11, No. 6 Suppl 6, pp. 29-31.

Journal code: 8712059. ISSN: 0890-9091.

United States PUB. COUNTRY: (CLINICAL TRIAL) DOCUMENT TYPE:

(CLINICAL TRIAL, PHASE I)

Journal; Article; (JOURNAL ARTICLE)

English LANGUAGE:

SOURCE:

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199709

Entered STN: 16 Sep 1997 ENTRY DATE:

Last Updated on STN: 16 Sep 1997

Entered Medline: 2 Sep 1997

This was a phase I dose-finding and pharmacokinetic study of vinorelbine AB (Navelbine) and docetaxel (Taxotere) as first-line chemotherapy for metastatic breast cancer. Vinorelbine dose, 20 or 22.5 mg/m2, on days 1 and 5, was followed on day 1 by docetaxel every 21 days, in doses increasing from 60 to 100 mg/m2. Two maximum tolerated doses were reached, the first at 75 mg/m2 of docetaxel and 22.5 mg/m2 of vinorelbine, and the second at 100 mg/m2 of docetaxel and 20 mg/m2 of vinorelbine. Symptomatic peripheral neuropathy was not observed.

The recommended doses for phase II studies are 75 to 85 mg/m2 of docetaxel on day 1 and 20 mg/m2 of vinorelbine on days 1 and 5, every 3 weeks. The treatment regimen, which included 3-day corticosteroid prophylaxis, resulted in only mild fluid retention. Responses were seen at all dose levels, with an 80% overall response rate at the higher recommended dose; the overall response rate for patients at all dose levels was 66%. A high rate of response, including a complete response, was observed in patients with liver metastases.

L12 ANSWER 36 OF 55 MEDLINE ON STN ACCESSION NUMBER: 96150144 MEDLINE DOCUMENT NUMBER: PubMed ID: 8546908

TITLE: A late phase II study of RP56976 (docetaxel) in

patients with advanced or recurrent breast cancer.

AUTHOR: Adachi I; Watanabe T; Takashima S; Narabayashi M; Horikoshi

N; Aoyama H; Taguchi T

CORPORATE SOURCE: Department of Medical Oncology, National Cancer Center

Hospital, Tokyo, Japan.

SOURCE: British journal of cancer, (1996 Jan) Vol. 73,

No. 2, pp. 210-6.

Journal code: 0370635. ISSN: .0007-0920.

PUB. COUNTRY: SCOTLAND: United Kingdom

DOCUMENT TYPE: (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199602

ENTRY DATE: Entered STN: 6 Mar 1996

Last Updated on STN: 6 Feb 1998 Entered Medline: 16 Feb 1996

A late phase II clinical trial of RP56976 (docetaxel), derived AΒ from Taxus baccata was performed to evaluate anti-tumour activity, time to progression and clinical toxicity in patients with advanced or recurrent breast cancer. The patients, between 15 and 80 years old with performance status (PS) of 0-2, received at least two cycles of docetaxel 60 mg m-2 intravenously at 3-4 week intervals. Of the 81 patients enrolled, the 72 eligible for the study were given a total of 327 cycles, with a median of four cycles each. Five patients obtained a complete response (CR) and 27 a partial response (PR); the response rate (RR) was 44.4% (95% confidence interval 32.7-56.6%). A relatively high RR of 9/28 (32.1%) was observed in patients who had received prior chemotherapy involving anthracyclines. The dose-limiting toxicity was grade 3-4 leucocytopenia or neutropenia, found in 78.9% and 85.9% patients respectively. Other severe (grade > 3) toxicities included alopecia (38%), anorexia (18.3%), nausea/vomiting (11.3%), and fatigue (9.9%). Hypersensitivity reactions, oedema and skin toxicity were not severe and were reversible. therapy-related death occurred 10 days after the initial dose was given. These findings indicate that docetaxel has potent activity against metastatic breast cancer, and that the dose of 60 mg m-2 is safe.

L12 ANSWER 37 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:123598 CAPLUS

DOCUMENT NUMBER: 136:161350

TITLE: Method of inhibiting angiogenesis associated with

malignant and neoplastic cells using active vitamin D

analogs

INVENTOR(S): Bishop, Charles W.; Mazess, Richard B.

PATENT ASSIGNEE(S): Bone Care International, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S.

Ser. No. 596,149.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002019375	A1	20020214	US 2001-891805	20010626
US 6573256	B2	20030603		
US 5763429	A	19980609	US 1996-781910	19961230 <
US 6537982	В1	20030325	US 1998-596149	19980223
PRIORITY APPLN. INFO.:			US 1996-781910	A3 19961230
			US 1998-596149	A2 19980223
			US 1993-119895	A2 19930910
		•	US 1994-265438	A2 19940624
			US 1995-415488	A2 19950403
			US 1995-486387	A2 19950607

MARPAT 136:161350 OTHER SOURCE(S):

Methods are disclosed which use active vitamin D analogs for the inhibition of angiogenesis associated with malignant and neoplastic cells. Methods comprise the application of an effective amount of a hypocalcemic hydroxyvitamin D compound to inhibit the angiogenesis of malignant cells, induce the apoptosis of malignant cells, and regress the growth of tumor cells.

114977-28-5, Docetaxel IT

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydroxyvitamin D compds. for inhibition of tumor-associated angiogenesis, and use with other agents)

114977-28-5 CAPLUS RN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 38 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

2002:72803 CAPLUS 136:113175

Method of treating malignancy-associated hypercalcemia

using active vitamin D analogs

Bishop, Charles W.; Mazess, Richard B.

Bone Care International, Inc., USA

U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S.

5,763,429.

CODEN: USXXCO

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S): PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

20

PATENT INFORMATION:

```
APPLICATION NO.
                                                                            DATE
                                    DATE
                            KIND
     PATENT NO.
                                                  ______
                                                                             _____
                                    _____
                            _ _ _ _
                                                                            20010626
                                                  US 2001-891763
                                    20020124
     US 2002010165
                             Α1
                             B2
                                    20030520
     US 6566353
                                                  US 1996-781910
                                                                            19961230 <--
                                    19980609
     US 5763429
                             Α
                                    20030109
                                                  CA 2002-2451037
                                                                            20020626
                             AΑ
     CA 2451037
                                    20030109
                                                  WO 2002-US20320
                                                                            20020626
                             A2
     WO 2003002060
                                    20040311
                             A3 ·
     WO 2003002060
              AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
              GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
              GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                    20040512
                                                 EP 2002-747979
                                                                            20020626
                             A2
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                                             20020626
                                    20040811
                                                  CN 2002-812871
     CN 1520301
                             Α
                                                                             20020626
                                    20041125
                                                  JP 2003-508302
     JP 2004535439
                             T2
                                    20031106
                                                  US 2003-441731
                                                                             20030520
     US 2003207810
                             A1
                                                  US 1996-781910
                                                                         A2 19961230
PRIORITY APPLN. INFO.:
                                                                         A2 19930910
                                                  US 1993-119895
                                                                         A2 19940624
                                                  US 1994-265438
                                                                         A2 19950403
                                                  US 1995-415488
                                                                         A2 19950607
                                                  US 1995-486387
                                                                         A3 19980223
                                                  US 1998-596149
                                                  US 2001-891763
                                                                             20010626
                                                                         W
                                                  WO 2002-US20320
                                                                             20020626
                            MARPAT 136:113175
OTHER SOURCE(S):
     Methods utilizing active vitamin D analogs for the treatment of
     malignancy-associated hypercalcemia. Methods comprise the application of an
     effective amount of a hypocalcemic vitamin D compound to alleviate
     hypercalcemia, lower serum parathyroid hormone related protein (PTHrP)
     levels. The hypocalcemic vitamin D compds. can be coadministered with a
     cytotoxic agent.
     114977-28-5, Docetaxel
IT
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
         (method of treating malignancy-associated hypercalcemia using active
         vitamin D analogs coadministered with cytotoxic agents)
     114977-28-5 CAPLUS
RN
```

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-

(CA

trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI)

Absolute stereochemistry.

INDEX NAME)

L12 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

. 2001:507531 CAPLUS

DOCUMENT NUMBER:

135:107247

TITLE:

Preparation of 3-heteroarylidenyl-2-indolinone

compounds for modulating protein kinase activity and

for use in cancer chemotherapy

INVENTOR(S):

Langecker, Peter J.; Shawver, Laura K.; Tang, Peng C.;

Sun, Li

PATENT ASSIGNEE(S):

SOURCE:

Sugen, Inc., USA

PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PA'	TENT NO.		KIN	D DATE	Al		CATIO	D	DATE				
WO	WO 2001049287			20010	W	0 200	00-119	31805	R	20000630			
WO				AT, AU,									
	CII.	CZ. I	DE. DK.	DM, DZ,	EE.	ES.	FI, C	3B, (GD, G	E, GI	I, GM,	HR,	HU,
	ID.	IL. 1	IN. IS.	JP, KE,	KG.	KP.	KR, I	KZ, I	LC, L	K, LI	LS,	LT,	LU,
				MK, MN,									
				TJ, TM,									
	RW: GH,	GM, F	Œ, LS,	MW, MZ,	SD,	SL, S	sz, 1	rz, t	JG, Z	W, A.	, BE,	CH,	CY,
	DE,	DK, E	ES, FI,	FR, GB,	GR,	IE,	IT, I	LU, N	MC, N	L, P:	SE,	BF,	ВJ,
				GA, GN,									
WO				WO 1999-US31232									
				AZ, BA,									
				GB, GD,									
				KZ, LC,									
	MW,	MX, N	10, NZ,	PL, PT,	RO,	RU, S	SD, S	SE, S	sg, s	I, SI	C, SL,	TJ,	TM,
				UŻ, VN,									
				MW, SD,									
				GB, GR,							s, BF,	BJ,	CF,
				GN, GW,							-	0001	220
	20030738			20030)417	U	2 13	99-4	/6232		1	9991	230 630.
	1259234					13.	P 200	JU-94	13334			0000	630
EP	1259234					CD (ו מים	וייי ד	т. т	т мт	. er	MC	DT
				DK, ES,				L1, 1	JI, D	J, 141	, JE,	MC,	FI,
TD	20035350			FI, RO,				11_5/	10655		2	0000	630
	20035350											0021	
	APPLN.			20031	1009				76232				
KIOKII.	L AFFUN.	IMFO. :	•						3123			9991:	
	•								59545				
									L4313			9981	
										_	_		

OTHER SOURCE(S):

MARPAT 135:107247

The present invention relates to 3-heteroarylidenyl-2-indolinone compds. AB [I; R1 = H, alkyl; R2 = O, S; R3 = H; R4, R5, R6, R7 = H, alkyl, alkoxy,aryl, aryloxy, alkaryloxy, halo, trihalomethyl, S(O)R, SO2NRR', SO3R, SR, NO2, NRR', OH, cyano, COR, O2CR, (CH2)nCO2R, CONRR'; A = a five membered heteroaryl selected from (un) substituted thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, etc.; n = 0-3; R, R' = H, alkyl, aryl] or physiol. acceptable salts or prodrugs thereof are prepared These compds. modulate the enzymic activity of protein kinases such as receptor protein tyrosine kinase, cellular tyrosine kinase, and serine threonine kinase and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. Furthermore, these compds. are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer. In a cellular-based assay for inhibiting the receptor phosphorylation, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2indolinone (II) inhibited Flk-1-autophosphorylation with IC50 of .apprx.1 μM . II in vitro inhibited proliferation of endothelial cells induced by VEGF with IC50 of .apprx.0.07 μM . Although II in vitro had no direct inhibitory effect on a variety of tumor cell lines at concentration up

to

CN

 $50~\mu\text{M},$ it in vivo demonstrated a significant suppression of tumor growth against a broad spectrum of tumor types s.c. implanted into immunocompromised mice and whose growth are driven by various growth factors such as PDGF, EGF, and Her2.

IT 114977-28-5, Docetaxel

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for cancer chemotherapy in combination with heteroarylidenylindolinone derivative; preparation of 3-heteroarylidenyl-2-indolinone compds. for modulating protein kinase activity for cancer chemotherapy)

RN 114977-28-5 CAPLUS

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 40 OF 55 MEDLINE ON STN ACCESSION NUMBER: 2000024226 MEDLINE DOCUMENT NUMBER: PubMed ID: 10560436

TITLE: A case of hepatic arterial infusion chemotherapy with

docetaxel for liver metastasis from breast cancer.

AUTHOR: Kim S J; Maeura Y; Ueda N; Saito M; Matsunaga S

CORPORATE SOURCE: Senri Hoken Medical Center, Dept. of Surgery, Shinsenri

Hospital.

SOURCE: Gan to kagaku ryoho. Cancer & chemotherapy, (1999

Oct) Vol. 26, No. 12, pp. 1959-62.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY: Japan

DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199911

ENTRY DATE: Entered STN: 13 Jan 2000

Last Updated on STN: 13 Jan 2000 Entered Medline: 26 Nov 1999

AB We experienced a case of hepatic arterial infusion chemotherapy using docetaxel for liver metastasis, which showed no response to CEF therapy, from breast cancer. A 63-year-old woman had undergone modified radical mastectomy for right breast cancer (T2aN1bM0: Stage II) in October, 1995. Six-cycle CMF therapy and toremifene citrate (40 mg/day) were administered as adjuvant therapy, but multiple recurrent tumors in liver, lung, and local site were detected in February 1997. Six-cycle CEF therapy was given for recurrent disease and there was a complete response for lung and local recurrence, but no change in liver metastasis. Chemoendocrine therapies using 5'-DFUR or CMitF in addition to TAM and fadrozole hydrochloride hydrate had developed progressive disease for liver metastasis. A catheter and port kit were operatively inserted and implanted in March 1998. Hepatic arterial infusion of docetaxel (30-40 mg/body/month, one hour administration) was repeated 4 times, once in our clinic. Leukopenia, general fatigue and fever, which were mild and did not require any treatment, appeared as side effects. This treatment reduced multiple liver metastatic sites on abdominal CT finding and was thought to be a partial response. However, the patient had multiple brain metastasis and died on August 2, 1998. While docetaxel, even by systemic administration, has a 36-77% response rate for liver metastasis, arterial infusion might have a good response and mild side effect with a lower dose than by intravenous administration.

L12 ANSWER 41 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2001:161407 CAPLUS

DOCUMENT NUMBER:

134:202681

TITLE:

Dietary supplementation with, and methods for,

administration of a yeast-derived selenium product.

and use in cancer chemotherapy

INVENTOR(S):

Hsia, Houn Simon; Yang, Ping; Arnold, Michael

PATENT ASSIGNEE(S):

Viva America Marketing Corporation, USA

SOURCE:

U.S., 9 pp., Cont.-in-part of U.S. 6,140,107.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
					
	US 6197295	B1	20010306	US 1999-303993	19990503
	US 6140107	Α	20001031	US 1996-719572	19960925 <
	US 6368643	B1	20020409	US 1999-298114	19990423
	US 2001043925	A1	20011122	US 2001-801124	20010305
	US 6576233	B2	20030610		
	PRIORITY APPLN. INFO.:			US 1996-719572	A2 19960925
				US 1997-802773	B2 19970221
				US 1998-15758	A2 19980129
				US 1998-82939P	P 19980424
				US 1999-303993	A3 19990503
				_	

The invention solves the need for nontoxic forms of selenium which is an AB essential part of the human diet. The invention provides dried-yeast products containing selenium, as well as a method of producing the dried yeast products. The method uses selenium having high biol. activity but low toxicity. The invention also provides nutritional supplements containing the selenium-containing dried yeast products and methods of administering these products and supplements to improve human health. The invention also provides a practically nontoxic yeast selenium product having increased intracellular selenium concns., as well as methods to reduce tumor cell growth by administration of a selenium yeast product comprising yeast Saccharomyces boulardii sequela PY31 (ATCC 74366) in combination with chemotherapeutic agents.

114977-28-5, Taxotere IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dietary supplementation with yeast-derived selenium product, and use in cancer chemotherapy)

114977-28-5 CAPLUS RN

Benzenepropanoic acid, β -[[(1,1-dimethylethoxy)carbonyl]amino]-CN α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1Hcyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, $(\alpha R, \beta S)$ - (9CI) INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 42 OF 55 MEDLINE on STN

ACCESSION NUMBER: 2001191709 MEDLINE

DOCUMENT NUMBER: PubMed ID: 11124653

TITLE: Chemotherapy-induced noncardiogenic pulmonary edema related

to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.

AUTHOR: Briasoulis E; Froudarakis M; Milionis H J; Peponis I;

Constantopoulos S; Pavlidis N

CORPORATE SOURCE: Department of Medical Oncology, Ioannina University

Hospital, Ioannina, Greece.. ebriasou@otenet.gr

SOURCE: Respiration; international review of thoracic diseases,

(2000) Vol. 67, No. 6, pp. 680-3.

Journal code: 0137356. ISSN: 0025-7931.

PUB. COUNTRY: Switzerland DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200104

ENTRY DATE: Entered STN: 10 Apr 2001

Last Updated on STN: 10 Apr 2001

Entered Medline: 5 Apr 2001

Several cancer therapeutic agents have been associated with pulmonary AB toxicity. Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema (NPE) while on treatment with gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor (G-CSF) support. Gemcitabine, a deoxycytidine analogue, is reported to produce mild self-limiting and only occasionally severe pulmonary toxicity. The microtubule stabilizer docetaxel has been associated with water retention complications. The combination of these two agents has shown promising activity in several solid tumors and is in a phase of clinical development with prophylactic G-CSF in most of the trials due to the high rate of dose-limiting neutropenia observed with this combination. In our case pulmonary toxicity resolved rapidly following the administration of corticosteroids. A possible deleterious synergy of the compounds involved in this case is discussed and the medical literature on NPE related to cancer therapy is shortly reviewed. We conclude that NPE should always be considered in patients with respiratory function deterioration while on therapy with the gemcitabine-docetaxel combination and G-CSF. Corticosteroids can provide maximum benefit if started early upon diagnosis coupled with withdrawal of the causative drugs. Copyright 2000 S. Karger AG, Basel

1999197818 MEDLINE ACCESSION NUMBER: PubMed ID: 10097745 DOCUMENT NUMBER:

A late phase II clinical study of RP56976 (

docetaxel) in patients with advanced or recurrent

gastric cancer: a cooperative study group trial (group B). Mai M; Sakata Y; Kanamaru R; Kurihara M; Suminaga M; Ota J;

Hirabayashi N; Taguchi T; Furue H

Dept. of Surgery, Cancer Research Institute, Kanazawa CORPORATE SOURCE:

University.

Gan to kagaku ryoho. Cancer & chemotherapy, (1999 SOURCE:

Mar) Vol. 26, No. 4, pp. 487-96.

Journal code: 7810034. ISSN: 0385-0684.

Japan PUB. COUNTRY:

AUTHOR:

(CLINICAL TRIAL) DOCUMENT TYPE:

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LANGUAGE: Japanese

Priority Journals FILE SEGMENT:

199904 ENTRY MONTH:

Entered STN: 13 Apr 1999 ENTRY DATE:

Last Updated on STN: 13 Apr 1999

Entered Medline: 1 Apr 1999

A late phase II clinical study of RP56976 (docetaxel) in AB patients with advanced or recurrent gastric cancer was performed to evaluate the anti-tumor activity and clinical toxicity as a multicenter cooperative trial. Docetaxel was administered intravenously at a dose of 60 mg/m2 every 3-4 weeks. Of 72 patients enrolled, 63 patients were eligible and 59 patients were evaluable for response. The anti-tumor effects obtained complete response (CR) in one patient partial response (PR) in 13, minor response (MR) in 3, no change (NC) in 20, and progressing disease (PD) in 22 patients. The overall response rate in 59 patients was 23.7% (14/59). For 14 CR or PR cases, a response appeared 10 to 107 days (median 33.5 days) and 1 to 8 (median 2) times of dosing after the initial administration. The response rate was 9.5% in the primary tumor, 31.3% livers, 50.0% abdominal tumor, and 24.1% lymph nodes, respectively. The major adverse reactions were gastrointestinal symptoms including nausea/vomiting, anorexia, fatigue, alopecia and fever. Leukocytopenia and neutrocytopenia were also observed with a high incidence, but they recovered after 8 days from the nadir. The results show that docetaxel is an effective anti-tumor agent for advanced or recurrent gastric cancer. It is necessary to conduct another clinical trial by concomitant administration with other anti-tumor agents.

MEDLINE on STN L12 ANSWER 44 OF 55 MEDLINE 1999014548 ACCESSION NUMBER: PubMed ID: 9797814 DOCUMENT NUMBER:

Late phase II clinical study of RP56976 (docetaxel TITLE:

) in patients with advanced/recurrent gastric cancer: a

Japanese Cooperative Study Group trial (group A).

Taguchi T; Sakata Y; Kanamaru R; Kurihara M; Suminaga M; **AUTHOR:**

Ota J; Hirabayashi N

Japan Society for Cancer Chemotherapy, Aomori Prefectural CORPORATE SOURCE:

Central Hospital.

Gan to kagaku ryoho. Cancer & chemotherapy, (1998 SOURCE:

Oct) Vol. 25, No. 12, pp. 1915-24. Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY: Japan

(CLINICAL TRIAL) DOCUMENT TYPE:

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals ENTRY MONTH: 199811

ENTRY DATE: Entered STN: 6 Jan 1999

Last Updated on STN: 6 Jan 1999 Entered Medline: 4 Nov 1998

A late phase II clinical study of RP56976 (docetaxel) was AB conducted in patients with advanced/recurrent gastric cancer as a multicenter cooperative trial. Docetaxel was administered intravenously at a dose of 60 mg/m2 every 3-4 weeks. Of the 76 patients enrolled, 66 patients were eligible and 59 patients were evaluable for response. One patient showed complete response (CR), 13 patients partial response (PR), 1 patient minor response (MR), 19 patients no change (NC) and 25 patients had progressive disease (PD). The overall response rate in 59 evaluable patients was 23.7% (95% CI = 13.6-36.6%). The primary tumor showed a 4.3% (1/23) response, while the metastatic lesions in the abdomen, pelvic mass, lung, liver, and lymph nodes showed response rates of 62.5% (5/8), 33.3% (1/3), 33.3% (1/3), 14.8% (4/27), and 13.9% (5/26), respectively. About hematological toxicity, severe (Grade 3 or more) leukopenia was observed in 36 patients (56.3%) and neutropenia in 52 patients (81.3%). Other major toxicity (Grade 3 or more) included nausea/vomiting in 11 patients (17.2%), anorexia in 9 patients (14.1%), fatigue in 5 patients (7.8%), and alopecia in 7 patients (10.9%), all which were tolerable. The results show that docetaxel is an effective anticancer agent for advanced/recurrent gastric cancer.

L12 ANSWER 45 OF 55 MEDLINE ON STN ACCESSION NUMBER: 2000464139 MEDLINE DOCUMENT NUMBER: PubMed ID: 11016005

TITLE: A case of effective chemotherapy using CAF followed by

docetaxel for advanced breast cancer.

AUTHOR: Kokufu I; Taniguchi H; Kim Y H; Fukuda K; Yamamoto M; Yano

T; Yamada K; Kitano H; Fukuda H

CORPORATE SOURCE: Dept. of Surgery, Itami City Hospital.

SOURCE: Gan to kagaku ryoho. Cancer & chemotherapy, (2000

Sep) Vol. 27, No. 10, pp. 1577-80. Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY: Japan

DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200010

ENTRY DATE: Entered STN: 19 Oct 2000

Last Updated on STN: 19 Oct 2000 Entered Medline: 10 Oct 2000

Ah uge mass measuring 13 x 12 cm and wide cutaneous edema were detected in the right breast of a 51-year-old woman. Under a diagnosis of locally advanced breast cancer (T4bN2M1, stage IV) with liver metastases, we attempted sequential neoadjuvant chemotherapy. After three courses of CAF therapy (cyclophosphamide, doxorubicin (DXR), 5-FU), the primary tumor was decreased by 56% and the liver metastases had disappeared. A minor pathologic response was observed. Subsequently, three courses of docetaxel (TXT) administration were carried out. The primary tumor was then decreased by 75% and the axillary metastases had disappeared. Histopathological examination showed gross viable tumor cells in the residual tumor and positive axillary lymph nodes. The only toxic effect was nausea (grade 1) and no major adverse effects were observed. Neoadjuvant chemotherapy with sequential DXR followed by TXT is a useful treatment for locally advanced breast cancer.

L12 ANSWER 46 OF 55 MEDLINE ON STN
ACCESSION NUMBER: 1999430325 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10500538

TITLE: A case of recurrent breast cancer successfully treated with

docetaxel.

Koshizuka K; Hada M; Muto S; Hagiwara J; Nakagomi H; Takano AUTHOR:

K; Kamiya K; Tada Y

Second Dept. of Surgery, Yamanashi Medical University. CORPORATE SOURCE:

Gan to kagaku ryoho. Cancer & chemotherapy, (1999 SOURCE:

Sep) Vol. 26, No. 10, pp. 1479-81.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY:

Japan

(CASE REPORTS) DOCUMENT TYPE:

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

Japanese

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199909

ENTRY DATE:

Entered STN: 12 Oct 1999

Last Updated on STN: 12 Oct 1999

Entered Medline: 30 Sep 1999

A 53-year-old female underwent mastectomy for left breast cancer in April, AB 1993. She was given oral tamoxifen but this had to be discontinued due to its side effects. In March, 1998, she developed bone and lung metastases, in spite of treatment with combination chemotherapy (CEF). We thus treated here with docetaxel 90 mg three times and 40 mg six times. After the chemotherapy, she achieved complete remissions of the lung metastases and a decrease in serum CEA, CA 15-3, NCC-ST439, and BCA225. Adverse reactions to docetaxel were grade 2 alopecia, grade 4 neutropenia, dysgeusia, and fluid retention. All were tolerable. This new agent may play an important future role in chemotherapy for recurrent breast cancer.

L12 ANSWER 47 OF 55 MEDLINE on STN ACCESSION NUMBER: 1998233482 MEDLINE

DOCUMENT NUMBER:

PubMed ID: 9571974

TITLE:

Breast cancer with liver metastasis responsive to

docetaxel: case report.

AUTHOR:

Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa

CORPORATE SOURCE:

Dept. of Surgery, Wakayama Medical College Kihoku Hospital. Gan to kagaku ryoho. Cancer & chemotherapy, (1998)

SOURCE:

Apr) Vol. 25, No. 5, pp. 743-6.

Journal code: 7810034. ISSN: 0385-0684.

PUB. COUNTRY:

Japan

(CASE REPORTS) DOCUMENT TYPE:

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

Japanese

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199805

ENTRY DATE:

Entered STN: 14 May 1998

Last Updated on STN: 14 May 1998

Entered Medline: 7 May 1998

A 59-year-old female underwent mastectomy for right breast cancer in AB November 1992. She received tamoxifen and anthracycline-containing chemotherapy as adjuvant therapy. In and after September 1994, she developed loco-regional recurrences five times in total, each of which was treated with surgery and conventional combination chemotherapy. In April 1997, she developed liver metastasis, which was refractory to biochemical modulation therapy (low-dose cisplatin + 5-FU). We, therefore, treated her six times with docetaxel 80 mg, which resulted in partial response of the liver metastasis and brought about a marked decrease in serum CA15-3 levels. Adverse effects of docetaxel were grade 3 alopecia and leucocytopenia. She has been well without re-growth of the liver metastasis for over five months.

ANSWER 48 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on L12

ACCESSION NUMBER: 1998:259786 BIOSIS PREV199800259786 DOCUMENT NUMBER:

TITLE: Antitumour effect of docetaxel in malignant

diseases.

AUTHOR(S): Eckhardt, Sandor [Reprint author]

CORPORATE SOURCE: Rath Gyorgy u. 7-9, 1122 Budapest, Hungary SOURCE: Orvosi Hetilap, (April 12, 1998) Vol. 139, No.

15, pp. 867-872. print.

CODEN: ORHEAG. ISSN: 0030-6002.

DOCUMENT TYPE: Article

General Review; (Literature Review)

LANGUAGE: Hungarian

ENTRY DATE: Entered STN: 9 Jun 1998

Last Updated on STN: 12 Aug 1998

In recent years numerous molecular biological discoveries enlightened the AB various steps of the neoplastic transformation. Based on new targets, this development made it possible to synthetize new tumour inhibitory substances. Among them taxanes capable to block depolymerization of tubulin - which is an essential molecule in cell division - play an important role. Docetaxel (Taxotere) belongs to this group and is an active drug in the treatment of breast cancer. Moreover, platinum-resistant tumours may also respond to the therapy. It is important to note that even visceral (hepatic) metastases may express chemosensitivity. Results of combination chemotherapy seem to be also promising. The antitumour effect of Taxotere in NSCLC and other malignant neoplasms In under investigation. The toxicity of Taxotere may be successfully reduced by premedication of steroids. The necessary protective measures render the Taxotere therapy safe and of being perspectivistic.

L12 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1999:325975 CAPLUS

DOCUMENT NUMBER:

130:357177

TITLE:

Detoxication of active pharmaceutical substances using

cyclodextrin oligomers

INVENTOR(S):

Moser, Joerg G.

PATENT ASSIGNEE(S):

Germany

SOURCE:

PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.					KIND DATE				APPL:							
	WO 9924474									WO 1	998-		19981111 <				
	W:	AL,	ΑU,	BA,	BB,	BG,	BR,	CA,	CN,	CU,	CZ,	EE,	GE,	HR,	HU,	ID,	IL,
		IS,	JP,	ΚP,	KR,	LC,	LK,	LR,	LS,	LT,	LV,	MG,	MK,	MN,	MX,	NO,	NZ,
		PL,	RO,	SG,	SI,	SK,	SL,	TR,	TT,	UA,	US,	UZ,	VN,	-YU,	AM,	ΑZ,	BY,
					RU,												
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	ES,
												SE,					
									SN,								
AU	9916											1669	4		19	9981	111 <
	EP 1045863												19981111 <				
	1045																•
	R:	AT,	BE.	CH.	DE,	ES,	FR,	GB,	IT,	LI,	NL						
JР	2001											5204	82	٠	19	9981	111
	2361											9611					
	6642											5542					
PRIORIT									1	DE 1	997-	1974	9801	7	A 19	9971:	111
	 -								1	DE 1	998-	1982	2416	2	A 19	99809	519
									7	NO 1	998-	EP72:	29	1	W 19	9981	111
			_				_	-	• .				-				•

AB Cyclodextrin oligomers with 2 cyclodextrins connected via a spacer B on the secondary side [CD-X-A-X-B-X-A-X-CD; CD = cyclodextrin; X = bond, NH,

O, S, C(O); A = bond, C2-4 aliphatic residue; B = rigid, preferably hydrophilic residue] form strongly hydrophilic inclusion compds. with pharmaceutical agents and thereby prevent toxic side effects of drugs on nontarget cells by inhibiting their uptake into the cells. The drugs can be targeted to specific tissue sites by attachment of affinity groups such as antibodies to the cyclodextrin residues, and the drug can be released at the target site by destruction of the cyclodextrin residues (e.g. with cyclodextrinase from Klebsiella oxytoca). Provided the cyclodextrins are connected on their secondary sides, their cavities will face each other; the distance between them is determined by the choice of spacer, and is Thus, β-cyclodextrin was condensed with preferably 0.8-1.8 nm. 4,4'-methylenebis(benzenesulfonyl chloride) and the product reacted with diaminopropane to form β -6(A-D)-diamidopropanediaminocyclodextrin Sep., 2-monotosyl- β -cyclodextrin reacted with 3-mercaptopropionic acid to form β -(2)cyclodextrin-(3-thiopropionic acid) (II). Reaction of II with carbonyldiimidazole, Nhydroxysuccinimide, and a 2.5-fold molar excess of I produced a cyclodextrin trimer. Nude mice bearing OAT SCLC cell tumors were treated with biotinylated monoclonal antibody ICO 25 i.p., followed 24 h later by NeutrAvidin i.p., and after an addnl. 48 h by a biotinylcadaverine-labeled CD dimer-paclitaxel complex. Growth of the tumors was inhibited without occurrence of side effects.

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 50 OF 55 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1998:213711 CAPLUS

DOCUMENT NUMBER:

128:289570

TITLE:

Pharmacokinetics of anticancer agents in patients with

impaired liver function

AUTHOR(S):

Donelli, M. G.; Zucchetti, M.; Munzone, E.; D'incalci,

M.; Crosignani, A.

CORPORATE SOURCE:

Dipartimento di Oncologia, Istituto di Ricerche Farmacologiche Mario Negri, Milan, 20157, Italy

SOURCE: Eu

European Journal of Cancer (1998), 34(1),

33-46

CODEN: EJCAEL; ISSN: 0959-8049

PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:

Elsevier Science Ltd. Journal; General Review

English

A review with 95 refs. This report reviews published information on the clin. pharmacokinetics of antitumor agents in patients with liver dysfunction, associated with primary liver disease or liver metastases. Information was available for anthracyclines and their related compds., antimetabolites, cyclophosphamide, vinca alkaloids, taxanes and epipodophyllotoxins. Changes in the pharmacokinetic profile or metabolism in . patients with mild or severe hepatobiliary dysfunction are described and the relationships between serum levels, parameters employed for measuring hepatic function and toxic or therapeutic effects are examined Current knowledge of the pharmacokinetics of antineoplastic agents in liver disease is far from complete, mostly obtained in small nos. of non-homogeneous patients often presenting only moderate liver dysfunction, and empirical guidelines for dose assessment are still largely applied in clin. practice. Because of the complex pathophysiol. mechanisms of liver insufficiency in cancer patients, there is still doubt whether endogenous markers are useful. Although caution in treating cancer patients with liver insufficiency is compulsory, for most compds. there seems no need to recommend dose redns. for moderate impairment. However, for the tubulin acting agents, vincristine, vinblastine and possibly for paclitaxel and docetaxel, there is strong evidence that dose adjustment is mandatory in order to avoid excessive neutropenia and neurotoxicity.

mandatory in order to avoid excessive neutropenia and neutrocoxicity.

REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

MEDLINE on STN L12 ANSWER 51 OF 55 MEDLINE 2000390579 ACCESSION NUMBER:

DOCUMENT NUMBER:

PubMed ID: 10895201

AUTHOR:

Preliminary results of multicenter phase II trial of

docetaxel (Taxotere) in combination with

doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.

Muthalib A; Darwis I; Prayogo N; Sutjipto

Dharmais National Cancer Center/School of Medicine, CORPORATE SOURCE:

University of Indonesia, Jakarta.

Gan to kagaku ryoho. Cancer & chemotherapy, (2000 SOURCE:

May) Vol. 27 Suppl 2, pp. 498-504.

Journal code: 7810034. ISSN: 0385-0684.

Japan PUB. COUNTRY:

DOCUMENT TYPE:

(CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE:

English

Priority Journals FILE SEGMENT:

ENTRY MONTH:

200008

ENTRY DATE:

Entered STN: 18 Aug 2000

Last Updated on STN: 18 Aug 2000

Entered Medline: 10 Aug 2000

RATIONALE: Docetaxel and doxorubicin have produced a high degree AB of activity in previously untreated/treated patients with metastatic breast cancer (MBC). The efficacy of Taxotere (T) single agent as 2nd line chemotherapy is well established in large randomized phase III OBJECTIVE: The objective of this study is to confirm the efficacy and safety of a combination of Taxotere with doxorubicin as 1st line chemotherapy in Indonesian MBC patients. TREATMENT AND METHOD: Eighteen patients age < or = 70 years with advanced or metastatic breast cancer (MBC) with no prior taxane chemotherapy or prior cumulative doxorubicin (D) of no more than 250 mg/m2 and no heart disease were enrolled in this phase II study of D (50 mg/m2) IV bolus followed one hour later by Taxotere (T) 60 mg/m2 IV infusion over 1 hour every 3 weeks for 6 cycles treatments. A 3-day oral corticosteroid premedication was administered starting one day before the infusion of each cycle. ventricular ejection fraction (LVEF) was evaluated at baseline and after cycle 6. PATIENTS CHARACTERISTICS: 18 patients (pts) have been treated with 108 cycles administered. Median age was 46 years (31-58), WHO PS 0 = 50%, 1 = 50% and number of organs involved were: 2 (72%), 3 (22%) and 4 (6%). RESULTS: After 3 cycles, partial (PR) and no change (NC) responses occurred in 15 pts (83.3%) and 3 pts (16.7%). The best overall response after 6 cycles, including complete (CR) and partial (PR) responses, occurred in 13 pts (72.2%) including 3 CRs and 10 PRs. Two patients with extensive liver metastases at the baseline had a complete disappearance after 6 cycles. No patients developed congestive heart failure (CHF). Grade 3/4 hematological toxicities included leukopenia in 18 pts (100%), febrile neutropenia in 6 pts (33%), leukopenia with infection in 2 pts (11%), leukopenia with fever in 1 pt (5.5%), and anemia in 6 pts (33.3%). Nonhematological toxicities grade 3/4 included alopecia (61%), asthenia (4.6%), nausea/vomiting (2.7%), pain (2.7%), stomatitis (2.7%), and diarrhoea (0.9%). Leukopenia was generally of short duration, occurred mainly during the first and second cycle, and did not require any dose reduction. There was one death due to progressive disease after six cycles of treatment. CONCLUSION: Taxotere--doxorubicin combination is very active in the first-line treatment of MBC, seems to be especially effective in patients with liver metastases, and is associated with a manageable toxicity profile.

2001:89699 BIOSIS ACCESSION NUMBER: PREV200100089699 DOCUMENT NUMBER:

Phase I study of weekly docetaxel in combination TITLE:

with capecitabine in patients with solid malignancies. Villalona-Calero, M. A. [Reprint author]; Shapiro, C.

AUTHOR (S): [Reprint author]; Otterson, G. A. [Reprint author]; Hauger, M. [Reprint author]; Kraut, E. [Reprint author]; Clinton, S. [Reprint author]; Shah, M. [Reprint author]; Stanek, M.

[Reprint author]; Monk, J. P. [Reprint author]

Arthur James Cancer Center and R Solove Research Institute, CORPORATE SOURCE:

Ohio State University, Columbus, OH, USA

Breast Cancer Research and Treatment, (November, SOURCE:

2000) Vol. 64, No. 1, pp. 125. print. Meeting Info.: 23rd Annual San Antonio Breast Cancer Symposium. San antonio, Texas, USA. December 06-09, 2000.

Cancer Therapy and Research Center Research Foundation. CODEN: BCTRD6. ISSN: 0167-6806.

Conference; (Meeting) DOCUMENT TYPE:

Conference; Abstract; (Meeting Abstract)

English LANGUAGE:

Entered STN: 14 Feb 2001 ENTRY DATE:

Last Updated on STN: 12 Feb 2002

L12 ANSWER 53 OF 55 MEDLINE on STN ACCESSION NUMBER: 2000339901 MEDLINE PubMed ID: 10885392 DOCUMENT NUMBER:

Metastasectomy as a cytoreductive strategy for treatment of TITLE:

isolated pulmonary and hepatic metastases from breast

cancer.

Bathe O F; Kaklamanos I G; Moffat F L; Boggs J; Franceschi AUTHOR:

D; Livingstone A S

Department of Surgery, University of Miami, FL 33136, USA.. CORPORATE SOURCE:

bathe@worldnet.att.net

Surgical oncology, (1999 Jul) Vol. 8, No. 1, pp. SOURCE:

35-42. Ref: 45

Journal code: 9208188. ISSN: 0960-7404.

Netherlands PUB. COUNTRY:

Journal; Article; (JOURNAL ARTICLE) DOCUMENT TYPE:

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

200007 ENTRY MONTH:

Entered STN: 28 Jul 2000 ENTRY DATE:

> Last Updated on STN: 28 Jul 2000 Entered Medline: 20 Jul 2000

The authors sought to examine the utility of resection in conjunction with AB adjuvant chemotherapy for treatment of metastases from breast cancer isolated to the liver or lungs. Limitations of regional therapy were examined and potential agents for systemic therapy were reviewed. As resection of metastases is a controversial therapeutic approach, no clinical trials are available for review. Rather, evidence for a potential role for surgery rests on retrospective studies of small series of patients. Technical advances have rendered resection of liver and lung metastases safe. Long-term results as reported by other investigators support the role of metastasectomy in selected patients. The site of failure following ablation of liver metastases is usually in the liver. Following resection of lung metastases, nonpulmonary and disseminated recurrences are most common. Adjuvant therapy with docetaxel or any other agent or combination with significant activity against visceral metastases might potentiate long-term results.

ANSWER 54 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

2001:77815 BIOSIS ACCESSION NUMBER:

PREV200100077815 DOCUMENT NUMBER:

A phase II trial of escalated dose docetaxel TITLE:

(TXT) with G-CSF support in patients (pts) with advanced

breast cancer.

Mitchell, P. [Reprint author]; Basser, R.; Harris, M. AUTHOR(S):

[Reprint author]; Ng, S.; Gibbs, P. [Reprint author]; Chipman, M. [Reprint author]; Grigg, A.; Jeffrey, A.; James, R.; Gargano, J.; Riva, A.; Appia, F.; Green, M.

Medical Oncology, Austin and Repatriation Medical Centre, CORPORATE SOURCE:

Heidelberg West, VIC, Australia

Breast Cancer Research and Treatment, (November, SOURCE:

2000) Vol. 64, No. 1, pp. 88. print.

Meeting Info.: 23rd Annual San Antonio Breast Cancer Symposium. San antonio, Texas, USA. December 06-09, 2000. Cancer Therapy and Research Center Research Foundation. CODEN: BCTRD6. ISSN: 0167-6806.

Conference; (Meeting) DOCUMENT TYPE:

Conference; Abstract; (Meeting Abstract)

English LANGUAGE:

Entered STN: 7 Feb 2001 ENTRY DATE:

Last Updated on STN: 12 Feb 2002

L12 ANSWER 55 OF 55 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on

ACCESSION NUMBER: 2001:132253 BIOSIS DOCUMENT NUMBER: PREV200100132253

Close correlation of paraneoplastic hyperfibrinolysis with TITLE:

relapse and remission of anaplastic small cell carcinoma: A

case report.

Kegel, T. [Reprint author]; Kellner, O. [Reprint author]; AUTHOR (S):

Grothey, A. [Reprint author]; Wolf, H.-H. [Reprint author];

Voigt, W. [Reprint author]; Dorligshaw, O. [Reprint

author]; Schmoll, H.-J. [Reprint author]

Dept. of Hematology/Oncology, University of Halle, Halle, CORPORATE SOURCE:

Germany

Onkologie, (October, 2000) Vol. 23, No. SOURCE:

Sonderheft 7, pp. 184. print.

Meeting Info.: Annual Meeting of the German and Austrian Society for Hematology and Oncology. Graz, Austria. October

21-25, 2000.

CODEN: ONKOD2. ISSN: 0378-584X.

DOCUMENT TYPE:

Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE:

English

Entered STN: 14 Mar 2001 ENTRY DATE:

Last Updated on STN: 15 Feb 2002